

CURRICULUM VITAE (October 27, 2023)

Name: Josep Dalmau Obrador

Date of Birth: July 24, 1953

Place of Birth: Barcelona (Catalunya), Spain
Citizenship: Spain, USA

Work Address: Department of Neurology
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)
Hospital Clinic
Villarroel, 170
Barcelona, Spain 08036
(34) 932271783 (t)
(34) 932271726 (f)
E-mail: jdalmau@clinic.cat

Home Address: Avda Mistral 49, 6
08015, Barcelona, Spain
(34) 674-090-017

Licensed Physician: Spain (active)
Pennsylvania (active)
New York (inactive)
Arkansas (inactive)

Education:
Ph.D. (Hons.) School of Medicine, Autònoma University of Barcelona, Spain, 1993
M.D. (Hons.) School of Medicine, Autònoma University of Barcelona, Spain, 1971-1977
B.S. Instituto Nacional de Enseñanza Media, Ausias March, Barcelona, Spain,
1968-1971

Certification:

- Medicine and Surgery, Spain, 1978
- Educational Commission for Foreign Medical Graduates (ECFMG), 1986
- Federal Licensing Examination (FLEX), 1992
- U.S. Board Certification (not eligible)

Postgraduate Training:

1992-1993	Fellow, Medical Oncology, Memorial Hospital for Cancer and Allied Diseases, New York, NY
1992-1993	Clinical Fellow, Neurology, New York Hospital, Cornell University, New York, NY
1988-1992	Research Fellow, Cotzias Laboratory of Neuro-Oncology, Sloan-Kettering Institute, New York, NY
1979-1983	Resident, Neurology, University Hospital de la Sta. Cruz y San Pablo, Barcelona,

Spain
 1978-1979 Spanish Army Service (Physician).
 1977-1978 Internship, Internal Medicine, University Hospital de la Sta. Cruz y San Pablo, Barcelona, Spain

Faculty Appointments:

1983-1988 Attending Neurologist, University Hospital of Sabadell, Barcelona, Spain
 1986-1988 Private practice, Barcelona, Spain, part time
 1993-1994 Clinical Assistant Neurologist, Memorial Hospital for Cancer and Allied Diseases, New York, NY
 1993-1999 Assistant Professor of Neurology and Neurosciences, Cornell University Medical College, New York, NY
 1994-1999 Assistant Attending Neurologist, Memorial Hospital for Cancer and Allied Diseases, New York, NY
 1999-2002 Associate Professor Neurology, University of Arkansas for Medical Sciences Little Rock, AR
 2002-2005 Associate Professor Neurology, University of Pennsylvania, Philadelphia, PA
 2003-2011 Associate Investigator, Abramson Comprehensive Cancer Research Institute, Philadelphia, PA
 2005-2011 Professor Neurology, University of Pennsylvania, Philadelphia, PA
 2011-present Adjunct Professor of Neurology, University of Pennsylvania, Philadelphia, PA
 2011-present ICREA Senior Investigator, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clinic, University of Barcelona, Spain
 2013-present Associate Professor, School of Medicine, University of Barcelona
 2013-present Guest Researcher at the National Institute of Health (NIH)/ National Institute of Neurological Disorders and Stroke (NINDS), with interim clinical privileges. Washington, DC
 2016-present Consultant Faculty, Hospital Sant Joan de Deu for Children, Barcelona, Spain

Hospital and Administrative Appointments:

1994-1999 Assistant Member, Memorial Sloan-Kettering Cancer Center, New York, NY
 1999-2002 Co-Director, Neuro-Oncology Program, University of Arkansas for Medical Sciences, Arkansas Cancer Research Center, Little Rock, AR
 2003-2011 Member, Neurology Clinical-Basic Research Committee, University of Pennsylvania, Philadelphia, PA
 2003-2011 Member, Subcommittee for Teaching Evaluation, School of Medicine, University of Pennsylvania, Philadelphia, PA
 2010-2011 Vice-Chair of the Neurology/Basic Research Committee
 2002-2011 Director, Laboratory Neuro-Oncology, Univ of Pennsylvania, Philadelphia, PA
 2011-present Director, Laboratory of Neuro-Oncology and Neuro-Immunology, IDIBAPS, Hospital Clinic, University of Barcelona, Spain
 2014-present Director, Center for Autoimmune Neurology, University of Pennsylvania
 2014-present Director, Consolidated Research Group, Generalitat de Catalunya Clinical and Experimental Neuroimmunology Group
 2015-2022 Director, CIBERER Group U764 (CB15/00010)

Scientific and Medical Societies:

- National Academy of Medicine (USA), International Member
- American Neurological Association (ANA), Active member
- American Academy of Neurology (AAN), Fellow member (FAAN)
- European Academy of Neurology (EAN), Fellow member
- European Neurological Society (ENS), Active member
- International Society of Neuroimmunology (ISNI), Active Member

Awards and Honors

- 2024 Cornell University-MSKCC, Keynote Speaker/Visiting Professor, *Plum-Posner Symposium*
- 2024 Universidad Autónoma de Madrid, *Conference Tatiana Pérez de Guzmán el Bueno*
- 2023 German Society of Neurology and Reemtsma Foundation, *former Zülch prize Special Lecture*
- 2023 European Academy of Neurology, *The Camillo Golgi Lecture*
- 2023 University of Maryland School of Medicine, *The Taylor Lecture in Neuropsychiatry*
- 2023 American Brain Foundation, *Scientific Breakthrough Award*
- 2022 Barcelona Medical Association, *Professional Excellence Award*
- 2022 Clarivate Analytics *Highly Cited Researcher*
- 2022 American Academy of Neurology, *Headtalk, "Standing on the shoulder of giants"*
- 2022 Brown Alpert Medical School/Rhode Island Hospital, *"Scott Wang lecture in Neuro-oncology"*
- 2021 Clarivate Analytics *Highly Cited Researcher*
- 2020 Boston Children's Hospital, Harvard University, *"Bresnan Lecture"*
- 2020 Clarivate Analytics *Highly Cited Researcher*
- 2020 American Psychiatry Association, *"Frontiers of Science Award Lecture"*
- 2019 Clarivate Analytics *Highly Cited Researcher*
- 2019 American Epilepsy Society, *"Award for Clinical Science Research"*
- 2019 Mayo Clinic Arizona, *"Donald and Maria Pellar Visiting Professor and Lecture"*
- 2019 The Lilly Prize for Biomedical Research, The Lilly Foundation, Madrid, Spain
- 2019 American Academy of Neurology, *"Invited Science: Infectious Diseases and Global Health"*
- 2019 University California Los Angeles (UCLA), *"The Robert Collins Lecture"*
- 2018 Clarivate Analytics *Highly Cited Researcher*
- 2018 *Sobek Award*, Sobek Foundation, Stuttgart, Germany
- 2018 *Don Gilden Lecture*, University of Colorado School of Medicine
- 2018 European College of Neuropsychopharmacology (ECNP) *Brain Prize Lecture*
- 2018 *Honorary Member* of the Japanese Society of Neurology
- 2018 *Zülch Prize for Basic Neurological Research*, Max Planck Society, Cologne, Germany
- 2018 Honorary Fellow of the Neurological Society of Thailand
- 2018 Neurological Society of Thailand, *"Athasit Lecture"*
- 2017 Clarivate Analytics (previously Thomson Reuters) *Highly Cited Researcher*
- 2017 College of Physicians and Surgeons, Columbia University, NY, *"The AM Lippard Lecture"*.
- 2017 *Doctor Honoris Causa*, University of Lyon (France)
- 2017 Award AQuAS (Generalitat de Catalunya)
- 2017 "Premio Rey Jaime I" (*Rey Jaime I Award*) in Medical Research/Clinical Medicine
- 2017 Dartmouth-Hitchcock and Geisel School of Medicine, Dartmouth, *"Bornstein Lecture"*
- 2017 Inaugural Conference, Master's Degree Program in Neuroscience, University of Barcelona.
- 2017 University of Cincinnati, *"Charlie Aring Lecture"*
- 2017 Vanderbilt Medical School, *"Flexner Discovery Lecture"*
- 2016 Thomson Reuters *Highly Cited Researcher*
- 2016 Calgary University, *"Mary Ann Lee Epilepsy Lecture"*

- 2016 American Academy of Neurology, “George C. Cotzias Presidential Lecture”
- 2016 French Society of Neurology, *Member of Excellence Lecture*
- 2016 McGill University, “Donald Baxter Lecture”
- 2015 Thomson Reuters *Highly Cited Researcher*
- 2015 Canadian Neurological Society, “Richardson Lecture”
- 2015 International Symposium of Pediatric Movement Disorders, “Surtees Lecture”
- 2015 Mayo Clinic Jacksonville, *Pellar Resident Visiting Professorship*
- 2014 Rush University, *8th Annual Visiting Professorship*
- 2014 International Society of Neuroimmunology (Mainz), “The John Newsom-Davis Lecture”
- 2014 Charité University of Medicine (Berlin), “Neurology Semester Lecture”
- 2014 The Hospital for Sick Children, University of Toronto, *The Haslam lecture*
- 2013 13th European School of Neuroimmunology (ESNI) *Career Award*
- 2013 Spanish Society of Neurology, *Conference “Lluís Barraquer Ferré”*
- 2013 Catalan Society of Neurology, *Career Trajectory Award*
- 2012 Intl Child Neurology Association & Asia Oceania Neurology Association, *Plenary Lecture*
- 2011 University of Chicago, *Stanley Gore lecture*
- 2011 Society of Biological Psychiatry, *Plenary Lecture*
- 2011 Catalan Society of Neurology, *Annual Distinguished Lecture*
- 2011 Turkish Neurological Society, *Annual Meeting, Key Note Lecture*
- 2011 Spanish Society of Neurology, *Plenary Lecture*
- 2011 Child Neurology Society (USA), *Presidential Symposium*
- 2010 Annals of Neurology, *Prize for the best manuscript in 2010*
- 2010 French Neurological Society, *Key Note Lecture*
- 2010 American Neurological Association, *Jacoby Award*
- 2010 Irish Institute of Clinical Neuroscience, *Guest Speaker*
- 2010 University of Toronto, *Distinguished Lectureship in Neurosciences*
- 2010 Association of British Neurologists, *Editors of Brain Lecture*
- 2010 Canadian Association of Child Neurology, *John Tibbles Lecture*
- 2010 American Association of Neuropathologists, *TEVA Neuroscience Parisi Lecture*
- 2010 American Academy of Neurology, *Frontiers in Clinical Neuroscience Lecture*
- 2010 International Society of Neuroimmunology, *Plenary session*
- 2010 University of Pennsylvania, Combined Degree and Physician Scholar Programs, *Guest Speaker*
- 2010 German Society of Neurology, *Key Note Lecture*
- 2009 University of Pennsylvania, *Lady Barbara Colyton Prize for Autoimmune Research*
- 2008 Japanese Society of Neurology, *Distinguished Lecturer*
- 2005 University of Pennsylvania, *Neurology Residents’ Award for Excellence in Teaching*
- 1986 Catalan Society of Neurology, *Young Investigator Award*

Grants (current and past):

- 01/24-12/27 Instituto Carlos III (FIS PI23/00858) (PI). La encefalitis mediada por anticuerpos LGII: síntomas, biomarcadores y mecanismos de la fase crónica de la enfermedad. (TC 202,500€)
- 09/22-09/23 CIBERER, Acciones Cooperativas y Complementarias Intramurales. Nuevos biomarcadores serológicos en pacientes con enfermedades neuroinmunológicas raras. (PI, Lluís Querol, Co-PI Josep Dalmau). (TC 53,000€)

- 12/22-11/25 CaixaResearch Health 2022 (HR22-00221). “Antibody-mediated NMDA receptor encephalitis: symptoms, biomarkers, and mechanisms of the prolonged recovery stage”
(TC 972,352€)
- 05/22-04/25 Euroimmun Inc, Lübeck, Germany (PI). “Identification of potential new autoantibodies and support in performance evaluation and improvement of autoantibody test systems related to neuronal inflammatory diseases”.
(TC \$330,000€)
- 04/22-03/27 NIH-NeuroNext/University of Utah (site PI Dalmau). “A Phase-2b, Double-Blind, Randomized Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-NMDA Receptor Encephalitis and Assess Markers of Disease
(TDC \$823,427)
- 01/22-12/24 ERA-NET NEURON/Instituto Carlos III (AC21-2/00053; project coordinator C Finke; site PI Dalmau): “Social and Psychological long-term impact of NMDA receptor encephalitis”. Instituto Carlos III and the Network of European Funding for Neuroscience Research.
(TDC 165,770€).
- 01/21-12/24 Instituto Carlos III (FIS PI20/00197) (PI). “Investigations in anti-NMDAR encephalitis: New diagnostic test, the role of inflammation in an animal model, and allosteric modulation of NMDAR as a therapeutic strategy”.
(TDC 276,182 €)
- 10/20-05/21 Instituto Carlos III, Consortium CIBER, Rare Diseases (ACCI Program) (ER20P3AC765)(Project coordinator L. Querol; site PI Dalmau). “Detección de neurofilamentos en pacientes con enfermedades neuroinmunológicas raras”.
(TDC 35,500 €)
- 08/20-08/23 Pablove Foundation Childhood Cancer Research Grant (co-PI with Thais Armangué). “Opsoclonus myoclonus syndrome: a novel approach to antigen identification and disease modeling”
(TDC \$100,000)
- 01/19-03/23 Sage Therapeutics (PI). “Studies on oxysterol-based allosteric potentiators (e.g., SGE-301) as potential antagonists of antibody-mediated NMDAR encephalitis.”
(TDC 341,118 €)
- 01/19-12/21 ERA-NET NEURON/Instituto Carlos III (AC18-00009; project coordinator L Groc; Dalmau, site PI). “Multi-scale exploration of autoantibodies against synaptic receptors”. Instituto Carlos III and the Network of European Funding for Neuroscience Research.
(TDC 123,800 €)
- 10/18-09/21 Edmond J.Safra Foundation Research grant (PI). A comprehensive multidisciplinary approach to improving outcomes in patients with antibody-mediated brain diseases.
(TDC 411,000 €)

- 09/18-12/22 La Caixa Health Research Banking Foundation Award (LCF/PR/HR17/52150001). “A translational model of antibody-mediated synaptic disease: Symptoms, neuronal circuits, and the mechanisms of memory loss and recovery”. (TDC 463,258 €)
- 01/18-12/19 Support of Research Groups 2017-2019, AGAUR, Generalitat de Catalunya (PI). Clinical and experimental neuroimmunology. (TDC 60,809 €)
- 01/18-12/20 Instituto Carlos III (FIS 17/00234) (PI). Encefalitis anti-NMDAR: Subclases de anticuerpos, y estudio de los efectos de la presencia crónica de anticuerpos en el cerebro de ratón adulto, desarrollo cerebral fetal, y sinaptogénesis. (TDC 147,620 €)
- 09/17-08/20 Hashimoto Encephalitis Research Award (P. Naithani, private foundation) (PI). (TDC \$360,000)
- 01/17-12/20 Instituto Carlos III (Proyectos Integrados de Excelencia, PIE 16/00014) (PI). “Immune mediated diseases of the synapse: symptoms, brain networks, and the link to human memory”. (TDC 557,000 €)
- 10/16-10/18 Foundation Alicia Koplowitz (Co-PI with Albert Compte). “Cognitive alterations in teenage patients with anti-NMDAR encephalitis: a possible dysfunction in the perception of temporal continuity and its mechanisms”. (TDC 43,000 €)
- 01/16-12/20 Instituto Carlos III, Consortium CIBER, Rare Diseases CB15/00010 (PI). (TDC 65,000 € per year)
- 05/15-12/20 Fundacio CELLEX, Barcelona, Spain (PI). “Investigations in synaptic autoimmunity and visualization of memory and brain circuits”. (TDC 1,437,652.82 €)
- 06/15-05/17: Institut National de la Sante et de la Recherche Medicale, France (co PI with J Honnorat). "Mechanisms of autoimmune encephalitis". (TDC 25,000 €)
- 01/15-12/17 Instituto Carlos III, (FIS, 14/00203) (PI). “New syndromes, antigens, and mechanisms of synaptic autoimmunity” (TDC 224,152.50 €)
- 01/14-12/16 Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR, Generalitat de Catalunya): Clinical and experimental neuroimmunology (PI) (TDC 35,000 €)
- 09/11-07/17 NIH Extramural-intramural, bedside-to-bench project, “Treatment of anti-NMDA receptor encephalitis” (Extramural PI)

(TDC \$65,000)

- 04/04-07/18 NINDS 9RO1NS077851-05A2 (previously RO1CA107192 (PI). “Paraneoplastic disorders of CNS: Autoantigen profiling”.
(TDC \$1,093,750)
- 08/11-04/16 NIMH, Eureka 1RO1MH094741-01 (co PI with R Balice-Gordon). “Caspr2, LGI-1 and novel antigen autoimmunity in neuropsychiatric dysfunction”.
(TDC \$800,000)
- 01/12-12/14 Instituto Carlos III (FIS, 11/01780) (PI). “Immune-mediated disorders of memory, behavior, cognition and psychosis”.
(TDC 257,070 €)
- 11/10-10/13 Fundació La Marató de TV3 (Catalan Telethon on Rare Diseases) (101530) (PI)
“Clinical spectrum and cellular and synaptic mechanisms of autoimmune synaptic encephalitides”.
(TDC 331.200 €)
- 2/10-1/13 McKnight Neuroscience of Brain Disorders Awards (co PI with R Balice-Gordon).
“Cellular, synaptic, and circuit mechanisms of autoimmune anti-glutamate receptor disorders of memory and cognition”.
(TDC \$300,000)
- 9/09-8/11 NINDS (ARRA Challenge Award), 1RC1NS068204-01 (co PI with R Balice-Gordon).
“Synaptic autoimmunity in disorders of memory, behavior, cognition and psychosis”.
(TDC \$604,786)
- 6/09- 12/17 Euroimmun Inc, Lübeck, Germany (PI).
“Studies for the identification of novel antibodies and autoantigens associated with CNS autoimmune disorders”.
(TC \$713,330)
- 9/07-9/08 NCI, 2R56-CA-089054-O6A1 (PI). Supplement to “Immunity to brain Ma proteins: A remote effect of cancer”.
(TDC \$171,962)
- 12/00-05/13 NCI, RO1CA89054 (PI). “Immunity to brain Ma proteins: A remote effect of cancer”
(TDC \$1,368,670)
- 1/06 Institute for Translational Medicine and Therapeutics (PI). “Immunologic profiling and neuro-oncologic outcome in patients with ovarian cancer and paraneoplastic cdr2 immunity”.
(TC \$150,000)
- 1/03-12/05 Tobacco Settlement Block Grant (PI: Glick), Commonwealth of Pennsylvania Project 8 (PI: Dalmau) “Immune responses in patients with cancer and neurologic disease”.

(TDC \$200,000)

- 2000-2003 Charles A. Dana Neuroscience Research Program Award (PI). “Cancer-Brain interactions mediated by the immunological system”.
(TC \$90,460)
- 1999 University of Arkansas for Medical Sciences (PI). Medical Research Endowment Award. “Clinical and molecular characterization of immunological responses in cancer patients”.
(TC \$11,850)
- 1996-2000 NIH 5 RO1 NS26064 (Co PI with J Posner). “Neurological paraneoplastic syndromes”.
(TDC \$737,517)
- 1994-1997 American Cancer Society (PI). Clinical Oncology Career Development Award.
(TDC \$ 95,000)
- 1991 Spanish National Institute of Health, FIS (PI).
(11,000 €)
- 1989 Spanish National Institute of Health, FIS (PI).
(11,000 €)
- 1988 Spanish National Institute of Health, FIS (PI).
(11,000 €)
- 1987 Spanish Society of Neurology Sandoz Award (PI).
(8,400 €)

Other activities:

- 2017-2019 Chair, Section Autoimmune Neurology, American Academy of Neurology
- 2017-2018 Awards Committee, Premi Josep Trueta, Acadèmia de Ciències Mèdiques i de la Salut de Catalunya i de Balears
- 2017- Nominating Committee, The Japan Prize Foundation
- 2015-2018 Grant Reviewer, Instituto Carlos III, Spain
- 2007-2011 Member, Basic Science Subcommittee, American Academy of Neurology
- 2007-2009 Abstract Review Committee, American Neurological Association
- 2006-2009 Chair, Neuro-Oncology Program, Scientific Program Subcommittee, American Academy of Neurology
- 2004 Ad Hoc reviewer, Research Resources Review Group (RIRG-G), NIH
- 2002-03 Abstract Review Committee, American Academy of Neurology
- 2002 Grants committee, Neuropathy Association
- 1999-2002 Protocol Review and Monitoring Committee, Arkansas Cancer Research Center
- 1997-1999 Director, Graduate Fellowship Training Program in Neuro-Oncology Memorial Sloan-Kettering Cancer Center

Editor, Editorial Board Member:

- 2015-present Editor-in-Chief, *Neurology: Neuroimmunology & Neuroinflammation*

2014-2015 Associate Editor, *Neurology: Neuroimmunology & Neuroinflammation*
2014-present Associate Editor, *Neurology*
2013-2017 Editorial Board, *J Neurology*
1998-2005 Editorial Board, *Neurología*

Thesis Advisor:

-Deborly Wade, 12/01-09/02, PhD. “Expression and Immunogenicity of the Ma Onconeural Proteins”, Program in Microbiology and Immunology”. University of Arkansas for Medical Sciences, Little Rock, AR, USA.

-Luis Bataller, 6/01-05/02, PhD “Clinical, immunological and radiological studies of the opsoclonus-myoclonus syndromes and other sporadic cerebellar disorders”. University of Valencia, Valencia, Spain.

-Mar Petit Pedrol, 09/12. Masters. “Autoimmunitat contra les proteïnes neuronals de membrana LGI1 i CASPR2”. Universitat Autònoma de Barcelona, Barcelona, Spain.

-Thais Armangue, 10/15, PhD. “Autoimmunitat sinàptica com a causa d'encefalitis associada a teratoma, epilèpsia i recidives post-encefalitis herpètica a la infància”. University of Barcelona, Barcelona, Spain.
(Awarded “Best doctoral thesis 2017, University of Barcelona”, and Special Prize by the Committee of PhD-Doctors, University of Barcelona, 2017).

-Francesco Mannara, 01/16, PhD. Animal modeling of autoimmune disorders of the central nervous system associated with antibodies against neuronal surface antigens. University of Barcelona, Barcelona, Spain.

-Jose Alfredo Ramirez-Gonzalez, 06/16, Masters. Prospective Multicenter Study in Pediatric Autoimmune Encephalitis Associated with CNS Antibodies. University of Barcelona, Barcelona, Spain.

-Marianna Spatola, 06/18, PhD. Neuronal antibody-mediated encephalitis: Clinical characterization and pathological mechanisms. Lausanne University, Lausanne, Switzerland.
(Awarded by the University of Lausanne with the Special Prize for Best Doctoral Thesis 2018).

-Estibaliz Maudes, 07/18, Masters. First steps towards animal modeling anti-mGluR5 encephalitis. University Barcelona, Barcelona, Spain.

-Mar Petit-Pedrol, 07/18, PhD. Antigens and mechanisms of immune-mediated encephalitis. University of Barcelona, Barcelona, Spain.
(Awarded by the Royal Academy of PhDs, Spain, Best Doctoral Thesis 2018 in Rare Diseases).

-Bastien Joubert, 12/19, PhD, Autoimmune neurological syndromes with anti-CASPR2 antibodies: Clinical, immunological and genetic characterization, University of Lyon, France.

-Anna Garcia Serra, 09/21, PhD. Animal models of anti-NMDAR encephalitis, University of Barcelona, Barcelona, Spain.

-Mar Guasp, 09/22, PhD. Contributions of anti-NMDAR encephalitis to Neurology and Psychiatry, University of Barcelona, Barcelona, Spain

-AmirPasha Zamani, 12/22, PhD. Spatial learning in the network of hippocampal place cells: Altering memory using a mouse model of anti-NMDAR encephalitis, Univeristy of Barcelona, Barcelona, Spain.

Patents:

1) Ma family polypeptides and anti-Ma antibodies (inventors Posner, Dalmau, Rosenfeld). USA Patent Number: US6387639; issued May 14th, 2002. Licensed to Athena Diagnostics, USA.

2) Methods and compositions for treatment and diagnosis of autoimmune encephalitis or epilepsy (NMDAR test)(inventors: Dalmau, Rosenfeld, Lynch). USA Patent Number: US7972796B2; issued July 5th, 2011. European Patent Number: EP2057466B1, Issued Oct 23, 2013. Also issued in Canada, China. Licensed to Euroimmun AG, Germany.

3) Methods for diagnosing and treating encephalitis or epilepsy (GABAB autoantibody test) (inventor: Dalmau). USA Patent Number: US8685656B2, issued April 1, 2014. European Patent Number: 2483417A4, issued March 29, 2017. Also issued in Denmark, Canada. Licensed to Euroimmun AG.

4) Diagnostic method for detecting a new form of autoimmune encephalitis and related subject-matter (DPPX) (inventor: Dalmau). USA Patent Number: US9719993B2, issued Aug 1, 2017; European Patent Number: EP2895507B1, issued Nov 14, 2018. Licensed to Euroimmun AG.

5) Diagnostic method for detecting a GABA(A) related autoimmune disease and related subject-matter (inventor: Dalmau). European Patent Number: EP3058376A1, issued Nov 27, 2019. Also issued in Denmark, China. Licensed to Euroimmun AG.

6) Diagnosis of a neurologic disease (IgLON5), (inventors: Graus, Dalmau). European Patent Number: EP3102949B1, issued Oct 28, 2020. USA Patent Number: US10962554B2, issued Mar 30, 2021. Also issued in Denmark, China. Licensed to Euroimmun AG.

INVITED LECTURES (last 5 years)

-Grand Rounds, Department of Neurology Hospital Sant Pau, University Autonomia of Barcelona, “Synaptic autoimmunity and disorders of the brain and mind”. Barcelona, Spain, January 9 2019.

-Grand Rounds, Department Psychiatry, Hospital Clinic, University of Barcelona, “Anti-NMDA receptor encephalitis: An immune- mediated synaptopathy that presents with psychosis”. Barcelona, Spain, January 11, 2019.

-Annual Teaching Lecture, School of Medicine, University of Barcelona, “Autoimmune channelopathies”. Barcelona, Spain, March 1, 2019.

-Weill-Cornell Medical School. Symposium, Autoimmune encephalitis: The bridge between neurology and psychiatry. “Antibody-mediated mechanisms in autoimmune encephalitis”. New York, USA, April 6, 2019.

-Moffitt Cancer Center Grand Rounds, “Paraneoplastic and autoimmune encephalitis”. Tampa, FL, USA, April 8, 2019.

-University of Barcelona, Master in Translational Medicine, “Translational research in Autoimmune Neurology”. Barcelona, Spain, April 26, 2019.

-Annual Meeting of the American Academy of Neurology, “What do I do Now?: Neurologic consultations in cancer patients II”: Paraneoplastic neurologic syndromes. Philadelphia, PA, USA, May 4, 2019.

-Annual Meeting of the American Academy of Neurology, “Invited Science Sessions, Infectious Diseases and Global Health”: Viral triggers of autoimmune encephalitis. Philadelphia, PA, USA, May 5, 2019.

-Annual Meeting of the American Academy of Neurology, “Autoimmune Neurology I Basics and Beyond: Autoimmune Encephalitis and Paraneoplastic Neurological Syndromes of the CNS and PNS”: Antibody-mediated encephalitis. Philadelphia, PA, USA, May 7, 2019.

-University of California Los Angeles, Annual Robert Collins Lecture, “Antibody-mediated encephalitis”. Los Angeles, CA, USA, May 29, 2019.

-SAGE Therapeutics, “Anti-NMDA receptor encephalitis: disease, mechanisms, and treatment approaches”, Cambridge, MA, USA, May 31, 2019.

-42th Nacional Congress of the Italian League against Epilepsy (LICE) “Immunity and neurological disorders”, Rome, Italy, June 6, 2019.

-Program in Neurosciences at IDIBAPS, “Translational research in autoimmune encephalitis”. University of Barcelona, Barcelona, Spain, June 11, 2019.

-Lilly Award, “Synaptic autoimmunity and diseases of the brain and mind”. Archeological Museum, Madrid, Spain, June 19, 2019.

-Fourth Annual Iberoamerican Course in Clinical Neurosciences (CIAN), “Autoimmune encephalitis: Neurology meets psychiatry”. Madrid, Spain, June 24, 2019.

-74th Meeting of the Catalan Society of Neuropsychology, “Autoimmune encephalopathies”, Barcelona, Spain, June 28, 2019.

-The 10th Oxford Neurology Course, “The neuroimmunology revolution”, Oxford, UK, July 2, 2019.

-92nd Congress of the German Neurological Association (DGN), “The concept of autoimmune epilepsy”, September, Germany, September 26-27, 2019.

-French Society of Neurology, Update on neuroinfectious diseases, “The role of infections in autoimmune encephalitis”, Paris, France, October 10-11, 2019.

-Mayo Clinic, Donald and Maria Pellar Lecture, “Antibody-mediated encephalitis: syndromes and mechanisms”, Phoenix, AZ, November 5, 2019.

-American Epilepsy Society, Research Recognition Award for Clinical Science Research, “The significance of seizures in autoimmune encephalitis”. Baltimore, MD, December 9, 2019.

-2020 Multiple Sclerosis Preceptorship, Cemcat, University Autònoma of Barcelona: “Autoimmune encephalitis”. Barcelona, Spain, January 28, 2020.

-2020 Annual Meeting of the American Psychiatric Association. Frontiers of Science Award: “The role of synaptic autoantibodies in psychiatric disease”. Philadelphia, PA, April 25, 2020 (via zoom).

-2020 Annual Course on Translational Research, School of Medicine, University of Barcelona: “Translational research in autoimmune neurology”. Barcelona, Spain, May 29, 2020 (via zoom).

-2020 Boston Children’s Hospital, Harvard University, *The Bresnan Lecture*, “Autoimmune encephalitis in children: Syndromes and mechanisms”. Boston, MA, USA, June 3, 2020 (via zoom).

-Immunotherapy for Neurologic Disorders 2020, University of Pennsylvania: “Autoimmune encephalitis –What’s new?” Philadelphia, PA, September 25, 2020 (via zoom).

-Annual Meeting, Pennsylvania Neurological Society: “Autoimmune encephalitis: syndromes and mechanisms”. Philadelphia, PA, October 17, 2020 (via zoom).

-50th Annual meeting of the National Academy of Medicine: “Confronting urgent threats to human health and society: Covid-19 and climate change”. Washington DC, October 17-19, 2020 (Member assistance via zoom).

-IX Symposium, Neuroinmunología y esclerosis múltiple: “Innovaciones en el diagnóstico y tratamiento de encefalitis autoinmune”. Madrid, Spain, October 20, 2020 (via zoom).

-Annual Meeting 2020, Swiss Neurological Society. “Current evidence and challenges in the management of non-infectious encephalitis”. Interlaken, Switzerland, November 19-20, 2020 (via zoom).

-Stanford University, Department of Neurology, Grand Rounds. “Antibody-mediated encephalitis: syndromes and mechanisms”. Stanford, CA, USA, December 11, 2020 (via zoom)

-Neuroinmuno Mendoza 2020 y Sociedad Neurológica Argentina. “Actualización en encefalitis autoinmunes”. Mendoza, Argentina, December 12, 2020 (via zoom).

-America’s Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Didactic Webinar Series. “Anti-NMDA receptor encephalitis and mechanisms of disease”. Middleton, Wisconsin, USA, December 18, 2020 (via zoom)

-Penn State Health College of Medicine, Neurology Grand Rounds: “Anti-NMDAR encephalitis and mechanisms of disease”. Philadelphia, PA, USA, January 22, 2021 (via zoom)

-Temple University, Neurology Grand Rounds: “Autoimmune encephalitis: syndromes and mechanisms”. Philadelphia, PA, USA, January 29, 2021 (via zoom)

-Harbor-UCLA Medical Center, Neurology Grand Rounds: “Autoimmune encephalitis: syndromes and mechanisms”. Los Angeles, CA, USA, February 19, 2021 (via zoom)

-International Child Neurology Association (ICNA), Grand Rounds: “Autoimmune encephalitis beyond NMDA receptor antibodies”, coordinated by McMaster Children’s Hospital, McMaster University, Hamilton, Canada. March 27, 2021 (via zoom)

-Emory University School of Medicine, Neurology Grand Rounds, “Autoimmune encephalitis: syndromes and mechanisms”. Atlanta, GA, USA. May 7, 2021 (via zoom)

-University of Toronto - Krembil Brain Institute, Neuroscience Rounds, “Autoimmune encephalitis: syndromes and mechanisms”, Toronto, ON, Canada. May 13, 2021 (via zoom)

-University of Barcelona, School of Medicine, “Autoimmune channelopathies”, Barcelona, Spain. May 14, 2021 (via zoom)

-Boston Children’s Hospital, Harvard University, Neurology Grand Rounds, “Autoimmune encephalitis beyond NMDAR antibodies”. Boston, MA, USA. June 2, 2021 (via zoom)

-University of Tel-Aviv, Neurology Grand Rounds, “Update on autoimmune encephalitis”. Tel-Aviv, Israel. June 8, 2021 (via zoom)

-University of Vienna, 16th Young Scientists Association, PhD Symposium: “Symptoms and mechanisms of anti-NMDAR encephalitis and other autoimmune synaptopathies”. Vienna, Austria, June 17-18, 2021 (via zoom)

-III International Symposium of Neuroradiology, Brazilian Society of Neuroradiology, “Imaging correlation of most common autoimmune encephalitis”. Brazil. June 21, 2021 (via zoom)

-Annual Research Boot Camp, Western University, London, Ontario: “How Neuro-oncology led me to Autoimmune Encephalitis”, London, Ontario, Canada. September 14, 2021.

-Universidad Internacional de Andalucia, Workshop, The Synaptic Dimension of Brain disorders: “Antibody-mediated synaptopathies” Baeza, Andalucia, Spain, October 6, 2021.

-ECTRIMS 2021, Educational session: Beyond MS: Paraneoplastic syndromes, iatrogenic demyelination and autoimmune encephalitis, “A practical update: Diagnosis and management of paraneoplastic and autoimmune encephalitis”, October 15, 2021 (via zoom).

-VII Congress of the Society of Neurology of Uruguay, “Encephalitis autoinmunes”, Montevideo, Uruguay, October 22, 2021 (via zoom).

-Department of Neurology Grand Rounds, Washington University, “Syndromes and mechanisms of synaptic autoimmune diseases”, St Louis, MO. October 29, 2021 (via zoom).

-Mass General, Harvard University, Behavioral Neurology-Neuropsychiatry Lecture Series, “Psychiatric manifestations of anti-NMDAR encephalitis: clinical diagnosis and mechanisms”, Boston, MA, November 3, 2021 (via zoom).

-7th Hong Kong Neurological Congress cum 34th Annual Scientific Meeting of the Hong Kong Neurological Society, “An update on Autoimmune Encephalitis”. Hong Kong, China, November 6, 2021 (via zoom).

-15th ISNI Congress, Symposium: Antibody-mediated diseases: new targets and mechanisms, “The different syndromes and mechanisms of neuronal synaptic autoantibodies”. Nice, France. November 9, 2021 (via zoom).

-Annual congress of the Argentine Neurology Society, “Actualization en encefalitis autoinmunes”. Buenos Aires, Argentina, November 11, 2021 (via zoom)

-The Royal Australian & New Zealand College of Psychiatrists, Section of Neuropsychiatry 2021 Conference, “Neuropsychiatry of immune mediated encephalitis”. Sydney, Australia, November 12, 2021 (via zoom)

-University of Barcelona, School of Medicine, Seminar: “Autoimmune encephalitis”. Barcelona, Spain, November 15, 2021.

-University of Barcelona, School of Medicine, Master on Autoimmune Diseases, “Autoimmune encephalitis”. Barcelona, Spain, November 26, 2021 (via zoom)

-Child Neurology Grand Rounds, TCH Child Neurology, Baylor College of Medicine, “Autoimmune encephalitis beyond NMDAR antibodies”, Houston, TX, USA, January 19, 2022 (via zoom)

-Brown University Neurology Grand Rounds - 8th Annual Wang Lectureship, “Antibody-mediated encephalitis: Symptoms and mechanisms”, Providence, RI, USA, February 2, 2022 (via zoom)

-Department of Neurology Grand Rounds, University of Miami Miller School of Medicine, “The different syndromes and mechanisms of neuronal synaptic autoantibodies”, Miami, FL, USA, February 4, 2022 (via zoom)

-Massachusetts General Hospital, Neuroscience Grand Rounds, “Diseases and models of autoantibodies against the neuronal synapse”, Boston, MA, USA, March 3, 2022 (via zoom)

-Univeristy of Barcelona, Medical School, “Autoimmune encephalitis”, March 30, 2022

-Department of Neurology, University of Utah, “John Greenlee and the discovery of the anti-Yo antibody”, Salt Lake City, Utah, USA, April 1, 2022

-American Academy of Neurology Annual meeting, Headtalk series, “Standing on the shoulder of giants”, Seattle, Washington, USA, April 7, 2022

- Neuroscience Grand Rounds, Upstate Medical University, “Diseases and models of autoantibodies against the neuronal synapse”, Syracuse, New York, USA, April 20, 2022 (via zoom)
- Master in Translational Medicine, University of Barcelona, “Basic Principles of Translational Medicine”, Barcelona, Spain, April 29, 2022
- Department of Biomedicina de la Facultat de Medicina, University of Barcelona, “Channelopathies and autoimmune encephalitis”, Barcelona, Spain, May 6, 2022
- ACTRIMS Didactic Webinar Series, “Anti-NMDAR encephalitis and mechanism of disease”, May 13, 2022 (via zoom)
- Arizona-Mayo Clinic Cancer Center Grand Rounds, “An Update on Anti-NMDAR encephalitis”, Phoenix, AZ, USA, May 19, 2022 (via zoom)
- XII Simposi de Neurobiologia, University of Barcelona School of Medicine, “Autoimmune encephalitis”, Barcelona, Spain, June 7, 2022
- SYNABS & CONNECT-GENERATE Symposium, “Keynote Speaker”, Tutzing, Germany, June 26, 2022
- Curso de Verano, Universidad del Pais Vasco (EHU-UPV), “Symptoms and mechanisms of anti-NMDAR encephalitis”, Donostia, Spain, July 1, 2022
- FENS Forum 2022, “Autoimmune encephalitis against NMDA, AMPA or Kainate receptors: distinct mechanisms and phenotypes”, Paris, France, July 12, 2022
- American Academy of Neurology, Summer Conference, “Autoimmune Encephalitis”, San Francisco, CA, USA, July 15, 2022
- XXX Brazilian Congress of Neurology, “An update on syndromes and mechanisms of autoimmune encephalitis”, Fortaleza, Brazil, Sept 21, 2022 (via zoom)
- Annual Congress of the Croatian Society for Infectious Diseases, “The antibody-mediated encephalitis, from discovery to new clinical insights and mechanisms”, Sibenik, Croatia, October 22, 2022 (via zoom)
- Mass General Brigham Neurology Grand Rounds, “A journey through autoimmune encephalitis: the first 20 years”, Boston, MA, USA, January 11, 2023 (via zoom)
- NIH-NIAID Grand Rounds, “Anti-NMDA receptor encephalitis: the first 15 years”, Bethesda, MD, USA, January 27, 2023 (via zoom)
- Einstein MC-Thomas Jefferson University Grand Rounds, “An update on autoimmune encephalitis”, Philadelphia, PA, USA, February 3, 2023 (via zoom)
- Jefferson University Grand Rounds, “An update on autoimmune encephalitis”, Philadelphia, PA, USA, February 10, 2023 (via zoom).

-Course of Neuroimmunology, Department of Neurology, Hospital Clinic Barcelona: Neuroimmunología, más allá de la esclerosis múltiple, “Anti-NMDAR encefalitis”, March 24, Barcelona, 2023.

-Temple University Neurology Gran Rounds, “An update on autoimmune encephalitis”, Philadelphia, PA, April 7, 2023 (via zoom).

-Göttingen Meeting of the German Neuroscience Society, “Anti-NMDA receptor encephalitis from discovery to new insights”, Göttingen, Germany, March 22-25, 2023.

COURSE DIRECTOR/ CHAIR (last 5 years)

-Symposium on Immunotherapy for Neurologic Disorders, Perelman School of Medicine, University of Pennsylvania (Co-Director), Philadelphia, PA 19103, March 18, 2016.

-13th International Society of Neuroimmunology (ISNI), Autoimmune channelopathies of the CNS. Jerusalem, Israel, September 27, 2016.

-Jornada multidisciplinaria sobre estudios de la encefalitis anti-NMDA (Multi-disciplinary Update on Anti-NMDA encephalitis). IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain. May 11, 2018

-The Lancet Summit: Inflammation and Immunity in Disorders of the Brain and Mind. Barcelona, Spain, November 15-17, 2018.

-Universidad Internacional de Andalucía, Workshop Current Trends in Biomedicine: “The Synaptic Dimension of Brain disorders”, Baeza, Andalucía, Spain, October 4-6, 2021.

PEER REVIEWED MANUSCRIPTS

-Chen L-W, Guasp M, Olivé-Cirera G, Martínez-Hernandez E, Ruiz-García R, Naranjo L, Saiz A, Armangue T, **Dalmau J**. Antibody associations in 2750 children with suspected autoimmune encephalitis. *Neurol Neuroimmunol Neuroinflamm*, in press.

-Fonseca E, Cabrera-Maqueda JM, Ruiz-García R, Naranjo L, Diaz-Pedroche C, Velasco R, Macias-Gómez A, Milisenda JC, Muñoz-Farjas E, Pascual-Goñi E, Gallego Perez-Larraya J, Saiz A, **Dalmau J**, Blanco Y, Graus F, Martínez-Hernandez E. Investigations on neurologic adverse events related to immune checkpoint inhibitors. *Lancet Neurol*, in press.

-Ceanga M, Rahmati V, Haselmann H, Schmidl L, Hunter D, Brauer A-K, Liebscher S, Kreye J, Prüss H, Groc L, Hallermann S, **Dalmau J**, Ori A, Heckmann M, Geis C. Human NMDAR 1 autoantibodies disrupt excitatory-inhibitory balance leading to hippocampal network hypersynchrony. *Cell Rep* 2023;42(10):113166.

-Blanco Y, Escudero D, Lleixà C, Llufríu S, Egri N, Ruiz-García R, Alba M, Aguilar E, Artola M, Aldea M, Alvarez S, Caballero E, Cabrera-Maqueda JM, Fonseca E, Guasp M, Hernando A, Martínez-Hernández E, Olivé-Cirera G, López-Contreras J, Martín-Aguilar L, Martínez-Martínez L, Rombauts A, Rodés M, Sabater L, Sepúlveda M, Solana E, Tejada-Illa C, Vidal-Fernández N,

Vilella A, Armangué T, **Dalmau J**, Querol L, Saiz A. mRNA COVID-19 vaccination does not exacerbate symptoms or trigger neural antibody responses in multiple sclerosis: 1-year of clinical and immunological assessments. *Neurol Neuroimmunol Neuroinflamm* 2023;10:e200163.

-Armangué T, Olivé-Cirera G, Martínez-Hernández E, Rodes M, Peris-Sempere V, Guasp M, Ruiz R, Palou E, González A, Ángeles Marcos M, Elena Erro M, Bataller L, Corral-Corral I, Planagumà J, Caballero E, Vlasea A, Alsina L, Fortuny C, Graus F, Saiz A, Mignot E, Vanderver A, Casanovas J-L, Zhang S-Y, **Dalmau J**. Neurological complications in herpes simplex encephalitis: clinical, immunological and genetic studies. *Brain* 2023;146:4306-43198. doi: 10.1093/brain/awad238. PMID: 37453099. (Highlighted publication with an Editorial comment).

-Guasp M, **Dalmau J**. Searching for antibodies in psychiatric diseases: moot findings that lead to frequent consultations. *Neurology* 2023;101:656-660. doi: 10.1212/WNL.0000000000207486.

-Arnaldos-Perez C, Vilaseca A, Naranjo L, Sabater L, **Dalmau J**, Ruiz-Garcia, Graus F. Algorithm to improve the diagnosis of paraneoplastic neurological syndromes associated with SOX1 antibodies. *Frontiers Immunol* 2023;14:1173484. doi: 10.3389/fimmu.2023.1173484. PMID: 37207233.

-Ariño H, Rioseras B, Naranjo L, Martínez-Hernández E, Ruiz-García R, Graus F, **Dalmau J**. Frequency and referral patterns of neural antibody studies during the COVID-19 pandemic: Experience from an autoimmune neurology center. *Neurol Neuroimmunol Neuroinflamm* 2023;10(4):e200129.

-Asseyer S, Asgari N, Bennett J, Bialer O, Blanco Y, Bosello F, Camos-Carreras A, Carnero Contentti E, Carta S, Chen J, Chien C, Chomba M, Dale RC, **Dalmau J**, Feldmann K, Flanagan EP, Froment Tilikete C, Garcia-Alfonso C, Havla J, Hellmann M, Jin Kim H, Klyszcz P, Konietschke F, La Morgia C, Lana-Peixoto M, Isabel Leite M, Levin N, Levy M, Llufríu S, Lopez P, Lotan I, Lugaresi A, Marignier R, Mariotto S, Mollan SP, Ocampo C, Cosima Oertel F, Olszewska M, Palace J, Pandit L, Peralta Uribe JL, Pittock S, Ramanathan S, Rattanathamsakul N, Saiz A, Samadzadeh S, Sanchez-Dalmau B, Saylor D, Scheel M, Schmitz-Hübsch T, Shifa J, Siritho S, Sperber PS, Subramanian PS, Tiosano A, Vaknin-Dembinsky A, Mejia Vergara AJ, Wilf-Yarkoni A, Zarco LA, Zimmermann HG, Paul F, Stiebel-Kalish H. The Acute Optic Neuritis Network (ACON): Study protocol of a non-interventional prospective multicenter study on diagnosis and treatment of acute optic neuritis. *Frontiers Neurol* 2023;14:1102353. doi: 10.3389/fneur.2023.1102353.

-Landa J, Serafim AB, Gaig C, Saiz A, Koneczny I, Hoftberger R, Santamaria J, **Dalmau J**, Graus F, Sabater L. Patients' IgLON5 autoantibodies interfere with IgLON5-protein interactions. *Frontiers Immunol* 2023;14:1151574.

-**Dalmau J**, Graus F. Diagnostic criteria for autoimmune encephalitis: Utility and pitfalls for antibody-negative disease. *Lancet Neurol* 2023;22(6):529-540. doi: 10.1016/S1474-4422(23)00083-2. (Highlighted publication with an Editorial comment).

-Galardi MM, Sowa GM, Crockett CD, Robert R, Smith A, Shwe E.E, San T, Linn K, Aye M, Ramachandran PS, Zia M, Hawes IA, Hlaing CS, Kyu EH, Thair C, Mar YY, Nway N, Storch GA, Wylie KM, Wylie TN, **Dalmau J**, Wilson MR, Mar SS. Pathogen and antibody identification in

children with encephalitis in Myanmar. *Ann Neurol* 2023;93:615-628. doi: 10.1002/ana.26560.

-**Dalmau J**, Graus F. Autoimmune encephalitis: misdiagnoses, misconceptions and how to avoid them. *JAMA Neurol* 2023;80:12-14.

-Muñoz-Sánchez G, Planagumà J, Naranjo L, Couso RS, Sabater L, Guasp M, Martínez-Hernández E, Graus F, **Dalmau J**, Ruíz-García R. The diagnosis of anti-LGI1 encephalitis varies with the type of immunodetection assay and sample examined. *Front Immunol* 2022;13:1069368. doi: 10.3389/fimmu.2022.1069368.

-Guasp M, Rosa-Justicia M, Muñoz-Lopetegui A, Martínez-Hernández E, Armangué T, Sugranyes G, Borràs R, Prades L, Ariño H, Llufríu S, Stein H, Planagumà J, de la Serna E, Escudero D, Sánchez-Valle R, Santamaria J, Compte A, Castro-Fornieles J, **Dalmau J**. Clinical characterization of patients in the post-acute stage of anti-NMDA receptor encephalitis: a prospective observational cohort study and comparison with patients with schizophrenia spectrum disorders. *Lancet Neurol* 2022;21:899-910. (Highlighted publication with: Editorial comment in *Lancet Neurol*; and Spotlight comment in *Trends Mol Med*).

-Gövert F, Becktepe J, Balint B, Ganos C, Hofstadt-van Oy U, Krogias C, Varley J, Irani SR, Titulaer MJ, de Vries JM, Boon AJW, Schreurs MWJ, Joubert B, Honnorat J, Vogrig A, Ariño H, **Dalmau J**, Scotton S, Jacob S, Melzer N, Bien C, Geis C, Lewerenz J, Prüb H, Wandinger K-P, Deuschl G, Leypoldt F on behalf of the GENERATE Investigators. Distinct movement disorders in contactin-associated-protein-like-2 antibody associated autoimmune encephalitis: An international, retrospective, comparative cohort study. *Brain* 2023;146:657-667. doi: 10.1093/brain/awac276.

-Maudes E, Mannara F, García-Serra A, Radosevic M, Mellado A, Serafim AB, Planagumà J, Sabater L, **Dalmau J**, Spatola M. Human metabotropic glutamate receptor 5 antibodies alter receptor levels and behavior in mice. *Ann Neurol* 2022;92:81-86.

-Mandel-Brehm C, Benson L, Tran B, Kung A, Mann S, Vazquez S, Retallack H, Sample H, Zorn K, Khan L, Kerr L, McAlpine P, Zhang L, McCarthy F, Elias J, Katwa U, Astley C, Tomko S, **Dalmau J**, Seeley W, Pleasure S, Wilson M, Gorman M, DeRisi J. Autoimmune profiling suggests paraneoplastic etiology in pediatric ROHHAD. *Ann Neurol* 2022;92:279-291.

-Joubert B, Petit-Pedrol M, Planagumà J, Mannara F, Radosevic M, Marsal M, Maudes E, García-Serra A, Aguilar E, Andrés-Bilbé A, Gasull X, Loza-Alvarez P, Sabater L, Rosenfeld MR, **Dalmau J**. Human CASPR2 antibodies reversibly alter memory and the CASPR2 protein complex. *Ann Neurol* 2022;91:801-813.

-Guasp M, Martín-Aguilar L, Sabater L, Bioque M, Armangué T, Martínez-Hernández E, Landa J, Maudes E, Borràs R, Muñoz-Lopetegui A, Saiz A, Castro-Fornieles J, Graus F, Parellada E, Querol L, **Dalmau J**. Neurofilament light chain levels in anti-NMDAR encephalitis and primary psychiatric psychosis. *Neurology* 2022;98:e1489-e1498

-**Dalmau J**, Graus F. Antibody-mediated neuropsychiatric disorders. *J Allergy Clin Immunol* 2022;149:37-40.

-Radosevic M, Planagumà J, Mannara F, Mellado A, Aguilar E, Sabater L, Landa J, García-Serra A,

Maudes E, Gasull X, Lewis M, **Dalmau J**. Allosteric modulation of NMDARs reverses patients' autoantibody effects in mice. *Neurol Neuroimmunol Neuroinflamm* 2021;13;9:e1122.

-Hirose S, Hara M, Kamei S, **Dalmau J**, Nakajima H. Characteristics of clinical relapses and patient-oriented long-term outcomes of patients with anti-N-methyl-d-aspartate receptor encephalitis. *J Neurol* 2022;269:2486-2492.

-Zrzavy T, Endmayr V, Bauer J, Macher S, Mossaheb N, Schwaiger C, Ricken G, Winklehner M, Glatter S, Breu M, Wimmer I, Kovacs GG, Risser DU, Klupp N, Simonitsch-Klupp I, Rötzer T, Rommer P, Berger T, Gelpi E, Lassmann H, Graus F, **Dalmau J**, Höftberger R. Neuropathological variability within a spectrum of NMDAR-encephalitis. *Ann Neurol* 2021;90:725-737.

-Nosadini M, Eyre M, Molteni E, Thomas T, Irani SH, **Dalmau J**, Dale RC, Ming L, Lim M; International NMDAR Antibody Encephalitis Consensus Group, Anlar B, Armangue T, Benseler S, Cellucci T, Deiva K, Gallentine W, Gombolay G, Gorman MP, Hacoheh Y, Jiang Y, Lim BC, Muscal E, Ndong A, Neuteboom R, Rostásy K, Sakuma H, Sartori S, Sharma S, Tenenbaum SN, Van Mater HA, Wells E, Wickstrom R, Yeshokumar AK. Use and safety of immunotherapeutic management of N-methyl-d-aspartate receptor antibody encephalitis: A meta-analysis. *JAMA Neurol* 2021;78:1333-1344.

-Gaig C, Compta Y, Heidebreder A, Martí MJ, Titulaer MJ, Crijnen YS, Högl B, Lewerenz J, Erro ME, García-Moncó JC, Nigro P, Tambasco N, Patalong-Ogiewa M, Erdler M, Macher S, Berger-Sieckowski E, Höftberger R, Geis C, Hutterer M, Milán-Tomás A, Martín-Bastida A, Lopez L, Quintas S, Höglinger GU, Möhn N, Schöberl F, Thaler F, Asioli GM, Provini F, Plazzi G, Berganzo K, Blaabjerg M, Brüggemann N, Farias T, Ng CF, Giordana C, Herrero-San Martín A, Huebra L, Kotschet K, Liendl H, Montojo T, Morata C, Pérez-Pérez MJ, Puertas I, Seifert-Held T, Seitz C, Simabukuro M, Téllez N, Villaciers-Álvarez J, Willekens B, Sabater L, Iranzo A, Santamaría J, **Dalmau J**, Graus F. Frequency and characterization of movement disorders in anti-IgLON5 disease. *Neurology* 2021;97:e1367-e1381.

-García-Serra A, Radosevic M, Ríos J, Aguilar E, Maudes E, Landa J, Sabater L, Martínez-Hernández E, Planagumà J, **Dalmau J**. Blocking placental class G immunoglobulin transfer prevents NMDAR antibody effects in newborn mice. *Neurol Neuroimmunol Neuroinflamm* 2021;8(6):e1061.

-Beghi E, Michael BD, Solomon T, Westenberg E, Winkler AS on behalf of the global COVID-19 Neuro Research Coalition.* Approaches to understanding COVID-19 and its neurological associations. *Ann Neurol* 2021;89:1059-1067. (**J Dalmau*** coalition member)

-Nosadini M, Thomas T, Eyre M, Anlar B, Armangue T, Benseler SM, Cellucci T, Deiva K, Gallentine W, Gombolay G, Gorman MP, Hacoheh Y, Jiang Y, Lim BC, Muscal E, Ndong A, Neuteboom R, Rostasy K, Sakuma H, Sharma S, Tenenbaum SN, Van Mater HA, Wells E, Wickstrom R, Yeshokumar AK, Irani SR, **Dalmau J**, Lim M, Dale RC. International consensus recommendations for the treatment of paediatric NMDAR-antibody encephalitis. *Neurol Neuroimmunol Neuroinflamm* 2021; 8(5):e1052.

-Guasp M, Landa J, Martínez-Hernández, E, Sabater L, Iizuka T, Simabukuro M, Nakamura M, Kinoshita M, Kurihara M, Kaida K, Bruna J, Kapetanovic S, Sánchez P, Ruiz-García R, Naranjo L,

Planagumà J, Muñoz A, Bataller L, Saiz A, **Dalmau J**,* Graus F.* Thymoma and autoimmune encephalitis: clinical manifestations and antibodies. *Neurol Neuroimmunol Neuroinflamm* 2021;8(5):e1053. (*co-corresponding authors)

-Ruiz-García R, Muñoz-Sánchez G, Naranjo L, Guasp M, Sabater L, Saiz A, **Dalmau J**, Graus F, Martínez-Hernández E. Limitations of commercial assays as diagnostic tests of autoimmune encephalitis. *Front Immunol* 2021;12:691536.

-Graus F, **Dalmau J**. Autoimmune encephalitis or autoimmune psychosis? *Eur Neuropsychopharmacol* 2021;50:112-114.

-Graus F, Vogrig A, Muñoz-Castrillo S, Antoine JC, Desestret V, Dubey D, Giometto B, Irani S, Joubert B, Leypoldt F, McKeon A, Prüss H, Psimaras D, Thomas L, Titulaer MJ, Vedeler CA, Verschuuren J, **Dalmau J**, Honnorat J. Updated diagnostic criteria for paraneoplastic neurological syndromes. *Neurol Neuroimmunol Neuroinflamm* 2021;8(4):e1014.

-Guasp M, Giné-Servén E, Maudes E, Rosa-Justicia M, Martínez-Hernandez E, Boix-Quintana E, Bioque M, Casado V, Módena-Ouarzi Y, Guanyabens N, Muriana D, Sugranyes G, Pacchiarotti I, Davi-Loscós E, Torres-Rivas C, Ríos J, Sabater L, Saiz A, Graus F, Castro-Fornieles J, Parellada E, **Dalmau J**. Clinical, neuroimmunologic, and CSF investigations in first episode psychosis. *Neurology* 2021;97(1):e61-e75. (Highlighted publication with Editorial comment and PodCast).

-Balint B, Bathia KP, **Dalmau J**. Antibody of unknown significance (AUS) – the issue of interpreting antibody test results. *Mov Disord* 2021;36(7):1543-1547.

-Landa J, Guasp M, Míguez-Cabello F, Guimarães J, Mishima T, Iizuka I, Oda F, Zipp F, Krajcinovic V, Fuhr P, Maudes E, García-Serra A, Honnorat J, Titulaer M, Simabukuro M, Planagumà J, Ruiz-García R, Martínez-Hernández E, Armangué T, Muñoz-Lopetegi A, Saiz A, Gasull X, Soto D, Graus F, Sabater L, **Dalmau J**. Encephalitis with autoantibodies against the glutamate kainate receptors GluK2. *Ann Neurol* 2021;90(1):101-117.

-Petit-Pedrol M, Guasp M, Armangué T, Lavarino C, Morales La Madrid A, Saiz A, Graus F, **Dalmau J**. Absence of GluD2 antibodies in patients with opsoclonus-myoclonus syndrome. *Neurology* 2021;96(7):e1082-e1087.

-Delmotte K, Claeys T, Poesen K, Dubois B, Schrooten M, **Dalmau J**, Lemmens R. Horizontal saccadic palsy as a prominent symptom of anti-NMDA receptor encephalitis. *Neurol Clin Pract* 2021;11(1):e20-e21.

-García-Serra A, Radosevic M, Pupak A, Brito V, Ríos J, Aguilar E, Maudes E, Ariño H, Spatola M, Mannara F, Pedreño M, Joubert B, Planagumà J, **Dalmau J**. Placental transfer of NMDAR encephalitis antibodies causes reversible synaptic and behavioral alterations in mice. *Neurol Neuroimmunol Neuroinflamm* 2020;8:e915.

-Landa J, Guasp M, Petit-Pedrol M, Martínez-Hernández E, Planagumà J, Saiz A, Ruiz-García R, García-Fernández L, Verschuuren J, Saunders-Pullman R, Ramirez-Gomez L, Geschwind MD, **Dalmau J**, Sabater L, Graus F. Seizure-related 6 homolog like 2 (SEZ6L2) autoimmunity: Neurologic syndrome and antibody effects. *Neurol Neuroimmunol Neuroinflamm* 2020;8:e916.

- Marin-Campos R, **Dalmau J**, Compte A, Linares D. StimuliApp: psychophysical tests on mobile devices. *Behav Res Methods* 2021; 53(3):1301-1307.
- Muñoz-Lopetegi, Graus F, **Dalmau J***, Santamaria J. Sleep disorders in antibody associated diseases of the central nervous system. *Lancet Neurol* 2020;19:1010-22. (*Corresponding author)
- Linares D, Amoretti S, Marin-Campos R, Sousa A, Prades L, **Dalmau J**, Bernardo M, Compte A. Spatial suppression and sensitivity for motion in schizophrenia. *Schizophrenia Bull Open* 2020; 1(1):sgaa045.
- Spatola M, Petit-Pedrol M, Maudes E, Simabukuro M, Muñoz-Castrillo S, Pinto A-L, Wandinger K-P, Spiegler J, Schramm P, Almeida-Dutra L, Iorio R, Kornblum C, Hoftberger R, Leypoldt F, Titulaer MJ, Sillevs-Smith P, Honnorat J, Rosenfeld MR, Graus F, **Dalmau J**. Clinical features, prognostic factors, and antibody effects in anti-mGluR1 encephalitis. *Neurology* 2020;95:e3012-e3025.
- Landa J, Gaig C, Planagumà J, Saiz A, Antonell A, Sanchez-Valle R, **Dalmau J**, Graus F, Sabater L. Effects of IgLON5 antibodies on neuronal cytoskeleton: a link between autoimmunity and neurodegeneration. *Ann Neurol* 2020;88:1023-1027.
- Stein H, Barbosa J, Rosa-Justicia M, Prades L, Morató A, Galan-Gadea A, Ariño H, Martinez-Hernandez E, Castro-Fornieles J, **Dalmau J**, Compte A. Reduced serial dependence suggests deficits in synaptic potentiation in anti-NMDAR encephalitis and schizophrenia. *Nat Commun.* 2020;11(1):4250.
- Ruiz-García R, Martínez-Hernández E, Saiz A, **Dalmau J**, Graus F. The diagnostic value of onconeural antibodies depends on how they are tested. *Front Immunol* 2020;11:1482.
- Mannara F, Radosevic M, Planagumà J, Soto D, Aguilar E, García-Serra A, Maudes E, Pedreño M, Paul S, Doherty J, Quirk M, Dai J, Gasull X, Lewis M, **Dalmau J**. Allosteric modulation of NMDA receptors prevents the antibody effects of patients with anti-NMDA receptor encephalitis. *Brain* 2020;143:2709-2720. (Highlighted publication with: journal cover, video-abstract, and “Editor’s choice” manuscript, September 2020).
- Carceles-Cordon M, Mannara F, Aguilar E, Castellanos A, Planagumà J, **Dalmau J**. NMDA receptor antibodies alter dopamine receptors and cause psychotic behavior in mice. *Ann Neurol* 2020;88:603-613.
- Barbosa J, Stein H1, Martinez R, Galan A, Li S, **Dalmau J**, Adam K, Valls-Solé J, Constantinidis C, Compte A. Interplay between persistent activity and activity-silent dynamics in prefrontal cortex underlies serial biases in working memory. *Nat Neurosci* 2020;23(8):1016-1024.
- Ariño H, Muñoz-Lopetegi A, Martinez-Hernandez E, Armangue T, Rosa M, Escudero D, Matos N, Graus F, Sugranyes G, Castro F, Compte A, **Dalmau J**, Santamaria J. Sleep disorders in anti-NMDAR encephalitis. *Neurology* 2020;95(6):e671-e684.
- Morales L, Tomas DP, **Dalmau J**, de la Rocha J, Jercog P. High-throughput task to study memory recall during spatial navigation in rodents. *Front Behav Neurosci* 2020;14:64.

-Graus F, Saiz A, **Dalmau J**. GAD antibodies in neurological disorders – insights and challenges. *Nat Rev Neurol* 2020;16(7):353-365.

-Martinez-Hernandez E, Guasp M, García-Serra A, Maudes E, Ariño H, Sepulveda M, Armangué T, Saiz A, Graus F, **Dalmau J**. Clinical significance of anti-NMDAR concurrent with glial or neuronal surface antibodies. *Neurology* 2020;94:e2303-2310. (Highlighted by *In Focus, Neurology*).

-Matute C, Palma A, Serrano-Regal MP, Maudes E, Barman S, Sánchez-Gómez MV, Domercq M, Goebels N, **Dalmau J**. N-methyl-D-aspartate receptor antibodies in autoimmune encephalopathy alter oligodendrocyte function. *Ann Neurol* 2020;87:670-676.

-Armangué T, Olivé-Cirera G, Martínez-Hernandez E, Sepulveda M, González-Álvarez V, Ruiz R, Muñoz M, Ariño H, Felipe A, Martínez-González MJ, Cantarín V, Miranda Herrera MC, Monje L, Tomas M, Miravet E, Arrambide G, Auger C, Tintore M, Vanderver A, Graus F, Saiz A, **Dalmau J**. Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study. *Lancet Neurol* 2020;19:234-246. (Highlighted publication with an Editorial comment and Press Release).

-Maudes E, Landa J, Muñoz-Lopetegui A, Armangué T, Alba M, Saiz A, Graus F, **Dalmau J**, Sabater L. Clinical significance of Kelch-like protein 11 antibodies. *Neurol Neuroimmunol Neuroinflamm* 2020;7:e666.

-Joubert B, Garcia A, Planagumà J, Martínez-Hernandez E, Kraft A, Iizuka T, Honnorat J, Leypoldt F, Graus F, **Dalmau J**. Pregnancy outcomes in anti-NMDA receptor encephalitis: Case series. *Neurol Neuroimmunol Neuroinflamm* 2020;7:e668.

-Guasp M, Módena-Ouarzi Y-E, Armangué T, **Dalmau J**, Graus F. Clinical significance of seronegative, but CSF antibody positive, anti-NMDA receptor encephalitis. *Neurol Neuroimmunol Neuroinflamm* 2020; 7(2):e659 (Highlighted publication with Podcast in journal, Neurology).

-Cellucci T, Van Mater H, Graus F, Muscal E, Gallentine W, S. Klein-Gitelman M, Benseler SM, Frankovich J, Gorman M, Van Haren K, **Dalmau J**, Dale RC. Clinical approach to the diagnosis of autoimmune encephalitis in the pediatric patient. *Neurol Neuroimmunol Neuroinflamm* 2020;7:e663.

-Ruiz-García R, Martínez-Hernández E, Joubert B, Petit-Pedrol M, Pajarón-Boix E, Fernández V, Salais L, del Pozo M, Armangué T, Sabater L, **Dalmau J**, Graus F. Paraneoplastic cerebellar ataxia and antibodies to metabotropic glutamate receptor 2. *Neurol Neuroimmunol Neuroinflamm* 2020;7:e658.

-Mattozzi S, Escudero D, Sabater L, Ariño H, Armangué T, Simambukuru M, Iizuka T, Hara M, Saiz A, Sotgiu S, **Dalmau J**, Graus F. Hashimoto encephalopathy in the XXI century. *Neurology* 2020;94:e217-e224. (highlight ed with Editorial Comment and Podcast).

-Giné-Servén E, Boix-Quintana E, Guanyabens-Buscà N, Casado-Ruiz V, Torres-Rivas C, Niubo-Gurgui M, **Dalmau J**, Palma-Sevillano C. Considerations of psychotic symptomatology in anti-NMDA encephalitis: similarity to cycloid psychosis. *Clin Case Rep* 2019;7:2456-2461.

-Sola-Valls N, Ariño H, Escudero D, Solana E, Lladó A, Sánchez-Valle R, Blanco Y, Saiz A, **Dalmau J**, Graus F. Telemedicine-based approach for assessing long-term cognitive and functional status in anti-LGI1 encephalitis. *Neurol Neuroimmunol Neuroinflamm* 2019;7:e652.

-Armangué T, Baucells BJ, Vlasea A, Petit-Pedrol M, Esteve-Solé A, Deyà-Martínez A, Ruiz-García R, Pérez de Diego R, **Dalmau J**, Alsina L. Toll-like receptor 3 deficiency in autoimmune encephalitis post-herpes simplex encephalitis. *Neurol Neuroimmunol Neuroinflamm* 2019;6:e611.

-Sepulveda M, Delgado-García G, Blanco Y, Sola-Valls N, Martinez-Lapiscina EH, Montejo C, Pulido-Valdeolivas I, Martinez-Hernandez E, Ariño H, Escudero D, Ruiz R, Llufríu S, **Dalmau J**, Graus F, Saiz A. Late-onset neuromyelitis optica spectrum disorder: the importance of autoantibody serostatus. *Neurol Neuroimmunol Neuroinflamm*. 2019;6:e607.

-Joubert B, **Dalmau J**. The role of infections in autoimmune encephalitides. *Rev Neurol (Paris)* 2019;175:420-426.

-**Dalmau J**, Armangué T, Planagumà J, Radosevic M, Mannara F, Leypoldt F, Geis C, Lancaster E, Titulaer MJ, Rosenfeld MR, Graus F. An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: Mechanisms and models. *Lancet Neurol* 2019;18(11):1045-1057.

-Carrera-García L, Natera-de Benito D, Lleixà C, Ortez C, Colomer J, Nascimento A, Saiz A, **Dalmau J**, Querol L, Armangué T. Chronic inflammatory demyelinating polyneuropathy associated with Contactin-1 antibodies in a child. *Neurol Neuroimmunol Neuroinflamm*. 2019;6:e602.

-Gaig C, Ercilla G, Daura X, Ezquerra M, Fernández-Santiago R, Palou E, Sabater L, Höftberger R, Heidebreder A, Högl B, Iranzo A, Santamaría J, **Dalmau J**, Graus F. Human leukocyte antigen and microtubule-associated protein tau H1 haplotype associations in anti-IgLON5 disease. *Neurol Neuroimmunol Neuroinflamm*. 2019;6:e605.

-Bien CI, Nehls F, Woermann F, **Dalmau J**, Bien CG. Identification of adenylate kinase 5 antibodies during routine diagnostics in a tissue-based assay: three new cases and a review of the literature. *J Neuroimmunol* 2019;334:576975.

-Gaig C, Iranzo A, Cajochen C, Vilaseca I, Embic C, **Dalmau J**, Graus F, Santamaria J. Characterization of the sleep disorder of anti-IgLON5 disease. *Sleep* 2019;42(9):zsz133.

-Ruiz-García R, Martínez-Hernández E, García-Ormaechea M, Español-Rego M, Sabater L, Querol L, Illa I, **Dalmau J**, Graus F. Caveats and pitfalls of SOX1 autoantibody testing with a commercial line blot assay in paraneoplastic neurological investigations. *Front Immunol* 2019;10:769.

-Freitas ME, Ruiz-Lopez M, **Dalmau J**, Erro R, Privitera M, Andrade D, Fasano A. Seizures and movement disorders: phenomenology, diagnostic challenges and therapeutic approaches. *J Neurol Neurosurg Psychiatry* 2019;90:920-928.

-Graus F, **Dalmau J**. Paraneoplastic neurological syndromes in the era of immune checkpoint inhibitors. *Nat Rev Clin Oncol* 2019;16:535-548.

-Geis C, Planaguma J, Carreño M, Graus F, **Dalmau J**. Autoimmune seizures and epilepsy. *J Clin Invest* 2019;129:926-940.

-Pedreño M, Sepúlveda M, Armangue T, Sabater L, Martínez-Hernández E, Arrambide G, Blanco Y, Llufríu S, Martínez-Lapiscina E, Mulero P, Sola-Valls N, Ruiz-García R, Tintore M, **Dalmau J**, Graus F, Saiz A. Frequency and relevance of IgM, and IgA antibodies against MOG in MOG-IgG-associated disease. *Mult Scler Relat Disord* 2019;28:230-234.

-Linnoila J, Pulli B, Armangue T, Planaguma J, Narsimhan R, Schob S, Zeller MWG, **Dalmau J**, Chen J. Mouse model of anti-NMDA receptor post-herpes simplex encephalitis. *Neurol Neuroimmunol Neuroinflamm* 2018;26:6:e529.

-Linares D, Marin-Campos R, **Dalmau J**, Compte A. Validation of motion perception of briefly displayed images using a tablet. *Sci Rep* 2018;8:16056.

-Bocos-Portillo J, Sánchez-Menoyo JL, Beldarrain MG, Saralegui Prieto I, Ontañón Garcés JM, **Dalmau J**, García-Moncó JC. Acute disseminated encephalomyelitis: a rare autoimmune complication of herpes simplex encephalitis in the adult. *Clin Neurol Neurosurg* 2018;175:47-49.

-Balu R, McCracken L, Lancaster E, Graus F, **Dalmau J***, Titulaer MJ. A score that predicts 1-year functional status in patients with anti-NMDA receptor encephalitis. (*Corresponding author) *Neurology* 2019;92(3):e244-e252. (Highlighted publication with an Editorial comment and Podcast).

-Petit-Pedrol M, Sell J, Planagumà J, Mannara F, Radosevic M, Haselmann H, Ceanga M, Sabater L, Spatola M, Soto D, Gasull X, **Dalmau J***, Geis C. LGI1 antibodies alter Kv1.1 and AMPA receptors changing synaptic excitability, plasticity, and memory. *Brain* 2018;141:3144-3159. (Highlighted publication with an Editorial comment, and Front Cover), (*Corresponding author)

-Haselmann H, Mannara F, Werner C, Planagumà J, Miguez-Cabello F, Schmidl L, Grünwald B, Petit-Pedrol M, Kirmse K, Classen J, Demir F, Klöcker N, Soto D, Doose S, **Dalmau J**, Hallermann S, Geis C. Human autoantibodies against the AMPA receptor subunit GluA2 induce receptor reorganization and memory dysfunction. *Neuron* 2018;100:91-105.

-Armangue T, Spatola M, Vlasea A, Mattozzi S, Cárceles-Cordon M, Martínez-Heras E, Llufríu S, Muchart J, Erro ME, Abaira L, Moris G, Monros-Giménez L, Corral-Corral I, Montejo C, Toledo M, Bataller L, Secondi G, Ariño H, Martínez-Hernández E, Juan M, Marcos MA, Alsina L, Saiz A, Rosenfeld MR, Graus F, **Dalmau J**. Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis. *Lancet Neurol* 2018;17:760-772 (Highlighted with Front Cover, Editor's choice publication, Editorial comment, Podcast, and recommended by F1000).

-Wells E, Hacohen Y, Waldman A, Tillema JM, Soldatos A, Ances B, Benseler S, Bielekova B, Dale RC, **Dalmau J**, Gaillard W, Gorman M, Greenberg B, Hyslop A, Pardo CA, Tasker RC, Yeh EA, Bar-Or A, Pittock S, Vanderver A, Banwell B. attendees of the International Neuroimmune meeting. Neuroimmune disorders of the central nervous system in children in the molecular era. *Nat Rev Neurol* 2018;14:433-445.

-Guasp M, Arino H, **Dalmau J**. Autoimmune encephalitis. *Rev Neurol* 2018;66:S1-S6.

-Ladépêche L, Planagumà J, Thakur S, Suárez I, Hara M, Borbely J, Sandoval A, Laparra-Cuervo L, **Dalmau J**, Lakadamyali M. Anti-NMDA receptor encephalitis antibodies lead to a subunit specific nanoscale redistribution of NMDA receptors. *Cell Reports* 2018;23:3759–3768. (Highlighted with Front Cover).

-Graus F, Escudero D, Oleaga L, Bruna J, Villarejo-Galende A, Ballabriga J, Barceló MI, Gilo F, Popkirov S, Stourac P, **Dalmau J**. Syndrome and outcome of antibody-negative limbic encephalitis. *Europ J Neurol* 2018;25:1011-1016.

-Spatola M, Sabater L, Planagumà J, Martínez-Hernandez E, Armangue T, Prüss H, Iizuka T, Caparó Oblitas RL, Antoine J-C, Li R, Heaney N, Tubridy N, Munteis Olivás E, Rosenfeld MRR, Graus F, **Dalmau J**. Encephalitis with mGluR5 antibodies: Symptoms and antibody effects. *Neurology* 2018;90(22):e1964-e1972.

-Hara M, Martínez-Hernandez E, Ariño H, Armangué T, Spatola M, Petit-Pedrol M, Saiz A, Rosenfeld MRR, Graus F, **Dalmau J**. Clinical and pathogenic significance of IgG, IgA, and IgM antibodies against the NMDA receptor. *Neurology* 2018;90:e1386-1394.

-**Dalmau J**, Graus F. Antibody-mediated encephalitis. *N Engl J Med* 2018;378:840-851.

-Patterson KR, **Dalmau J**, Lancaster E. Mechanisms of Caspr2 antibodies in autoimmune encephalitis and neuromyotonia. *Ann Neurol* 2018;83:40-51.

-Guasp M, **Dalmau J**. Encefalitis por anticuerpos contra el receptor NMDA. *Med Clin (Barc)* 2018;151:71-79.

-Sepúlveda M, Solà N, Escudero D, Rojc B, Barón M, Hernández-Echebarría L, Gómez B, **Dalmau J**, Saiz A, Graus F. Clinical profile of patients with paraneoplastic neuromyelitis optica spectrum disorder and aquaporin-4 antibodies. *Mult Scler* 2018;24:1753-1759.

-Jézéquel J, Johansson EM, Dupuis JP, Rogemond V, Gréa H, Kellermayer B, Hamdani N, Le Guen E, Rabu C, Lepleux M, Spatola M, Mathias E, Bouchet D, Ramsey AJ, Yolken RH, Tamouza R, **Dalmau J**, Honnorat J, Leboyer M, Groc L. Dynamic disorganization of synaptic NMDA receptors triggered by autoantibodies from psychotic patients. *Nat Commun* 2017;8:1791.

-Malviya M, Barman S, Golombeck KS, Planagumà J, Mannara F, Strutz-Seebohm N, Wroz C, Demir F, Baksmeier C, Steckel J, Kristin Falk K, Gross CC, Kovac S, Bönke K, Johnen A, Wandinger KP, Martín-García E, Becker AJ, Elger CE, Klöcker N, Wiendl H, Meuth SG, Hartung HP, Seebohm G, Leypoldt F, Maldonado R, Stadelmann-Nessler C, **Dalmau J**, Melzer N, Goebels N. NMDAR encephalitis: passive transfer from man to mouse by a recombinant antibody. *Ann Clin Transl Neurol* 2017;4:768-783.

-Escudero D, Guasp M, Ariño H, Gaig C, Martínez-Hernandez E, **Dalmau J**, Graus F. Antibody-associated CNS syndromes without signs of inflammation in the elderly. *Neurology* 2017;89:1471-1475.

-Van Sonderen A, Petit-Pedrol M, **Dalmau J**, Titulaer MJ. The value of LGI1, Caspr2, and voltage-gated potassium channel antibodies in encephalitis. *Nat Rev Neurol* 2017;13:290-301.

-**Dalmau J**, Geis C, Graus F. Autoantibodies to synaptic receptors and neuronal cell-surface proteins in autoimmune diseases of the central nervous system. *Physiol Rev* 2017;97: 839–887.

-Gaig C, Graus F, Compte Y, Högl B, Bataller L, Brüggemann N, Giordana C, Heidebreder A, Kotschet K, Lewerenz J, Macher S, Martí MJ, Montojo T, Pérez J, Puertas I, Seitz C, Simabukuro M, Téllez N, Wandinger K-P, Iranzo A, Ercilla G, Sabater L, Santamaría J, **Dalmau J**. Clinical manifestations of the anti-IgLON5 syndrome. *Neurology* 2017;88:1736-1743. (Highlighted with Editorial Comment and Front Cover)

-Torres-Vega E, Mancheño N, Cebrián-Silla A, Herránz-Pérez A, Chumillas MJ, Morís G, Joubert B, Honnorat J, Sevilla T, Vilchez J, **Dalmau J**, Graus F, Garcia Verdugo JM, Bataller L. Netrin1-receptor antibodies in thymoma-associated neuromyotonia with myasthenia gravis. *Neurology* 2017;88:1235-1242.

-Spatola M, **Dalmau J**. Seizures and risk of epilepsy in autoimmune and other inflammatory encephalitis. *Curr Opin Neurol* 2017;30:345-353.

-Hara M, Ariño H, Petit-Pedrol M, Sabater L, Titulaer MJ, Martinez-Hernandez E, WJ Schreurs M, Rosenfeld MR, Graus F, **Dalmau J**. DPPX-antibody associated encephalitis: main syndrome and antibody effects. *Neurology* 2017;88:1340-1348. (Highlighted with Front Cover)

-Spatola M, Petit-Pedrol M, Simabukuro MM, Armangué T, Castro FJ, Barcelo-Artigues MI, Julià Benique MR, Benson L, Gorman M, Felipe A, Caparó-Oblitas R, Rosenfeld MR, Graus F, **Dalmau J**. Investigations in GABA_A receptor antibody-associated encephalitis. *Neurology* 2017;88:1012-1020. (Highlighted with Editorial Comment)

-Carreño M, Bien C, Asadi-Pooya AA, Sperling M, Marusic P, Elisak M, Pimentel J, Wehner T, Mohanraj R, Uranga J, Gómez-Ibáñez A, Villanueva V, Gil F, Donaire A, Bargalló N, Rumià J, Roldán P, Setoain X, Pintor L, Boget T, Bailles E, Falip M, Aparicio J, **Dalmau J**, Graus F. Epilepsy surgery in drug resistant temporal lobe epilepsy associated with neuronal antibodies. *Epilepsy Res* 2017;129:101-105.

-**Dalmau J**. NMDA receptor encephalitis and other antibody-mediated disorders of the synapse. The 2016 Cotzias Lecture. *Neurology* 2016;87:2471-2482. (Front Cover)

-Guasp M, Solà-Valls N, Martínez-Hernández E, Gil MP, González C, Brieva L, Saiz A, **Dalmau J**, Graus F, Ariño H. Cerebellar ataxia and autoantibodies restricted to glutamic acid decarboxylase 67 (GAD67). *J Neuroimmunol* 2016;300:15-17.

-Sabater L, Planagumà J, **Dalmau J**, Graus F. Cellular investigations with human antibodies associated with the anti-IgLON5 syndrome. *J Neuroinflamm* 2016 Sep 1;13(1):226.

-Erazo R, González J, Quintanilla C, Devaud C, Gayoso C, Toledo X, Rauch E, Riffo C, Alvarez C, Salazar M, Salvo D, **Dalmau J**, Carmona O. Subacute anti-N-methyl-D-aspartate receptor encephalitis. A series of 13 pediatric cases. *Rev Chil Pediatr* 2016;87:487-493.

-Planagumà J, Haselmann H, Mannara F, Petit-Pedrol M, Grünwald B, Aguilar E, Röpke L, Martín-García E, Titulaer MJ, Jercog P, Graus F, Maldonado R, Geis C, **Dalmau J**. Ephrin-B2

prevents NMDA receptor antibody effects on memory and neuroplasticity. *Ann Neurol* 2016;80:388-400.

-Gelpi E, Höftberger R, Graus F, Ling H, Holton JL, Dawson T, Popovic M, Pretnar-Oblak J, Högl B, Schmutzhard E, Poewe W, Ricken G, Santamaria J, **Dalmau J**, Budka H, Revesz T, Kovacs GG. Neuropathological criteria of anti-IgLON5-related tauopathy. *Acta Neuropathol* 2016;132:531-543. (Front Cover)

-Maccaferri GE, Rossetti AO, **Dalmau J**, Berney A. Anti-N-Methyl-D-aspartate receptor encephalitis: a new challenging entity for consultation-liaison psychiatrist. *Brain Disord Therapy* 2016 May;5(2). pii: 215.

-Torres-Vega E, Durán-Moreno M, Sánchez del Pino M, Yáñez Y, Cañete A, Castel V, López-Cuevas R, Vílchez JJ, **Dalmau J**, Graus F, GarcíaVerdugo JM, Bataller L. Immunoproteomic studies on paediatric opsoclonus-myoclonus associated with neuroblastoma. *J Neuroimmunol* 2016;297:98-102.

-Ariño H, Armangué T, Petit-Pedrol M, Sabater L, Martínez-Hernandez E, Hara M, Lancaster E, Saiz A, **Dalmau J**, Graus F. Anti-LGI1-associated cognitive impairment: Presentation and long-term outcome. *Neurology* 2016;87:759-65. (Highlighted with a Neurology Podcast and Front Cover)

-Sepúlveda M, Armangué T, Martínez-Hernandez E, Arrambide G, Sola-Valls N, Sabater L, Téllez N, Midaglia L, Ariño H, Peschl P, Reindl M, Rovira A, Montalban X, Blanco Y, **Dalmau J**, Graus F, Saiz A. Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes. *J Neurol* 2016;263:1349-1360.

-van Sonderen A, Ariño H, Petit-Pedrol M, Leypoldt F, Körtvelyessy P, Lancaster E, Wirtz PW, Schreurs MWJ, Sillevs-Smitt PAE, Graus F, **Dalmau J**, Titulaer MJ. The clinical spectrum of Caspr2-antibody associated disease. *Neurology* 2016;87:521-528. (Highlighted with Neurology Podcast and Front Cover)

-Williams TJ, Benavides DR, Patrice K-A, **Dalmau J**, de Avila AL, Le DT, Lipson EJ, Probasco JC, Mowry EM. Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. *JAMA Neurol* 2016;73:928-933. (Highlighted publication with an Editorial Comment)

-Gresa-Arribas N, Planagumà J, Petit-Pedrol M, Kawachi I, Katada S, Glaser CA, Simabukuro MM, Armangué T, Martínez-Hernandez E, Graus F, **Dalmau J**. Human neurexin-3alpha antibodies associate with encephalitis and alter synapse development. *Neurology* 2016;86:1-8. (Highlighted with Editorial Comment and Front Cover)

-Masdeu JC, **Dalmau J**, Berman KF. NMDA receptor internalization by autoantibodies: a reversible mechanism underlying psychosis? *Trends Neurosci* 2016;39:300-310.

-Iizuka T, Kaneko J, Tominaga N, Someko H, Nakamura M, Ishima D, Kitamura E, Masuda R, Oguni E, Yanagisawa T, Kanazawa N, **Dalmau J**, Nishiyama K. . Association of progressive cerebellar atrophy with long-term outcome in patients with anti-N-Methyl-d-Aspartate receptor

encephalitis. JAMA Neurol 2016;73:706-713. (Highlighted with Editorial Comment)

-Martinez-Hernandez E, Ariño H, McKeon A, Iizuka T, Titulaer MJ, Simabukuro MM, Lancaster E, Petit-Pedrol M, Blanco Y, Harvey RJ, Saiz A, Graus F, **Dalmau J**. Clinical and immunological investigations in patients with stiff-person spectrum disease. JAMA Neurol 2016;73:714-720.

-Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, Cortese I, Dale RC, Gelfand J, Geschwind M, Glaser CA, Honnorat J, Höftberger R, Iizuka T, Irani SR, Lancaster E, Leypoldt F, Prüss H, Rae-Grant A, Reindl M, Rosenfeld MR, Rostasy K, Saiz A, Venkatesan A, Vincent A, Wandinger K-P, Waters P, **Dalmau J**. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 2016;15:391-404. (Highlighted with Editorial Comment and Lancet Neurol Podcast)

-Gövert F, Witt K, Erro R, Hellriegel H, Paschen S, Martinez-Hernandez E, Wandinger K-P, Deuschl G, **Dalmau J**, Leypoldt F. Orthostatic myoclonus associated with CASPR2 antibodies. Neurology 2016;86:1353-1355.

-Armangué T, Sabater L, Torres-Vega E, Martínez-Hernández E, Ariño H, Petit-Pedrol M, Planagumà J, Bataller L, **Dalmau J**, Graus F. Clinical and immunological features of opsoclonus-myoclonus in the era of neuronal cell surface antibodies. JAMA Neurol 2016;73:417-24. (Highlighted with Editorial Comment)

-Sabater L, Saiz A, **Dalmau J**, Graus F. Pitfalls in the detection of CV2 (CRMP5) antibodies. J Neuroimmunol 2016;290:80-83.

-Kayser MS, **Dalmau J**. Anti-NMDA receptor encephalitis, autoimmunity, and psychosis. Schizophr Res 2016;176:36-40.

-Ng AS, Kramer J, Centurion A, **Dalmau J**, Huang E, Cotter JA, Geschwind MD. Clinico-pathological correlation in adenylate kinase 5 autoimmune limbic encephalitis. J Neuroimmunol 2015;287:31-35

-Panzer JA, Anand R, **Dalmau J**, Lynch DR. Antibodies to dendritic neuronal surface antigens in opsoclonus myoclonus ataxia syndrome. J Neuroimmunol 2015;286:86-92.

-Höftberger R, Rosenfeld MR, **Dalmau J**. Update on neurological paraneoplastic syndromes. Curr Opin Oncol 2015;27:489-495.

-Simabukuro MM, Sabater L, Adoni T, Cury RG, Haddad MS, Moreira CH, Oliveira L, Boaventura M, Alves RC, Azevedo Soster L, Nitrini R, Gaig C, Santamaría J, **Dalmau J**, Graus F. Sleep disorder, chorea, and dementia associated with IgLON5 antibodies. Neurol Neuroimmunol Neuroinflamm. 2015;2(4):e136.

-Armangué T, Moris G, Cantarin-Extremera V, Conde C, Rostasy K, Erro E, Portilla-Cuenca JC, Turon E, Málaga I, Cabello Muñoz B, Torres-Torres C, Llufríu S, López-Solana G, González G, Casado Naranjo I, Rosenfeld M, Graus F, **Dalmau J**. Autoimmune post-herpes simplex encephalitis of adults and teenagers. Neurology 2015;85:1736-1743. (Highlighted with Editorial Comment, and Front Cover)

-Piepgras J, Höltje M, Michel K, Li Q, Otto C, Drenckhahn C, Probst C, Schemann M, Stöcker W, Buchert R, **Dalmau J**, Ahnert-Hilger G, Ruprecht K. Anti-DPPX encephalitis: pathogenic effects of antibodies in gut and brain neurons. *Neurology* 2015;85:890-897.

-Spatola M, Novy J, Du Pasquier R, **Dalmau J**, Rossetti AO. Status epilepticus of inflammatory etiology: a cohort study. *Neurology* 2015;85:464–470.

-Ariño H, Höftberger R, Gresa-Arribas N, Martínez-Hernández E, Armangue T, Kruer MC, Arpa J, Domingo J, Rojc B, Bataller L, Saiz A, **Dalmau J**, Graus F. Paraneoplastic neurological syndromes and glutamic acid decarboxylase antibodies. *JAMA Neurol* 2015; 72:874-881.

-Bergink V, Armangue T, Titulaer MJ, Markx S, **Dalmau J**, Kushner SA. Autoimmune encephalitis in postpartum psychosis. *Am J Psychiatry*. 2015;172:901-908.

-Huijbers MG, Querol LA, Niks EH, Plomp JJ, van der Maarel SM, Graus F, **Dalmau J**, Illa I, Verschuuren JJ. The expanding field of IgG4-mediated neurological autoimmune disorders. *Eur J Neurol*. 2015;22:1151-1161.

-Leon-Caballero J, Pacchiarotti I, Murru A, Valenti M, Colom F, Benach B, Perez V, **Dalmau J**, Vieta E. Bipolar disorder and antibodies against the N-methyl-D-aspartate receptor: a gate to the involvement of autoimmunity in the pathophysiology of bipolar illness. *Neurosci Biobehav Rev* 2015;55:403-412.

-Olsen AL, Lai Y, **Dalmau J**, Scherer SS, Lancaster E. Caspr2 autoantibodies target multiple epitopes. *Neurol Neuroimmunol Neuroinflamm* 2015 Jul 2;2(4):e127.

-Ramberger M, Peschl P, Schanda K, Irschick R, Höftberger R, Deisenhammer F, Rostásy K, Berger T, **Dalmau J**, Reindl M. Comparison of diagnostic accuracy of microscopy and flow cytometry in evaluating N-methyl-D-aspartate receptor antibodies in serum using a live cell based assay. *PLoS One*. 2015 Mar 27;10(3):e0122037.

-Gresa-Arribas N, Ariño H, Martínez-Hernández E, Petit-Pedrol M, Sabater L, Saiz A, **Dalmau J**, Graus F. Antibodies to inhibitory synaptic proteins in syndromes of glutamic acid decarboxylase autoimmunity. *PLoS One*. 2015 Mar 16;10(3):e0121364.

-Bigi S, Hladio M, Twilt M, **Dalmau J**, Benseler S. The growing spectrum of antibody-associated inflammatory brain diseases in children. *Neurol Neuroimmunol Neuroinflamm* 2015 Apr 2;2(3):e92.

-Simabukuro MM, Petit-Pedrol M, Castro LH, Nitrini R, Lucato LT, Zambon AA, Silva LG, Fortes GCR, Soares Neto HR, **Dalmau J**. GABA_A – Receptor and LGI1 antibody encephalitis in a patient with thymoma. *Neurol Neuroimmunol Neuroinflamm* 2015 Feb 12;2:e73.

-Höftberger R, van Sonderen A, Leypoldt F, Geschwind M, Gelfand J, Paredes M, Houghton D, Sabater L, Saiz A, Titulaer MJ, Graus F, **Dalmau J**. Encephalitis and AMPA receptor antibodies: novel findings in a case series of 22 patients. *Neurology*. 2015;84:2403-2412.

-Armangue T, Santamaria J, **Dalmau J**. When a serum test overrides the clinical assessment.

Neurology 2015;84:1379-1381. (Highlighted with Neurology podcast)

-Leypoldt F, Höftberger R, Titulaer MJ, Armangue T, Gresa-Arribas N, Jahn H, Rostasy K, Schlumberger W, Meyer T, Wandinger K-P, Rosenfeld MR, Graus F, **Dalmau J**. CXCL13 is a biomarker of response to treatment and outcome in anti-NMDA receptor encephalitis. JAMA Neurol 2015;72:180-186.

-Höftberger R, Sepulveda M, Armangue T, Blanco Y, Rostásy K, Cobo Calvo A, Olascoaga J, Ramió-Torrentà Ll, Reindl M, Benito-León J, Casanova B, Arrambide G, Sabater L, Graus F, **Dalmau J**, Saiz A. Antibodies to MOG and AQP4 in adults with NMO and suspected limited forms of the disease. Mult Scler 2015;21:866-874.

-Leypoldt F, Armangue T, **Dalmau J**. Autoimmune encephalopathies. Ann NY Acad Sci 2015;1338:94-114.

-Montejo T, Petit-Pedrol M, Graus F, **Dalmau J**. Clinical spectrum and diagnostic value of antibodies against the potassium channel related protein complex (article in Spanish). Neurologia 2015;30:295-301.

-Stokin GB, Popović M, Gelpi E, Kogoj A, **Dalmau J**, Graus F. Neuropathological features of anti-Dipeptidyl-Peptidase-Like Protein-6 antibody encephalitis. Neurology 2015;84:430-432.

-Planagumà J, Leypoldt F, Mannara F, Gutiérrez-Cuesta J, Martín-García E, Aguilar E, Titulaer MJ, Petit-Pedrol M, Jain A, Balice-Gordon R, Lakadamyali M, Graus F, Maldonado R, **Dalmau J**. Human N-Methyl-D-aspartate receptor antibodies alter memory and behavior in mice. Brain 2015; 138:94-109. (Highlighted with editorial comment and Front Cover)

-Martinez-Hernandez E, Sepulveda M, Rostasy K, Höftberger R, Graus F, Saiz A, **Dalmau J**. Antibodies to aquaporin 4, myelin-oligodendrocyte glycoprotein, and the glycine receptor $\alpha 1$ subunit in patients with isolated optic neuritis. JAMA Neurol 2015;72:187-193.

-Peng X, Hughes EG, Moscato EH, Parsons TD, **Dalmau J**, Balice-Gordon R. Cellular plasticity induced by anti- α -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor encephalitis antibodies. Ann Neurol 2015;77:381-398.

-Linnoila JJ, Rosenfeld MR, **Dalmau J**. Neuronal surface antibody-mediated autoimmune encephalitis. Semin Neurol 2014;34:458-466.

-Spatola M, Stojanova V, Prior JO, **Dalmau J**, Rossetti AO. Serial brain 18 F-FDG-PET in anti-AMPA receptor limbic encephalitis. J Neuroimmunol 2014 Jun 15;271:53-55.

-Gallardo E, Martínez-Hernández E, Titulaer MJ, Huijbers MG, Martínez MA, Ramos A, Querol L, Díaz-Manera J, Rojas-García R, Hayworth CR, Verschuuren J, Balice-Gordon R, **Dalmau J**, Illa I. Cortactin autoantibodies in myasthenia gravis. Autoimmun Rev 2014 Oct;13:1003-1007.

-Doss S, Wandinger KP, Hyman BT, Panzer JA, Synofzik M, Dickerson B, Mollenhauer B, Scherzer CR, Ivinson AJ, Finke C, Schöls L, Müller vom Hagen J, Trenkwalder C, Jahn H, Höltje M, Biswal BB, Harms L, Ruprecht K, Buchert R, Höglinger GU, Oertel WH, Unger MM,

Körtvélyessy P, Bittner D, Priller J, Spruth EJ, Paul F, Meisel A, Lynch DR, Dirnagl U, Endres M, Teegen B, Probst C, Komorowski L, Stöcker W, **Dalmau J**, Prüss H. High prevalence of NMDA receptor IgA/IgM antibodies in different dementia types. *Ann Clin Transl Neurol* 2014;1:822–832.

-Moscato EM, Peng X, Jain A, Parsons TD, **Dalmau J**, Balice-Gordon R. Acute mechanisms underlying antibody effects in anti-NMDA receptor encephalitis. *Ann Neurol* 2014;76:108-119.

-Cobo-Calvo A, Izquierdo-Gracia C, Quiñones SM, Torro CM, Saiz A, **Dalmau J**, Martínez-Yélamos S. Optic neuritis in the setting of NMDA receptor encephalitis. *J Neuro-ophthalmol* 2014;34:316-319.

-Greene M, Lai Y, Baella N, **Dalmau J**, Lancaster E. Antibodies to Delta/Notch-like Epidermal growth factor-related Receptor (DNER) in patients with anti-Tr, Paraneoplastic Cerebellar Degeneration, and Hodgkin's Lymphoma. *JAMA Neurol* 2014;71:1003-1008.

-Ariño H, Gresa-Arribas N, Blanco Y, Martínez-Hernández E, Sabater L, Petit M, Rouco I, Bataller L, **Dalmau J**, Saiz A, Graus F. Cerebellar ataxia and glutamic acid decarboxylase antibodies: Immunological profile and long-term impact of immunotherapy. *JAMA Neurol* 2014;71:1009-1016.

-Graus F, Ariño H, **Dalmau J**. Paraneoplastic neurological syndromes in Hodgkin and non-Hodgkin lymphomas. *Blood* 2014; 123:3230-3238.

-Sabater L, Gaig C, Gelpi E, Bataller L, Lewerenz J, Torres-Vega E, Contreras A, Giometto B, Compta Y, Embid C, Vilaseca I, Iranzo A, Santamaría J, **Dalmau J**, Graus F. A novel NREM and REM parasomnia with sleep breathing disorder associated with antibodies against IgLON5: a case series, pathological features, and characterization of the antigen. *Lancet Neurol* 2014;13:575-586. (Highlighted with editorial and entry in NEJM Journal Watch)

-Rosenfeld MR, **Dalmau J**. Autoimmune encephalitis update. *Neuro Oncol* 2014;16:771-778.

-Armangue T, Leypoldt F, **Dalmau J**. Autoimmune encephalitis in the differential diagnosis of infectious encephalitis. *Curr Opin Neurol* 2014;27:361-368.

-Gleichman AJ, Baumann BH, **Dalmau J**, Lynch DR. Antigenic and mechanistic characterization of anti-AMPA receptor encephalitis". *Ann Clin Transl Neurol* 2014;1:180-189.

-Höftberger R, Sabater L, Velasco F, Ciordia R, **Dalmau J**, Graus F. Carbonic anhydrase-related protein VIII antibodies and paraneoplastic cerebellar degeneration. *Neuropathol Appl Neurobiol* 2014;40:650-653.

-Titulaer MJ, Höftberger R, Iizuka T, Leypoldt F, McCracken L, Cellucci T, Benson LA, Shu H, Irioka T, Hirano M, Singh G, Cobo Calvo A, Kaida K, Morales PM, Wirtz PW, Yamamoto T, Reindl M, Rosenfeld MR, Graus F, Saiz A, **Dalmau J**. Overlapping demyelinating syndromes and anti-NMDA receptor encephalitis. *Ann Neurol* 2014;75:411-428. (cited by Faculty of 1000)

-Petit-Pedrol M, Armangue T, Peng X, Bataller L, Cellucci T, Davis R, McCracken L, Martinez-Hernandez E, Mason WP, Kruer MC, Ritacco DG, Grisold W, Meaney BF, Alcalá C, Sillevs-Smitt P, Titulaer MJ, Balice-Gordon R, Graus F, **Dalmau J**. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABA_A receptor: a case series characterization of the antigen, and

analysis of the effects of antibodies. *Lancet Neurol* 2014;13:276-286. (Highlighted with editorial)
(cited by Faculty of 1000)

-Gresa-Arribas N, Titulaer MJ, Torrents A, Aguilar E, McCracken L, Leypoldt F, Gleichman AJ, Balice-Gordon R, Rosenfeld MR, Lynch D, Graus F, **Dalmau J**. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. *Lancet Neurol* 2014;13:167-177. (Highlighted with editorial)

-Armangue T, Leypoldt F, Málaga I, Raspall-Chaure M, Marti I, Nichter C, Pugh J, Vicente-Rasoamalala M, Lafuente-Hidalgo M, Macaya A, Ke M, Titulaer MJ, Höftberger R, Sheriff H, Glaser C, **Dalmau J**. Herpes simplex virus encephalitis is a trigger of brain autoimmunity. *Ann Neurol* 2014;75:317-323.

-Querol L, Nogales-Gadea G, Rojas-Garcia R, Diaz-Manera J, Pardo J, Ortega-Moreno A, Sedano MJ, Gallardo E, Berciano J, Blesa R, **Dalmau J**, Illa I. Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg. *Neurology* 2014;82:879-886.

-Leypoldt F, Wandinger K-P, Bien CG, **Dalmau J**. Autoimmune encephalitis. *Eur Neurol Rev*, 2014;175:336-348.

-Titulaer MJ, Leypoldt F, **Dalmau J**. Antibodies to NMDA and other synaptic receptors in choreoathetosis and relapsing symptoms post-Herpes virus encephalitis. *Mov Disord* 2014;29:3-6.

-Grau-Rivera O, Sánchez-Valle R, Saiz A, Molinuevo JL, Bernabé R, Munteis E, Pujadas F, Salvador A, Saura J, Ugarte A, Titulaer M, **Dalmau J**, Graus F. Determination of neuronal antibodies in suspected and definite Creutzfeldt-Jakob disease. *JAMA Neurol* 2014;71:74-78.

-Kruer MC, Höftberger R, Lim KY, Coryell JC, Svoboda MD, Woltjer RL, **Dalmau J**. Aggressive course in encephalitis with opsoclonus, ataxia, chorea, and seizures: the first pediatric case of g-aminobutyric acid type B receptor autoimmunity. *JAMA Neurol* 2014;71:620-623.

-Armangue T, Titulaer MJ, Sabater L, Pardo-Moreno J, Gresa-Arribas N, Barbero-Bordallo N, Kelley GR, Kyung-Ha N, Takeda A, Nagao T, Takahashi Y, Lizcano A, Carr AS, Graus F, **Dalmau J**. A novel treatment-responsive encephalitis with frequent opsoclonus and teratoma. *Ann Neurol* 2014;75:435-441. (Highlighted with editorial)

-Clardy SL, Lennon VA, **Dalmau J**, Pittock SJ, Royden Jones H, Renaud DL, Harper CM, Matsumoto JY, McKeon A. Childhood onset of stiff-man syndrome. *JAMA Neurol* 2013;70:1531-1536.

-Höftberger R, Sabater L, Marignier R, Aboul-Enein F, Bernard-Valnet R, Rauschka H, Ruiz A, Blanco Y, Graus F, **Dalmau J**, Saiz A. An optimized immunohistochemistry technique improves NMO-IgG detection: study comparison with cell-based assays. *PLoS One* 2013;8(11): e79083.

-Bravo-Oro A, Abud-Mendoza C, Quezada-Corona A, **Dalmau J**, Campos-Guevara V. Encefalitis por anticuerpos contra el receptor NMDA: experiencia con 6 pacientes pediátricos; potencial eficacia de Metotrexato [Encephalitis associated with antibodies against the NMDA receptor: experience with 6 pediatric patients; efficacy of Methotrexate]. *Rev Neurol* 2013;57:405-410.

- Merwick A, **Dalmau J**, Delanty N. Insights into antibody-associated encephalitis: Bickerstaff's 1950's papers revisited. *J Neurol Sci* 2013;334:167-168.
- Leypoldt F, Titulaer MJ, Aguilar E, Walther J, Bönstrup M, Havemeister S, Teegen B, Lütgehetmann M, Rosenkranz M, Magnus T, **Dalmau J**. Herpes simplex virus-1 encephalitis can trigger anti-NMDA receptor encephalitis – A case report. *Neurology* 2013;81:1637-1639.
- Höftberger R, Titulaer M, Sabater L, Dome B, Rózsás A, Hegedus B, Hoda MA, Laszlo V, Ankersmit HJ, Harms L, Boyero S, de Felipe A, Saiz A, **Dalmau J**, Graus F. Encephalitis and GABA_B receptor antibodies: novel findings in a new case series of 20 patients. *Neurology* 2013;81:1500-1506.
- Titulaer MJ, McCracken L, Gabilondo I, Iizuka T, Kawachi I, Bataller L, Torrents A, Rosenfeld MR, Balice-Gordon R, Graus F, **Dalmau J**. Late-onset anti-N-methyl-D-aspartate receptor encephalitis. *Neurology* 2013;81:1058-1063.
- Graus F, **Dalmau J**. Paraneoplastic Neuropathies. *Curr Opin Neurol* 2013;26:489-495.
- Thomas A, Rauschkolb P, Gresa-Arribas N, Schned A, **Dalmau J**, Fadul CE. Anti- N-methyl-D-aspartate receptor encephalitis: a patient with refractory illness after 25 months of intensive immunotherapy. *JAMA Neurol* 2013;70:1566-1568.
- Dalmau J**, Berenguer J, Saiz A. Clinical-pathological conference, case 149-2012: A 40-years old woman with headache and diplopia. *Med Clin* 2013;141:543-549.
- Davis R, **Dalmau J**. Autoimmunity, seizures and status epilepticus. *Epilepsia* 2013;54 Suppl 6:46-49.
- Fleisher F, Richie M, Price R, Scherer S, **Dalmau J**, Lancaster E. Acquired neuromyotonia heralding recurrent thymoma in myasthenia gravis. *JAMA Neurol* 2013;70:1311-1314.
- Martin-Garcia H, Mannara F, Gutierrez-Cuesta J, Sabater L, **Dalmau J**, Maldonado R, Graus F. Intrathecal injection of P/Q type voltage-gated calcium channel antibodies from paraneoplastic cerebellar degeneration cause ataxia in mice. *J Neuroimmunol* 2013;261:53-59.
- Kayser MS, Titulaer MJ, Gresa-Arribas N, **Dalmau J**. Frequency and characteristics of isolated psychiatric episodes in anti-N-methyl-d-aspartate receptor encephalitis. *JAMA Neurol* 2013;70:1133-1139. (Highlighted by NEJM Journal Watch)
- Sabater L, Höftberger R, Boronat A, Saiz A, **Dalmau J**, Graus F. Antibody repertoire in paraneoplastic cerebellar degeneration and small cell lung cancer. *PLoS One* 2013;8(3):e60438.
- Höftberger R, Armangue T, Leypoldt F, Graus F, **Dalmau J**. Clinical neuropathology practice guide 4-2013: post-herpes simplex encephalitis: N-methyl-D-aspartate receptor antibodies are part of the problem. *Clin Neuropathol* 2013;32:251.
- Titulaer MJ, McCracken L, Gabilondo I, Armangue T, Glaser C, Iizuka T, Honig LS, Benseler S, Kawachi I, Martinez-Hernandez E, Aguilar E, Gresa-Arribas N, Ryan-Flourance N, Torrents A, Saiz

A, Rosenfeld MR, Balice-Gordon R, Graus F, **Dalmau J**. Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study. *Lancet Neurol* 2013;12:157-165. (Highlighted as “editor’s choice” publication, with Editorial comment, Podcast, and Journal cover)

-Höftberger R, Kovacs GG, Sabater L, Nagy P, Racz G, Miquel R, **Dalmau J**, Graus F. Protein kinase C gamma antibodies and paraneoplastic cerebellar degeneration. *J Neuroimmunol* 2013;256:91-93.

-Labate A, Quattrone A, **Dalmau J**, Gambardella A. Anti-N-methyl-D-aspartate-glutamate-receptor encephalitis presenting as paroxysmal exercise-induced foot weakness. *Mov Disord* 2013;28:820-822.

-Höftberger R, Sabater L, Ortega A, **Dalmau J**, Graus F. Patient with Homer 3 antibodies and cerebellitis. *JAMA Neurol* 2013;70:506-509.

-Armangue T, Titulaer MJ, Málaga I, Bataller L, Gabilondo I, Graus F, **Dalmau J**. Pediatric Anti-NMDAR encephalitis-Clinical analysis and novel findings in a series of 20 patients. *J Pediatrics* 2013;162:850-856. (Highlighted with editorial comment)

-Mat A, Adler H, Merwick A, Chadwick G, Gullo G, **Dalmau J**, Tubridy N. Ophelia Syndrome with metabotropic glutamate receptor 5 antibodies in CSF. *Neurology* 2013;80:1349-1350.

-Boronat A, Gelfand JM, Gresa-Arribas N, Jeong H-Y, Walsh M, Roberts K, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R, Graus F, Rudy B, **Dalmau J**. Encephalitis and antibodies to DPPX, a subunit of Kv4.2 potassium channels. *Ann Neurol* 2013;73:120-128.

-McKeon A, Martinez-Hernandez E, Lancaster E, Matsumoto JY, Harvey RJ, McEvoy KM, Pittock SJ, Lennon VA, **Dalmau J**. Glycine receptor autoimmunity in Stiff-Man syndrome phenotypes. *JAMA Neurol* 2013;70:44-50. (Highlighted with editorial)

-Hansen H-C, Klingbeil C, **Dalmau J**, Li W, Weißbrich B, Wandinger K-P. Persistent intrathecal antibody synthesis 15 years after recovering from anti-NMDAR encephalitis. *JAMA Neurol* 2013;70:117-9.

-Slettedal IO, Dahl HM, Sandvig I, **Dalmau J**, Strømme P. Psychosis, dementia and seizures in a young girl. *J Norwegian Med Association (Tidsskr Nor Laegeforen)* 2012;132:2073-2076.

-Rosenfeld MR, Titulaer M, **Dalmau J**. Paraneoplastic syndromes and autoimmune encephalitis: Five new things. *Neurology Clin Practice* 2012;2:215-223.

-Graus F, **Dalmau J**. Paraneoplastic neurological syndromes. *Curr Opin Neurol* 2012;25:795-801.

-Höftberger R, **Dalmau J**, Graus F. Clinical Neuropathology Practice News 5-2012: updated guideline for the diagnosis of anti-neuronal antibodies. *Clin Neuropathol* 2012;31:337-341.

-Prüss H, Finke C, Hölte M, Hofmann J, Klingbeil C, Probst C, Borowski K, Ahnert-Hilger G, Harms L, Schwab JM, Ploner CJ, Stoecker W, **Dalmau J**, Wandinger KP. N-methyl-D-aspartate

receptor antibodies in herpes simplex encephalitis. *Ann Neurol* 2012;72:902-911.

-Rosenfeld MR, **Dalmau J**. Paraneoplastic neurologic disorders: A brief overview. *Memo* 2012;5:197-200.

-Gleichman AJ, Spruce LA, **Dalmau J**, Seeholzer SH, Lynch DR. Anti-NMDA receptor encephalitis antibody binding is dependent on amino acid identity of a small region within the GluN1 amino terminal domain. *J Neurosci* 2012;32:11082-94.

-Armangue T, Petit M, **Dalmau J**. Autoimmune encephalitis in children. *J Child Neurol* 2012;27:1460-1469.

-Schmitt SE, Pargeon K, Frechette E, Hirsch LJ, **Dalmau J**, Friedman D. "Extreme Delta Brush": a unique EEG pattern in adults with anti-NMDA receptor encephalitis. *Neurology* 2012;79:1094-1100.

-Günther A, Brodoehl S, Witte O, Freesmeyer M, **Dalmau J**, Redecker C. Atypical posthypoxic MRI changes in hypermetabolic regions in anti-NMDA-receptor encephalitis. *Neurology* 2012;79:720-721.

-**Dalmau J**, Graus F. Paraneoplastic syndromes: From remote to clear and present knowledge. *Brain* 2012;135:1650-1653.

-Zhao CZ, Erickson J, **Dalmau J**. Clinical reasoning: Agitation and psychosis in a patient after post-renal transplantation. *Neurology* 2012;79:e41-44.

-Lancaster E, **Dalmau J**. Neuronal autoantigens: pathogenesis, associated disorders, and antibody testing. *Nat Review Neurol* 2012;8:380-390.

-Prüss H, Hölting M, Maier N, Gomez A, Buchert R, Harms L, Ahnert-Hilger G, Schmitz D, Terborg C, Kopp U, Klingbeil C, Probst C, Kohler S, Schwab JM, Stoecker W, **Dalmau J**, Wandinger KP. IgA NMDA receptor antibodies are markers of synaptic immunity in slow cognitive impairment. *Neurology* 2012;78:1743-1753.

-Leypoldt F, Buchert R, Kleiter I, Marienhagen J, Gelderblom M, Magnus T, **Dalmau J**, Gerloff C, Lewerenz J. Fluorodeoxyglucose positron emission tomography in anti-N-methyl-D-aspartate receptor encephalitis: distinct pattern of disease. *J Neurol Neurosurg Psychiatry* 2012;83:681-686.

-Tanyi JL, Marsh EB, **Dalmau J**, Chu CS. Reversible paraneoplastic encephalitis in three patients with ovarian neoplasms. *Acta Obstet Gynecol Scand* 2012;91:630-634.

-Gable MS, Sheriff H, **Dalmau J**, Tilley DH, Glaser CA. The frequency of autoimmune N-methyl-D-aspartate acid receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project. *Clin Infect Dis* 2012;54:899-904.

-Boronat A, Sepúlveda M, Llufrí S, Sabater L, Blanco Y, Gabilondo I, Villoslada P, **Dalmau J**, Graus F, Saiz A. Analysis of antibodies to surface epitopes of contactin-2 in multiple sclerosis. *J Neuroimmunol.* 2012;244:103-106.

-Bseikri M, Barton J, Kulhanjian J, **Dalmau J**, Cohen R, Glaser C, Roy-Burman A. Anti-N-methyl-D-aspartate receptor encephalitis mimics viral encephalitis. *Pediatr Infect Dis J*. 2012;31:202-204.

-Finke C, Kopp UA, Prüss H, **Dalmau J**, Wandinger KP, Ploner CJ. Cognitive deficits following anti-NMDAR encephalitis. *J Neurol Neurosurg Psychiatry* 2012;83:195-198.

-Graus F, **Dalmau J**. CNS autoimmunity: new findings and pending issues. *Lancet Neurol* 2012;11:17-19.

-Kayser M, **Dalmau J**. Anti-NMDA receptor encephalitis in psychiatry. *Curr Psychiatry Rev* 2011;7:189-193.

-Cash SS, Larvie M, **Dalmau J**. Case records of the Massachusetts General Hospital. Case 34-2011: A 75-year-old man with memory loss and partial seizures. *N Engl J Med* 2011;365:1825-1833.

-Wray SH, **Dalmau J**, Chen A, King S, Leigh RJ. Paraneoplastic disorders of eye movements. *Ann NY Acad Sci* 2011;1233:279-84.

-Lancaster E, Martinez-Hernandez E, Titulaer MJ, Boulos M, Weaver S, Antoine J-C, Leifers E, Kornblum C, Bien C, Honnorat J, Wong S, Xu J, Contractor A, Balice-Gordon R, **Dalmau J**. Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome. *Neurology* 2011;77:1698-1701.

-Yeo KK, Walter AW, Miller RE, **Dalmau J**. Rituximab as potential therapy for paraneoplastic cerebellar degeneration in pediatric Hodgkin disease. *Pediatr Blood Cancer* 2012;58:986-987.

-Wray SH, **Dalmau J**, Maheshwari A, Chen A, King S, Pitman MB, Leigh RJ. Paraneoplastic upbeat nystagmus: Evidence for underlying mechanisms. *Neurology* 2011;77:691-693.

-Martinez-Hernandez E, Horvath J, Shiloh-Malawsky Y, Sangha N, Martinez-Lage M, **Dalmau J**. Analysis of complement and plasma cells in the brain of patients with anti-NMDAR encephalitis. *Neurology* 2011;77:589-593.

-Lancaster E, Martinez-Hernandez E, **Dalmau J**. Encephalitis and antibodies to synaptic and neuronal cell surface proteins. *Neurology* 2011;77:179-189. (cited in [Faculty of 1000.com/12091957](http://Facultyof1000.com/12091957))

-Panzer J, **Dalmau J**. Movement disorders in paraneoplastic and autoimmune disease. *Curr Opin Neurol* 2011;24:346-353.

-Reyes-Botero G, Uribe CS, Hernandez-Ortiz OE, Ciro J, Guerra A, **Dalmau J**. Anti-NMDA receptor paraneoplastic encephalitis: complete recovery after ovarian teratoma removal. *Rev Neurol* 2011;52:536-540.

-Luca N, Daengsuwan T, **Dalmau J**, Jones K, deVeber G, Kobayashi J, Laxer RM, Benseler SM. Anti-N-Methyl-D-Aspartate receptor encephalitis: A newly recognized inflammatory brain disease in children. *Arthritis Rheum* 2011;63:2516-2522.

- Uchino A, Iizuka T, Urano Y, Arai M, Hara A, Hamada J, Hirose R, **Dalmau J**, Mochizuki H. Pseudo-piano playing motions and nocturnal hypoventilation in anti-NMDA receptor encephalitis: response to prompt tumor removal and immunotherapy. *Intern Med* 2011;50:627-630.
- Hara M, Morita A, Kamei S, Yamaguchi M, Homma T, Nemoto N, Sugita K, Yamamoto T, **Dalmau J**. Anti-N-Methyl-D-Aspartate receptor encephalitis associated with carcinosarcoma with neuroendocrine differentiation of the uterus. *J Neurol* 2011;258:1351-1353.
- Frechette ES, Zhou L, Galetta SL, Chen L, **Dalmau J**. Prolonged follow-up and cerebrospinal fluid antibody titers in a patient with anti-NMDA receptor encephalitis. *Neurology* 2011;76: S64-S66.
- Kayser MS, **Dalmau J**. The emerging link between autoimmune disorders and neuropsychiatric disease. *J Neuropsychiatry Clin Neurosci* 2011;23:90-97.
- Boronat A, Sabater L, Saiz A, **Dalmau J**, Graus F. GABA_B receptor antibodies in limbic encephalitis and anti-GAD-associated neurological disorders. *Neurology* 2011;76:795-800.
- Andrade DM, Tai P, **Dalmau J**, Wennberg R. Tonic seizures: a diagnostic clue of anti-LGI1 limbic encephalitis. *Neurology* 2011;76:1355-1357.
- Rubio-Agustí I, **Dalmau J**, Sevilla T, Burgal M, Beltran E, Bataller L. Isolated hemidystonia associated with NMDA receptor antibodies. *Mov Disord* 2011;26:351-352.
- Arratibel-Echarren I, Albright K, **Dalmau J**, Rosenfeld MR. Use of Bevacizumab for neurological complications during initial treatment of malignant gliomas. [Utilización de Bevacizumab en las complicaciones neurológicas durante el tratamiento inicial de los gliomas malignos]. *Neurología* 2011;26:74-80.
- Erkmen CP, McGowan AK, Black CC, Nugent WC, **Dalmau J**, Fadul CE, Erkmen K. Thymoma-associated paraneoplastic limbic encephalopathy (TAPLE). *J Thorac Cardiovasc Surg* 2011;141:e17-20.
- Rosenfeld MR, **Dalmau J**. Anti-NMDA-receptor encephalitis and other synaptic autoimmune disorders. *Curr Treat Options Neurol* 2011;13:324-332.
- Dalmau J**, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and investigations on anti-NMDA receptor encephalitis. *Lancet Neurol* 2011;10:63-74. (Highlighted by journal, cited by Faculty of 1000: <http://f1000.com/8406956>)
- Lancaster E, Huijbers MGM, Bar V, Lai M, Boronat A, Wong A, Martinez-Hernandez E, Wilson C, Jacobs D, Walker RW, Graus F, Bataller L, Illa I, Markx S, Strauss KA, Peles E, Scherer SS, **Dalmau J**. Investigations of Caspr2, an autoantigen of encephalitis and neuromyotonia. *Ann Neurol* 2011;69:303-311.
- Wandinger K-P, Saschenbrecker S, Stoecker W, **Dalmau J**. Anti-NMDA-receptor encephalitis: A severe, multistage, treatable disorder presenting with psychosis. *J Neuroimmunol* 2011;231:86-91.

-Titulaer, MJ, Soffiatti R, **Dalmau J**, Gilhus NE, Giometto B, Graus F, Grisold W, Honnorat J, Sillevis PAE, Tanasescu R, Vedeler CA, Voltz R, Verschuuren JJGM. Screening for malignancies in paraneoplastic syndromes: report of an EFNS Task Force. *Eur J Neurol* 2011;18:19-e3.

-Manto M, **Dalmau J**, Didelot A, Rogemond V, Honnorat J. Afferent facilitation of corticomotor responses is increased by IgGs of patients with NMDA-receptor antibodies. *J Neurol* 2011;258:27-33.

-Verhelst H, Verloo P, Dhondt K, De Paepe B, Menten B, **Dalmau J**, Van Coster R. Anti-NMDA-receptor encephalitis in a 3 year old patient with chromosome 6p21.32 microdeletion including the HLA cluster. *Eur J Paediatr Neurol* 2011;15:163-166.

-Herrero-Velázquez S, Guerrero-Peral AL, Gámez-Leyva G, Fernández-Buey N, Conde A, Saíz A, M Rodríguez M, Graus F, Pascual J, Fernández R, **Dalmau J**. Limbic encephalitis with antibodies to NMDA receptor: Report of a patient without tumor and review of the literature. *Rev Neurol* 2010;50:661-666.

-**Dalmau J**, Rosenfeld MR. Update on paraneoplastic neurologic disorders. *Community Oncol.* 2010 May 1;7:219-224.

-Manto M, **Dalmau J**, Didelot A, Rogemond V, Honnorat J. In vivo effects of antibodies from patients with anti-NMDA receptor encephalitis: further evidence of synaptic glutamatergic dysfunction. *Orphanet J Rare Dis* 2010 Nov 26;5:31.

-Florance-Ryan N, **Dalmau J**. Update on anti-NMDAR encephalitis in children and adolescents. *Curr Opin Pediatr* 2010;22:739-744.

-Prüss H, **Dalmau J**, Harms L, Höltje M, Ahnert-Hilger G, Borowski K, Stoecker W, Wandinger KP. Retrospective analysis of anti-glutamate receptor (type NMDA) antibodies in patients with encephalitis of unknown origin. *Neurology* 2010;75:1735-1739.

-Johnson N, Henry JC, Fessler AJ, **Dalmau J**. Anti-NMDAR encephalitis causing prolonged non-convulsive status epilepticus. *Neurology* 2010;75:1480-1482.

-Lai M, Huijbers MGM, Lancaster E, Graus F, Bataller L, Balice-Gordon R, Cowell JK, **Dalmau J**. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. *Lancet Neurol* 2010;9:776-785. (Highlighted with editorial)

-González-Valcárcel J, Rosenfeld MR, **Dalmau J**. Differential diagnosis in anti-NMDA receptor encephalitis [Diagnóstico diferencial en la encefalitis por anticuerpos contra el receptor NMDA]. *Neurología* 2010;25:409-413.

-Moscato EH, Jain A, Peng X, Hughes EG, **Dalmau J**, Balice-Gordon R. Mechanisms underlying autoimmune synaptic encephalitis leading to disorders of memory, behavior and cognition: insights from molecular, cellular and synaptic studies. *Eur J Neurosci* 2010;32:298-309.

-Rosenfeld, MR, **Dalmau J**. Update on paraneoplastic neurology disorders. *The Oncologist* 2010;15:603-617.

-Kumar MA, Jain A, Dechant VE, Saito T, Rafael T, Aizawa H, Dysart KC, Katayama T, Ito Y, Araki N, Abe T, Balice-Gordon R, **Dalmau J**. Anti-NMDA receptor encephalitis during pregnancy. *Arch Neurol* 2010;67:884-887.

-Novillo-López ME, Gómez-Ibáñez A, Rosenfeld M, **Dalmau J**. Gliomatosis cerebri: Review of 22 patients. *Neurología* 2010;25:168-173.

-Iizuka T, Yoshii S, Kan S, Hamada J, **Dalmau J**, Sakai F, Mochizuki H. Reversible brain atrophy in anti-NMDA receptor encephalitis: a long-term observational study. *J Neurol* 2010;257:1686-1691.

-Wong-Kisiel L, Ji T, Renaud DL, Kotagal SL, Patterson MC, **Dalmau J**, Mack KJ. Immunotherapy response to rituximab in a 20-month-old boy with anti-NMDA receptor encephalitis. *Neurology* 2010;74:1550-1551.

-Hughes EG, Peng X, Gleichman AJ, Lai M, Zhou L, Tsou R, Parsons TD, Lynch DR, **Dalmau J**, Balice-Gordon RJ. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. *J Neurosci* 2010;30:5866-5875. (Highlighted publication)

-Kayser MS, Kohler CG, **Dalmau J**. Psychiatric manifestations of paraneoplastic disorders. *Am J Psychiatry* 2010;167:1039-50.

-Kruer MC, Koch TK, Bourdette DM, Chabas D, Waubant E, Mueller S, Moscarello MA, **Dalmau J**, Woltjer RL, Adamus G. NMDA receptor encephalitis mimicking seronegative neuromyelitis optica. *Neurology* 2010;74:1473-5.

-Kayser MS, **Dalmau J**. Psychiatric manifestations of autoimmune encephalopathies. *Psychiatric Times* 2010 ;27:1-8.

-Prüß H, **Dalmau J**, Arolt V, Wandinger KP. Anti-NMDA-receptor encephalitis: An interdisciplinary clinical picture. *Nervenarzt* 2010;81:396-408.

-Ferioli S, **Dalmau J**, Kobet CA, Zhai QJ, Broderick JP, Espay AJ. Anti-NMDA-receptor encephalitis: Characteristic behavioral and movement disorder. *Arch Neurol* 2010;67:250-251.

-Breese EH, **Dalmau J**, Lennon VA, Apiwattanakul M, Sokol DK. Anti-N-methyl-D-aspartate receptor encephalitis: early treatment is beneficial. *Ped Neurol* 2010;42:213-214.

-Bataller L, Galiano R, García-Escrig M, Martínez B, Sevilla T, Blasco R, Vilchez JJ, **Dalmau J**. Reversible limbic encephalitis associated with breast cancer and antibodies to the AMPA glutamate receptor. *Neurology* 2010;74:265-267.

-Kurian M, Lalive PH, **Dalmau J**, Horvath J. Opsoclonus-myoclonus in anti-NMDA-receptor encephalitis. *Arch Neurol* 2010;67:118-121.

-Lancaster E, Lai M, Peng X, Hughes E, Constantinescu R, Raizer J, Friedman D, Skeen MK, Grisold W, Kimura A, Ohta K, Iizuka T, Guzman M, Graus F, Moss SJ, Balice-Gordon R, **Dalmau**

J. Antibodies to the GABA_B receptor in limbic encephalitis with seizures: a case series and characterization of the antigen. *Lancet Neurol* 2010;9:67-76. (Highlighted with editorial)

-**Dalmau J.** Status epilepticus due to paraneoplastic and non-paraneoplastic encephalitides. *Epilepsia* 2009;50(Suppl. 12): 58–60.

-Moss HE, Liu GT, **Dalmau J.** Glazed (vision) and confused. *Survey Ophthalmol*, 2010;55:169-173.

-Tüzün E, Zhou L, Baehring JM, Bannykh S, Rosenfeld MR, **Dalmau J.** Evidence for antibody-mediated pathogenesis in anti-NMDAR encephalitis associated with ovarian teratoma. *Acta Neuropathol* 2009;118:737-743.

-Wu-Chen WY, Jacobs DA, Volpe NJ, **Dalmau J,** Moster ML. Secondary neoplasms induced by radiation therapy for pituitary adenoma. *J Neuro-ophthalm* 2009;29:289-295.

-Poduval A, Antal Z, Lee T, Bar A, **Dalmau J,** Muzumdar R. Immune-mediated encephalitis and virilization in association with a mature cystic ovarian teratoma in an adolescent girl. *Horm Res* 2009;72:252-256.

-Parratt KL, Allan M, Lewis SJ, **Dalmau J,** Halmagyi GM, Spies JM. Acute psychiatric illness in a young woman: an unusual form of encephalitis. *Med J Austral* 2009;191:284-286.

-Gable MS, Gavali S, Radner A, Tilley DH, Lee B, Dyer L, Collins A, Dengel A, **Dalmau J,** Glaser CA. Anti-NMDA receptor encephalitis: report of 10 cases and comparison with viral encephalitis. *Europ J Clin Microbiol Infect Dis* 2009;28:1421-1429.

-Berger JR, Bensalem M, **Dalmau J.** A brainstem paraneoplastic syndrome associated with prostate cancer. *J Neurol Neurosurg Psychiatry* 2009;80:934-935.

-Florance NR, Davis RL, Lam C, Szperka C, Zhou L, Ahmad S, Campen CJ, Moss H, Peter N, Gleichman AJ, Glaser CA, Lynch DR, Rosenfeld MR, **Dalmau J.** Anti-NMDA receptor encephalitis in children and adolescents. *Ann Neurol* 2009;66:11-18. (Highlighted with editorial)

-Niehusmann P, **Dalmau J,** Rudlowski C, Vincent A, Elger CE, Rossi JE, Bien CG. Diagnostic value of anti-NMDAR antibodies in young women with new-onset epilepsy. *Arch Neurol* 2009;66:458-64.

-Lai M, Hughes EG, Peng X, Zhou L, Gleichman AJ, Shu H, Matà S, Kremens D, Vitaliani R, Geschwind MD, Bataller L, Kalb RG, Davis R, Graus F, Lynch DR, Balice-Gordon R, **Dalmau J.** AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. *Ann Neurol* 2009;65:424-434. Awarded the best manuscript of 2009 by *Annals of Neurology* at the 135th Meeting of the American Neurological Association (ANA), San Francisco, CA, September 14, 2010.

-Kataoka H, **Dalmau J,** Taoka T, Ueno S. Reduced N-acetylaspartate in the basal ganglia of a patient with anti-NMDA receptor encephalitis. *Mov Disord* 2009;24:784-786.

-Takahashi Y, Yamazaki E, Nishimura S, Tsunogae H, Niwa K, **Dalmau J**, Imai K, Fujiwara T. Acute limbic encephalitis and NMDA type-glutamate receptor. *Rinsho Shinkeigaku* 2008;48:926-929.

-**Dalmau J**. Limbic encephalitis and variants related to neuronal cell membrane autoantigens. *Rinsho Shinkeigaku* 2008;48:871-874.

-**Dalmau J**. Paraneoplastic disorders of the nervous system. *Rinsho Shinkeigaku* 2008;48:799-803.

-Ishiura H, Matsuda S, Higashihara M, Hasegawa M, Hida A, Hanajima R, Yamamoto T, Shimizu J, **Dalmau J**, Tsuji S. Response of anti-NMDA receptor encephalitis without tumor to immunotherapy including rituximab. *Neurology* 2008;71:1921-1923.

-Kimura M, Onozawa M, Fujisaki A, Arakawa T, Takeda K, Dalmau J, Hattori K. Anti-Ma2 paraneoplastic encephalitis associated with testicular germ cell tumor treated by carboplatin, etoposide and bleomycin. *Int J Urol* 2008;15:942-943.

-**Dalmau J**, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, Dessain SK, Rosenfeld MR, Balice-Gordon R, Lynch D. Anti-NMDA receptor encephalitis: case series and analysis of the effects of antibodies. *Lancet Neurol* 2008;7:1091-1098. (Highlighted as “editor’s choice” publication , with editorial comment and journal cover) (cited by F 1000 Biology)

-Graus F, Saiz A, Lai M, Bruna J, López F, Sabater L, Blanco Y, Rey M.J, Ribalta T, **Dalmau J**. Neuronal surface antigen antibodies in limbic encephalitis: clinical-immunological associations. *Neurology* 2008;71:930-936.

-Shimazaki H, Morita M, Nakano I, **Dalmau J**. Inverse ocular bobbing in a patient with encephalitis associated with antibodies to the NMDA receptor. *Arch Neurol* 2008;65:1251.

-**Dalmau J**. Paraneoplastic disorders of the memory and cognition: clinical aspects and therapeutic approaches. *Handb Clin Neurol* 2008;89:873-876.

-Gállego Pérez-Larraya J, **Dalmau J**. Classical paraneoplastic síndromes: Diagnostic and treatment approach. *Neurología* 2008; 23:441-448.

-Sabater L, Bataller L, Suárez M, Saiz A, **Dalmau J**, Graus F. ZIC antibodies in paraneoplastic cerebellar degeneration and small cell lung cancer. *J Neuroimmunol* 2008;201-202:163-165.

-Martínez-Hernández E, Rosenfeld MR, Pruitt A, **Dalmau J**. Neurological complications of transplantation. *Neurología* 2008;23:373-386.

-Ko MW, **Dalmau J**, Galetta SL. Neuro-ophthalmologic manifestations of paraneoplastic syndromes. *J Neuro-ophthalm* 2008;28:58-68.

-Rosenfeld MR, **Dalmau J**. Paraneoplastic limbic encephalitis with small-cell lung cancer. *Community Oncology* 2007;4:491-494.

-**Dalmau J**, Rosenfeld MR. Paraneoplastic syndromes of the CNS. *Lancet Neurol* 2008;7:327-340.

- Kataoka H, **Dalmau J**, Ueno S. Paraneoplastic encephalitis associated with ovarian teratoma and N-methyl-D-aspartate receptor antibodies. *Europ J Neurol* 2008;15:e5-6.
- Novillo-López ME, Rossi JE, **Dalmau J**, Masjuan J. Treatment-responsive subacute limbic encephalitis and NMDA receptor antibodies in a man. *Neurology* 2008;70:728-729.
- Carpenter EL, Vance BA, Duerman R, Voloschin A, **Dalmau J**, Vonderheide RH. Functional analysis of CD8⁺ T cell responses to the onconeural self protein cdr2 in patients with paraneoplastic cerebellar degeneration. *J Neuroimmunol* 2008;193:173-182.
- Seki M, Suzuki S, Iizuka T, Shimizu T, Nihei Y, Suzuki N, **Dalmau J**. Neurological response to early removal of ovarian teratoma in anti-NMDAR encephalitis. *J Neurol Neurosurg Psychiatry* 2008;79:324-326.
- Graus F, **Dalmau J**. Paraneoplastic neurological syndromes: diagnosis and treatment. *Curr Opin Neurol* 2007;20:732-737.
- Dalmau J**, Bataller L. Limbic encephalitis: the new cell membrane antigens and proposal of a clinical-immunological classification with treatment implications. *Neurología* 2007;22:526-537.
- Tüzün E, **Dalmau J**. Limbic encephalitis and variants: Classification, diagnosis and treatment. *The Neurologist*, 2007;13:261-271.
- Iizuka T, Sakai F, Ide T, Monzen T, Yoshii S, Iigaya M, Suzuki K, Lynch DR, Suzuki N, Hata T, **Dalmau J**. Anti-NMDAR encephalitis in Japan: Long-term outcome without tumor removal. *Neurology* 2008;70:504-511. (Highlighted with editorial)
- Khella SL, Souyah N, **Dalmau J**. Thymoma, myasthenia gravis, encephalitis and a novel anticytoplasmic neuronal antibody. *Neurology* 2007;69:1302-1303.
- Díaz-Manera J, Rojas-García R, Gallardo E, Juárez C, Martínez-Domeño A, Martínez-Ramírez S, **Dalmau J**, Blesa R, Illa I. Antibodies to AChR, MuSK and VGKC in a patient with myasthenia gravis and Morvan's Syndrome. *Nat Clin Pract Neurol* 2007;3:405-410.
- Tüzün E, Rossi JE, Karner SF, Centurion AF, **Dalmau J**. Adenylate kinase 5 autoimmunity in treatment refractory limbic encephalitis. *J Neuroimmunol* 2007; 186:177-180.
- Sansing LH, Tüzün E, Ko MW, Baccon J, Lynch DR, **Dalmau J**. A patient with encephalitis associated with NMDA receptor antibodies. *Nat Clin Pract Neurol* 2007;3:291-296.
- Narula S, LaRosa DF, Kamoun M, **Dalmau J**, Levinson AI. Progressive multifocal leukoencephalopathy in a patient with common variable immunodeficiency and abnormal CD8⁺ T cell subset distribution. *Ann Allergy, Asthma, Immunol* 2007;98:483-489.
- Pilo de la Fuente B, **Dalmau J**, Rosenfeld M. Update in the treatment of gliomas [Actualización en el tratamiento de los gliomas]. *Neurología* 2007;22:159-169.
- Dalmau J**, Gonzalez RG, Lerwill MF. Case records of the Massachusetts General Hospital: Case

4-2007. A 56-year-old woman with rapidly progressive vertigo and ataxia. *N Engl J Med* 2007;356:612-620.

-Matsumoto L, Yamamoto T, Higashihara M, Sugimoto I, Kowa H, Shibahara J, Nakamura K, Shimizu J, Ugawa Y, Goto J, **Dalmau J**, Tsuji S. Severe hypokinesia caused by paraneoplastic anti-Ma2 encephalitis associated with bilateral intratubular germ-cell neoplasia. *Mov Disord* 2007;22:728-731.

-**Dalmau J**, Tüzün E, Wu H-Y, Masjuan J, Rossi JE, Voloschin A, Baehring JM, Shimazaki H, Koide R, King D, Mason W, Sansing LH, Dichter M, Rosenfeld MR, Lynch DR. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. *Ann Neurol* 2007;61:25-36. (Highlighted with editorial)(cited by F1000 Biology)

-Mathew RM, Vandenberghe R, Garcia-Merino A, Yamamoto T, Landolfi JC, Rosenfeld MR, Rossi JE, Thiessen B, Dropcho EJ, **Dalmau J**. Orchiectomy for suspected microscopic tumor in patients with anti-Ma2-associated encephalitis. *Neurology* 2007;68:900-905. (Highlighted with editorial)

-Bataller L, Kleopa KA, Wu GF, Rossi JE, Rosenfeld MR, **Dalmau J**. Autoimmune limbic encephalitis in 39 patients: immunophenotypes and outcomes. *J Neurol Neurosurg Psychiatry* 2007;78:381-385. (Highlighted with editorial)

-Koide R, Shimizu T, Koike K, **Dalmau J**. EFA6A-like antibodies in paraneoplastic encephalitis associated with immature ovarian teratoma: a case report. *J Neurooncol* 2007;81:71-74.

-**Dalmau J**, Bataller L. The clinical and immunological diversity of limbic encephalitis: a model for paraneoplastic disorders. *Hematol Oncol Clin North Am* 2006;20:1319-1335.

-Mathew RM, Cohen AB, Galetta SL, Alavi A, **Dalmau J**. Paraneoplastic cerebellar degeneration: Yo-expressing tumor revealed after a 5-year follow-up with FDG-PET. *J Neurol Sci* 2006;250:153-155.

-Castle J, Sakonju A, **Dalmau J**, Newman-Toker D. Anti-Ma2-associated encephalitis with normal FDG-PET: a case of pseudo-Whipple's disease. *Nat Clin Pract Neurol* 2006;10:566-572.

-Sabater L, Bataller L, Aguirre L, Carpentier A, Saiz A, Delattre J-Y, **Dalmau J**, Graus F. Protein kinase C γ autoimmunity in paraneoplastic cerebellar degeneration and non-small cell lung cancer. *J Neurol Neurosurg Psychiatry* 2006;77:1359-1362.

-Pruitt A, **Dalmau J**, Detre J, Alavi A, Rosenfeld MR. Episodic neurologic dysfunction with migraine and reversible imaging findings after radiation. *Neurology* 2006;67:676-678.

-Blumenthal DT, Salzman K, Digre KB, Jensen RL, Dunson W, **Dalmau J**. Early pathological findings and long-term improvement in anti-Ma2 associated encephalitis. *Neurology* 2006;67:146-149.

-Rosenfeld MR, **Dalmau J**. Current therapies for neuromuscular manifestations of paraneoplastic syndromes. *Curr Neurol Neurosci Rep* 2006;6:77-84.

- Ramchandren S, **Dalmau J**. Metastases to the peripheral nervous system. *J Neurooncol* 2005;75:101-110.
- Vitaliani R, Mason W, Ances B, Zwerdling T, Jiang Z, **Dalmau J**. Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma. *Ann Neurol* 2005;58:594-604.
- Rudnicki SA, **Dalmau J**. Paraneoplastic syndromes of the peripheral nerves. *Curr Opin Neurology* 2005;18:598-603.
- Ances BM, **Dalmau J**, Tsai J, Hasbani MJ, Galetta SL. Downbeating nystagmus and muscle spasms in a patient with glutamic-acid decarboxylase (GAD) antibodies. *Am J Ophthalmol* 2005;140:142-144.
- Graus F, Lang B, Pozo-Rosich P, Sabater L, Saiz A, Vincent A, **Dalmau J**. Anti-glial nuclear antibody: a new marker of lung cancer-related neurological syndromes. *J Neuroimmunol* 2005;165:166-171.
- Ances BM, Vitaliani R, Taylor RA, Liebeskind DS, Voloschin A, Houghton DH, Galetta SL, Dichter M, Alavi A, Rosenfeld MR, **Dalmau J**. Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates. *Brain* 2005;128:1764-1777. (Highlighted and Front cover)
- Fadul CE, Stommel EW, Dragnev KH, Eskey CJ, **Dalmau J**. Focal paraneoplastic limbic encephalitis presenting as orgasmic epilepsy. *J Neurooncol* 2005;72:195-198.
- Mut M, Schiff D, **Dalmau J**. Paraneoplastic recurrent multifocal encephalitis presenting with epilepsy partialis continua. *J Neurooncol* 2005;72:63-66.
- Rousseau A, Benyahia B, **Dalmau J**, Connan F, Guillet JG, Delattre JY, Choppin J. T-cell response against HuD peptides in patients with the "anti-Hu syndrome". *J Neurooncol* 2005;71:231-236.
- Cohen AB, Zupa-Fernandez A, **Dalmau J**, Galetta SL. Unusual neuro-ophthalmologic findings in a patient with anti-Yo associated cerebellar degeneration. *J Neurol Sci* 2004;225:153-155.
- Dalmau J**, Graus F, Villarejo A, Posner JB, Blumenthal D, Thiessen B, Saiz A, Meneses P, Rosenfeld MR. Clinical analysis of anti-Ma2 associated encephalitis. *Brain* 2004;127:1831-1844.
- Graus F, Delattre JY, Antoine JC, **Dalmau J**, Giometto B, Grisold W, Honnorat J, Sillevs-Smitt P, Vedeler C, Verschuuren J, Vincent A, Voltz R. Recommended diagnostic criteria for paraneoplastic neurological syndromes. *J Neurol Neurosurg Psychiatry* 2004;75:1135-1140.
- Bataller L, Wade DF, Graus F, Stacey HD, Rosenfeld MR, **Dalmau J**. Antibodies to Zic4 in paraneoplastic neurologic disorders and small-cell lung cancer. *Neurology* 2004;62:778-782.
- Bataller L, **Dalmau J**. Neuro-ophthalmology and paraneoplastic syndromes. *Curr Opin Neurology* 2004;17:3-8.

- Overeem S, **Dalmau J**, Bataller L, Nishino S, Mignot E, Verschuuren J, Lammers GJ. Anti-Ma2 antibodies in idiopathic and paraneoplastic hypoproteinemic narcolepsy. *Neurology* 2004;62:138-140.
- Schiff D, **Dalmau J**, Myers DJ. Anti-GAD antibody positive stiff-limb syndrome in multiple myeloma. *J Neurooncol* 2003;65:173-175.
- Gill S, Murray N, **Dalmau J**, Thiessen B. Paraneoplastic sensory neuronopathy and spontaneous regression of small cell lung cancer. *Can J Neurol Sci* 2003;30:269-271.
- Bataller L, Dalmau J. Paraneoplastic neurologic syndromes. *Neurol Clin* 2003;21:221-47.**
- Bataller L, Rosenfeld MR, Graus F, Vilchez JJ, Cheung NK, **Dalmau J**. Autoantigen diversity in the opsoclonus-myoclonus syndrome. *Ann Neurol* 2003;53:347-353.
- Bernal F, Shamsili S, Rojas I, Sanchez-Valle R, Saiz A, **Dalmau J**, Honnorat J, Sillevs-Smitt P, Graus F. Clinical and immunological features of patients with anti-Tr antibodies. *Neurology* 2003;60:230-234.
- Bataller L, Wade DF, Graus F, Rosenfeld MR, **Dalmau J**. The MAZ protein is an autoantigen of Hodgkin's disease and paraneoplastic cerebellar dysfunction. *Ann Neurol* 2003;53:123-127.
- Rosenfeld MR, **Dalmau J**. Current therapy of paraneoplastic syndromes. *Curr Treat Opt Neurol* 2003;5:69-77.
- Bataller L, Wade DF, Fuller GN, Rosenfeld MR, **Dalmau J**. Cerebellar degeneration and autoimmunity to zinc-finger proteins of the cerebellum (Zic). *Neurology* 2002;59:1985-1987.
- Sutton IJ, Barnett MH, Watson JDG, Ell JJ, **Dalmau J**. Paraneoplastic brainstem encephalitis and anti-Ri antibodies. *J Neurol* 2002;249:1597-1598.
- Greenlee JE, Steffens JD, Clawson SA, Hill K, **Dalmau J**. Anti-Hu antibodies in Merkel cell carcinoma. *Ann Neurol* 2002;52:111-115.
- Bataller L, Graus F, **Dalmau J**. Retinopatía paraneoplásica y anticuerpos antirecoverina (Paraneoplastic retinopathy and antirecoverin antibodies). *Neurología* 2002;17:156.
- Eichen J, **Dalmau J**, Demopoulos A, Wade D, Posner JB, Rosenfeld MR. The photoreceptor cell-specific nuclear receptor (PNR) is an autoantigen of cancer-associated retinopathy. *J Neuroophthalmol* 2001;21:168-172.
- Rosenfeld MR, Eichen J, Wade D, Posner JB, **Dalmau J**. Molecular and clinical diversity in paraneoplastic immunity to Ma proteins. *Ann Neurol* 2001;50:339-348.
- Croteau D, Owainati A, **Dalmau J**, Rogers LR. Paraneoplastic choreiform disorder in a patient with small-cell lung carcinoma: identification of a unique antineuronal antibody and successful response to chemotherapy. *Neurology* 2001;57:719-722.

- Prestigiacomo CJ, Balmaceda C, **Dalmau J**. Anti-Ri associated paraneoplastic opsoclonus-ataxia syndrome in a man with transitional cell carcinoma. *Cancer* 2001;91:1423-1428.
- Barnett M, Prosser J, Sutton I, Halmagyi GM, Davies L, Harper C, **Dalmau J**. Paraneoplastic brainstem/limbic encephalitis in a woman with anti-Ma2 antibody. *J Neurol Neurosurg Psychiatry* 2001;70:222-225.
- Rudnicki SA, **Dalmau J**. Paraneoplastic syndromes of the spinal cord, nerve, and muscle. *Muscle Nerve* 2000;23:1800-1818.
- Rojas I, Graus F, Keime-Guibert F, Reñé R, Delattre JY, Ramón JM, **Dalmau J**, Posner JB. Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. *Neurology* 2000;55:713-715.
- Antunes NL, Khakoo Y, Matthay KK, Seeger RC, Stram DO, Gerstner E, Abrey L, **Dalmau J**. Antineuronal antibodies in patients with neuroblastoma and paraneoplastic opsoclonus-myoclonus. *J Pediatr Hematol Oncol* 2000;22:315-320.
- Sutton I, Winer J, Rowlands D, **Dalmau J**. Limbic encephalitis and anti-Ma antibodies: A paraneoplastic presentation of breast cancer. *J Neurol Neurosurg Psychiatry* 2000;69:266-268.
- Gultekin SH, Rosenfeld MR, Voltz R, Eichen J, Posner JB, **Dalmau J**. Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings, and tumor association in 50 patients. *Brain* 2000;123:1481-1494.
- Lousa M, Sanchez-Alonso S, Rodriguez-Diaz R, **Dalmau J**. Status epilepticus without antibodies to glutamate receptor 3 (GluR3): Response to plasma exchange. *Neurology* 2000;54:2163-2165.
- Gultekin SH, Rosai J, Demopoulos A, Graus YF, Posner JB, **Dalmau J**, Rosenblum MK. Hu-immunolabeling as a marker of neural and neuroendocrine differentiation in normal and neoplastic human tissues: assessment using a recombinant anti-Hu Fab fragment. *Int J Surg Pathol* 2000;8:109-117.
- Fritzier MJ, Kerfoot SM, Feasby TE, Zochodne DW, Westendorf JM, **Dalmau J**, Chan EKL. Autoantibodies from patients with idiopathic ataxia bind to M-phase phosphoprotein-1 (MPP1). *J Invest Med* 2000;48:28-39.
- Saiz A, Graus F, **Dalmau J**, Pifarré A, Marín C, Tolosa E. Detection of 14-3-3 brain protein in the cerebrospinal fluid of patients with paraneoplastic neurologic disorders. *Ann Neurol* 1999;46:774-777.
- Dalmau J**. Complicaciones neurológicas metastásicas en pacientes con cáncer (Metastatic neurologic complications in cancer patients). *Rev Neurol* 1999;29:188-191.
- Porta-Etessam J, **Dalmau J**. Análisis de las consultas neurológicas en un hospital oncológico: contribuciones de la neuro-oncología (Analysis of the neurologic consultations in an oncologic hospital: contributions of neuro-oncology). *Neurología* 1999;14:266-274.

-Greenlee JE, **Dalmau J**, Lyons T, Clawson S, Smith RH, Pirch HR. Association of anti-Yo (type I) antibody with paraneoplastic cerebellar degeneration in the setting of transitional cell carcinoma of the bladder: detection of Yo antigen in tumor tissue and fall in antibody titers following tumor removal. *Ann Neurol* 1999;45:805-809.

-Drabkin HA, West JD, Hotfilder M, Heng YM, Erickson P, Calvo R, **Dalmau J**, Gemmill RM, Sablitzky F. DEF-3(g16/NY-LU-12), an RNA binding protein from the 3p21.3 homozygous deletion region in SCLC. *Oncogene* 1999;18:2589-2597.

-Voltz R, Gultekin SH, Rosenfeld MR, Gerstner E, Eichen J, Posner JB, **Dalmau J**. A serological marker of paraneoplastic limbic and brainstem encephalitis in patients with testicular cancer. *N Engl J Med* 1999;340:1788-1795. (Highlighted publication)

-Rosenfeld MR, Gutin PH, **Dalmau J**. Aspectos prácticos en el diagnóstico y tratamiento de los gliomas cerebrales (Practical aspects in the diagnosis and treatment of brain tumors). *Neurología* 1999;14:111-121.

-**Dalmau J**, Gultekin HS, Posner JB. Paraneoplastic neurologic syndromes: pathogenesis and physiopathology. *Brain Pathol* 1999;9:275-284.

-Bennett JL, Galetta SL, Frohman LP, Mourelatos Z, Gultekin SH, **Dalmau JO**, Posner JB. Neuro-ophthalmologic manifestations of a novel paraneoplastic syndrome associated with testicular carcinoma. *Neurology* 1999;52:864-867.

-Saiz A, **Dalmau J**, Butler MH, Chen Q, Delattre J-Y, De Camilli P, Graus F. Anti-amphiphysin I antibodies in patients with paraneoplastic neurologic disorders associated with small-cell lung carcinoma. *J Neurol Neurosurg Psychiatry* 1999;66:214-217.

-Benyahia B, Liblau R, Merle-Béral H, Tourani J-M, **Dalmau J**, Delattre J-Y. Cell-mediated autoimmunity in paraneoplastic neurologic syndromes with anti-Hu antibodies. *Ann Neurol* 1999;45:162-167. (Highlighted publication)

-**Dalmau J**, Gultekin SH, Voltz R, Hoard R, DesChamps T, Balmaceda C, Batchelor T, Gerstner E, Eichen J, Frennier J, Posner JB, Rosenfeld MR. Ma1, a novel neuronal and testis specific protein, is recognized by the serum of patients with paraneoplastic neurologic disorders. *Brain* 1999;122:27-39. (Highlighted publication)

-Abrey LE, **Dalmau JO**. Neurologic complications of ovarian carcinoma. *Cancer* 1999;85:127-133.

-Voltz RD, Carpentier AF, Rosenfeld MR, Posner JB, **Dalmau J**. P/Q-type voltage gated calcium channel antibodies in patients with paraneoplastic disorders of the central nervous system. *Muscle Nerve* 1999;22:119-122.

-**Dalmau J**, Posner JB. Paraneoplastic syndromes. *Arch Neurol* 1999;56:405-408.

-Carpentier AF, Rosenfeld MR, Delattre J-Y, Whalen RG, Posner JB, **Dalmau J**. DNA vaccination with HuD inhibits tumor growth of a neuroblastoma in mice. *Clin Cancer Res* 1998;4:2819-2824.

- Voltz R, **Dalmau J**, Posner JB, Rosenfeld MR. T-cell receptor analysis in anti-Hu associated paraneoplastic encephalomyelitis. *Neurology* 1998;51:1146-1150.
- Graus F, Gultekin S.H, Ferrer I, Reiriz J, Alberch J, **Dalmau J**. Localization of the neuronal antigen recognized by anti-Tr antibodies from patients with paraneoplastic cerebellar degeneration and Hodgkin's disease in the rat nervous system. *Acta Neuropathol* 1998;96:1-7.
- Carpentier AF, Voltz RD, Deschamps T, Posner JB, **Dalmau J**, Rosenfeld MR. Absence of HuD gene mutations in paraneoplastic small cell lung cancer tissue. *Neurology* 1998;50:1919.
- Levin MC, Krichavsky M, Berk J, Foley S, Rosenfeld M, **Dalmau J**, Chang G, Posner JB, Jacobson S. Neuronal molecular mimicry in immune-mediated neurologic disease. *Ann Neurol* 1998;44:87-98.
- Vincent A, Honnorat J, Antoine JC, Giometto B, **Dalmau J**, Lang B. Autoimmunity in paraneoplastic neurological disorders. *J Neuroimmunol* 1998;84:105-109.
- Graus YF, Verschuuren JJ, Degenhardt A, van Breda Vriesman PJ, De Baets MH, Posner JB, Burton DR, **Dalmau J**. Selection of recombinant anti-HuD Fab fragments from a phage display antibody library of a patient with paraneoplastic encephalomyelitis/sensory neuropathy. *J Neuroimmunol* 1998;82:200-209.
- Degenhardt A, Duvoisin RM, Frennier J BS, Gultekin SH, Rosenfeld MR, Posner JB, **Dalmau J**. Absence of antibodies to non-NMDA glutamate receptors in patients with paraneoplastic cerebellar degeneration. *Neurology* 1998;50:1392-1397.
- Verschuuren JJ, **Dalmau J**, Tunkel R, Lang B, Graus F, Schramm L, Posner JB, Newsom-Davis J, Rosenfeld MR. Antibodies against the calcium channel β -subunit in Lambert-Eaton myasthenic syndrome. *Neurology* 1998;50:475-479.
- Batchelor TT, Platten M, Palmer-Toy DE, Hunter GJ, Lev MH, **Dalmau J**, Hochberg FH. Chorea as a paraneoplastic complication of Hodgkin's disease. *J Neuro-oncol* 1998;36:185-190.
- Gultekin SH, **Dalmau J**, Graus Y, Posner JB, Rosenblum MK. Anti-Hu immunolabeling as an index of neuronal differentiation in human brain tumors- A study of 112 central neuroepithelial neoplasms. *Am J Surg Pathol* 1998;22:195-200.
- Verschuuren J, **Dalmau J**, Hoard R, Posner JB. Paraneoplastic anti-Hu serum: Studies on human tumor cell lines. *J Neuroimmunol* 1997;79:202-210.
- Schenck CH, Ullevig CM, Mahowald MW, **Dalmau J**, Posner JB. A controlled study of serum anti-locus ceruleus antibodies in REM sleep behaviour disorder. *Sleep* 1997;20:349-351.
- Voltz RD, Graus F, Posner JB, **Dalmau J**. Paraneoplastic encephalomyelitis: An update of the effects of the anti-Hu immune response on the nervous system and tumor. *J Neurol Neurosurg Psychiatry* 1997;63:133-136.
- Mason WP, Graus F, Lang B, Honnorat J, Delattre J-Y, Valldeoriola F, Antoine JC, Rosenblum

MK, Rosenfeld MR, Newsom-Davis J, Posner JB, **Dalmau J**. Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. *Brain* 1997;120:1279-1300.

-Graus F, **Dalmau J**, Reñé R, Torà M, Malats N, Verschuuren JJ, Cardenal F, Viñolas N, García del Muro J, Vadell C, Mason WP, Rosell R, Posner JB, Real FX. Anti-Hu antibodies in patients with small cell lung cancer: association with complete response to therapy and improved survival. *J Clin Oncol* 1997;15:2866-2872.

-Rosenfeld M, **Dalmau J**. Tumores cerebrales primarios: realidad y bases moleculares de futuros tratamientos (Primary brain tumors: reality, and molecular studies for future therapies). *Neurología* 1997;12:185-196.

-Forsyth PA, **Dalmau J**, Graus F, Cwik V, Rosenblum MK, Posner JB. Motor neuron syndromes in cancer patients. *Ann Neurol* 1997;41:722-730. (Highlighted publication)

-Honorat J, Trillet M, Antoine J-C, Aguera M, **Dalmau J**, Graus F. Paraneoplastic opsomyoclonus, cerebellar ataxia and encephalopathy associated with anti-Purkinje cell antibodies. *J Neurol* 1997;244:333-339.

-Graus F, **Dalmau J**, Valldeoriola F, Ferrer I, Reñé R, Marin C, Vecht ChJ, Arbizu T, Targa C, Moll JWB. Immunological characterization of a neuronal antibody (anti-Tr) associated with paraneoplastic cerebellar degeneration and Hodgkin's disease. *J Neuroimmunol* 1997;74:55-61.

-Mason WP, **Dalmau J**, Curtin JP, Posner JB. Normalization of the tumor marker CA-125 after oophorectomy in a patient with paraneoplastic cerebellar degeneration without detectable cancer. *Gynecol Oncol* 1997;65:173-176.

-Honorat J, Guillon B, De Ferron E, Aguera M, Antoine JC, **Dalmau J**. Association of antineuronal autoantibodies in a patient with paraneoplastic cerebellar syndrome and small cell lung cancer. *J Neurol Neurosurg Psychiatry* 1997;62:425-426.

-Byrne T, Mason WP, **Dalmau J**, Posner JB. Spontaneous neurological improvement in anti-Hu associated encephalomyelitis. *J Neurol Neurosurg Psychiatry* 1997;62:276-278.

-Rosenfeld MR, Malats N, Schramm L, Graus F, Cardenal F, Viñolas N, Rosell R, Real FX, Posner JB, **Dalmau J**. Serum anti-p53 antibodies are not a prognostic marker in small cell lung cancer. *J Natl Cancer Inst* 1997;89:381-385. (Highlighted publication)

-Corradi JP, Yang C, Darnell JC, **Dalmau J**, Darnell RB. A post-transcriptional regulatory mechanism restricts expression of the paraneoplastic cerebellar degeneration antigen cdr2 to immune privileged tissues. *J Neurosci* 1997;17:1406-1415.

-Sillevis-Smitt P, Manley G, **Dalmau J**, Posner JB. The HuD paraneoplastic protein shares immunogenic regions between PEM/PSN patients and several strains and species of experimental animals. *J Neuroimmunol* 1996;71:199-206.

-Ben David Y, Warner E, Levitan M, Sutton DMS, Malkin MG, **Dalmau J**. Autoimmune

paraneoplastic cerebellar degeneration in ovarian carcinoma treated with plasmapheresis and immunoglobulin - a case report. *Cancer* 1996;78:2153-2156.

-Sillevis-Smitt P, Manley G, Moll JWB, **Dalmau J**, Posner JB. Pitfalls in the diagnosis of auto-antibodies that are associated with paraneoplastic neurological disease. *Neurology* 1996;46:1739-1741.

-Krackawer J, Balmaceda CM, Posner JB, **Dalmau J**. Anti-Yo associated paraneoplastic cerebellar degeneration in a man with adenocarcinoma of unknown origin. *Neurology* 1996;46:1486-1487.

-Verschuuren J, Chuang L, Rosenblum MK, Lieberman F, Pryor A, Posner JB, **Dalmau J**. Inflammatory infiltrates and complete absence of Purkinje cells in anti-Yo associated paraneoplastic cerebellar degeneration. *Acta Neuropathol* 1996;91:519-525.

-Posner JB, **Dalmau J**. Neurological paraneoplastic syndromes: a review of diagnosis and prospects for therapy. *J Clin Neuroscience* 1996;3:8-15.

-Rosenfeld MR, Meneses P, **Dalmau J**, Drobnjak M, Cordon-Cardo C, Kaplitt MG. Gene transfer of wild-type p53 results in restoration of tumor suppressor function in a medulloblastoma cell line. *Neurology* 1995;45:1533-1539.

-Manley GT, Sillevis Smitt P, **Dalmau J**, Posner JB. Hu Antigens: Reactivity with Hu antibodies, tumor expression, and major immunogenic sites. *Ann Neurol* 1995;38:102-110.

-Liu J, **Dalmau J**, Szabo A, Rosenfeld M, Huber J, Furneaux H. Paraneoplastic encephalomyelitis antigens bind to the AU-rich elements of mRNA. *Neurology* 1995;45:544-550.

-Posner JB, **Dalmau J**. Clinical enigmas of paraneoplastic neurological disorders. *Clin Neurol Neurosurg* 1995;97:1-11.

-**Dalmau J**, Graus F, Cheung NK, Rosenblum MK, Ho A, Cañete A, Delattre JY, Thompson SJ, Posner JB. Major histocompatibility (MHC) proteins, anti-Hu antibodies and paraneoplastic encephalomyelitis in neuroblastoma and small cell lung cancer. *Cancer* 1995;75:99-109.

-**Dalmau J**, Posner JB. Neurologic paraneoplastic antibodies (anti-Yo; anti-Hu; anti-Ri): the case for a nomenclature based on antibody and antigen specificity. *Neurology* 1994;44:2241-2246.

-Hormigo A, **Dalmau J**, Rosenblum M, River ME, Posner JB. Immunological and pathological study of anti-Ri associated encephalopathy. *Ann Neurol* 1994;36:896-902.

-Hersh B, **Dalmau J**, Dangond F, Gultekin S, Geller E, Wen PY. Paraneoplastic opsoclonus-myoclonus associated with anti-Hu antibody. *Neurology* 1994;44:1754-1755.

-Verschuuren J, Twijnstra A, De Baets M, Thunnissen F, **Dalmau J**, Posner JB, Vriesman PVB. Hu-antigen and anti-Hu antibodies in a patient with myxoid chondrosarcoma. *Neurology* 1994;44:1551-1552.

-Manley G, Wong E, **Dalmau J**, Elkon K, Posner J, Furneaux H. Sera from some patients with

antibody-associated paraneoplastic encephalomyelitis/ sensory neuronopathy recognize the Ro-52K antigen. *J Neuro-oncol* 1994;19:105-112.

-Ahern GL, O'Connor M, **Dalmau J**, Coleman A, Posner JB, Schomer DL, Herzog AG, Kolb DA, Mesulam M. Paraneoplastic temporal lobe epilepsy with testicular neoplasm and atypical amnesia. *Neurology* 1994;44:1270-1274.

-Balmaceda CM, Walker RW, Castro-Malaspina H, **Dalmau J**. Reversal of Amphotericin B-related encephalopathy. *Neurology* 1994;44:1183-1184.

-Younger DS, **Dalmau J**, Inghirami G, Sherman WH, Hays AP. Anti-Hu-associated peripheral nerve and muscle microvasculitis. *Neurology* 1994;44:181-183.

-Jean WC, **Dalmau J**, Ho A, Posner JB. Analysis of the IgG subclass distribution and inflammatory infiltrates in patients with anti-Hu associated paraneoplastic encephalomyelitis. *Neurology* 1994;44:140-147.

-Condom E, Vidal A, Rota R, Graus F, **Dalmau J**, Ferrer I. Paraneoplastic intestinal pseudo-obstruction associated with high titres of Hu autoantibodies. *Virchows Archiv A Pathol Anat* 1993;423:507-511.

-Rosenfeld MR, **Dalmau J**. Paraneoplastic syndromes and progressive motor dysfunction. *Semin Neurol* 1993;3:291-298.

-Rosenfeld MR, Wong E, **Dalmau J**, Manley G, Posner JB, Sher E, Furneaux HM. Serum from patients with Lambert-Eaton myasthenic syndrome recognize the beta subunit of calcium channel complexes. *Ann NY Acad Sci* 1993;681:408-411.

-Graus F, Rowe G, Fueyo G, Darnell RB, **Dalmau J**. The neuronal nuclear antigen recognized by the human anti-Ri autoantibody is expressed in central but not peripheral nervous system neurons. *Neuroscience Letters* 1993;150:212-214.

-Rosenfeld MR, Wong E, **Dalmau J**, Manley G, Posner JB, Sher E, Furneaux HM. Cloning and characterization of a Lambert-Eaton myasthenic syndrome antigen. *Ann Neurol* 1993; 33:113-120. (Expedited publication)

-Schlegel U, Rosenfeld MR, Volkenandt M, Rosenblum M, **Dalmau J**, Furneaux H. p53 gene mutations in primary lung tumors are conserved in brain metastases. *J Neuro-oncol* 1992;14:93-100.

-**Dalmau J**, Furneaux HM, Cordon-Cardo C, Posner JB. The expression of the Hu (paraneoplastic encephalomyelitis/sensory neuronopathy) antigen in human normal and tumor tissues. *Am J Pathol* 1992; 141:881-886.

-**Dalmau J**, Graus F, Rosenblum MK, Posner JB. Anti-Hu associated paraneoplastic encephalomyelitis/ sensory neuronopathy. A clinical study of 71 patients. *Medicine* 1992; 71:59-72.

-Szabo A, **Dalmau J**, Manley G, Rosenfeld M, Wong E, Henson J, Posner JB, Furneaux HM. HuD, a paraneoplastic encephalomyelitis antigen contains RNA binding domains and is homologous to

Elav and Sex-Lethal. Cell 1991; 67:325-333.

-**Dalmau J**, Furneaux HM, Rosenblum MK, Graus F, Posner JB. Detection of the anti-Hu antibody in specific regions of the nervous system and tumor from patients with paraneoplastic encephalomyelitis/ sensory neuronopathy. Neurology 1991;41:1757-1764.

-**Dalmau J**, Furneaux HM, Gralla RJ, Kris MG, Posner JB. Detection of the anti-Hu antibody in the serum of patients with small cell lung cancer - A quantitative Western blot analysis. Ann Neurol 1990;27:544-552.

-Furneaux HM, Rosenblum MK, **Dalmau J**, Wong E, Woodruff P, Graus F and Posner JB. Selective expression of Purkinje-cell antigens in tumor tissue from patients with paraneoplastic cerebellar degeneration. N Engl J Med 1990; 322:1844-1851.

-**Dalmau J**, Marco M, Graus F. "Hot and dry foot", as initial manifestation of neoplastic lumbosacral plexopathy. Neurology 1989;39:871-872.

-Marco M, **Dalmau J**, Aguilar M. Hypoglossal nerve palsy associated with cancer. Neurología 1989;4:277-281.

-**Dalmau J**, Graus F, Marco M. Lumbosacral plexopathy in cancer patients. Med Clin 1988; 91:40-46.

-Marco M, **Dalmau J**, Aguilar M, Diestre G, Dalmau B, Segura F, Ripoll E. Cerebrovascular disease in Sabadell. A prospective study in the community hospitals of Sabadell. Neurología 1986; 1:194-197.

-**Dalmau J**, Martí-Vilalta, Aguilar M. Wilson's disease. (Hepatolenticular degeneration). Med Clin 1984; 83:78-85.

-**Dalmau J**, Marco M, Pradas J, Illa I. Acute muscle weakness secondary to treatment with Clopamide. Rev Clin Esp 1984; 173:245-247.

-Martí-Vilalta JL, **Dalmau J**. Cerebrovascular disease and mitral valve prolapse. Med Clin 1984; 82:484-486.

-**Dalmau J**, Roig C, Oliver B, Coll J. Pituitary apoplexy. A case report and review. Arch Neurobiol 1983; 5:311-316.

-**Dalmau J**, Roig C, Martí-Vilalta JL, Grau JM. Wilson's disease. A case report, and review of treatment. Sant Pau 1981; 2:181-187.

BOOKS

Dalmau J, Graus F. Autoimmune Encephalitis and Related Disorders of the Nervous System. 1st ed, Cambridge, UK, Cambridge University Press 2022.

CHAPTERS

-**Dalmau J**, Rosenfeld MR, Graus F. Paraneoplastic neurologic syndromes and autoimmune encephalitis. In: Loscalzo, Fauci, Kasper, Hauser, Longo, Jameson (eds). Harrison's Principles of Internal Medicine, 21th edition. New York, McGraw-Hill, Inc, New York, 2022:728-736.

-Rosenfeld MR, **Dalmau J**. Paraneoplastic disorders of the nervous system. In: Jankovic J, Mazziotta JC, Pomeroy SL, Newman NJ (eds). Bradley and Daroff's Neurology in Clinical Practice, 7th ed, London, Elsevier 2022;1255-1263.

-Rosenfeld MR, **Dalmau J**. Autoimmune encephalopathies with antibodies to cell surface antigens. In: Jankovic J, Mazziotta JC, Pomeroy SL, Newman NJ (eds). Bradley and Daroff's Neurology in Clinical Practice, 8th ed, London, Elsevier 2022: 1263-1268.

-**Dalmau J**, Rosenfeld MR. Paraneoplastic neurologic syndromes. In: Niederhuber JE, Armitage J, Doroshow J, Kastan M, Tepper J (eds). Abeloff's Clinical Oncology, 6th edition. Philadelphia: Elsevier, 2020, pp 676-688.

-Armangue T, **Dalmau J**. Autoimmune encephalitis. In: Nelson Textbook of Pediatrics, 21th ed. Kliegman RM, Stanton BF, Geme J St, Schor N, eds. Philadelphia, Elsevier, 2020;3179-3180.

-Rosenfeld MR, **Dalmau J**. Paraneoplastic neurologic syndromes. In: Wen P, Lee EQ (eds). Neurol Clin, Neuro-oncology. Philadelphia, Elsevier, 2018;36:675-685.

-**Dalmau J**, Rosenfeld MR. Neurologic paraneoplastic syndromes. In: Jameson, Fauci, Kasper, Hauser, Longo, Loscalzo (eds). Harrison's Principles of Internal Medicine, 20th edition. New York: McGraw-Hill, Inc, 2018;668-674.

-Rosenfeld MR, **Dalmau J**. Paraneoplastic syndromes of the nervous system. In: Schiff D, Arrillaga I, Wen PCY (eds). Cancer Neurology in Clinical Practice- Neurological Complications of Cancer and its Treatment, 3rd ed, New York, Springer, 2018;221-240.

-Rosenfeld MR, **Dalmau J**. Paraneoplastic disorders of the nervous system. In: Daroff RB, Jankovic J, Mazziotta JC, Pomeroy SL (eds). Bradley's Neurology in Clinical Practice, 7th ed, London, Elsevier 2016;1187-1196.

-Rosenfeld MR, **Dalmau J**. Autoimmune encephalopathies with antibodies to cell surface antigens. In: Daroff RB, Jankovic J, Mazziotta JC, Pomeroy SL (eds). Bradley's Neurology in Clinical Practice, 7th ed, London, Elsevier 2016: 1196-1201.

-Rosenfeld MR, Titulaer M, **Dalmau J**. Overview: Other proven and putative autoimmune diseases. In, Neurobiology of Disease, 2nd edition, Chapter 142. Johnston M, Adams Jr H, Fatemi A (eds)., Newgen Knowledge Works, Chinna, India 2016, 1019-1023.

-Armangue T, **Dalmau J**. Autoimmune encephalitis. In: Nelson Textbook of Pediatrics, 20th ed. Kliegman RM, Stanton BF, Geme J St, Schor N, eds. Philadelphia, Elsevier, 2016; pp 2905-2911.

-Rosenfeld MR, **Dalmau J**. General approach to the diagnosis and treatment of paraneoplastic neurologic disorders. International Neurology, 2nd edition. Lisak RP, Truong DD, Carroll WM,

Bhidayashi R (eds). Wiley-Blackwell, 2016, 599-601.

-Rosenfeld MR, **Dalmau J**. Autoimmune encephalitis with neuronal cell surface antibodies. *International Neurology*, 2nd edition. Lisak RP, Truong DD, Carroll WM, Bhidayashi R (eds). Wiley-Blackwell, 2016, 98-100.

-**Dalmau J**, Rosenfeld MR. Paraneoplastic neurologic syndromes. In: Hauser SL, Tinsley RH, Josephson S (eds). *Harrison's Neurology in Clinical Medicine*, 3rd edition. New York: McGraw-Hill, Inc 2015;614-619.

-Rosenfeld MR, **Dalmau J**. Paraneoplastic syndromes and motor dysfunction. In: DS Younger (ed). *Textbook of Motor Disorders*, 3rd edition. Philadelphia, Lippincott Williams & Wilkins, 2015;791-798.

-Valdeoriola F, **Dalmau J**. Paraneoplastic and immunologically mediated movement disorders. In: Jancovic J, Tolosa E (eds). *Parkinson's Disease & Movement Disorders*, 6th ed. Philadelphia: Wolters Kluwer, 2015;351-356.

-Valdeoriola F, **Dalmau J**. Paraneoplastic movement disorders. In: Poewe W, Jankovic J, (eds), *Movement Disorders in Neurologic and Systemic Diseases*. Cambridge University Press, 2014, pp 39-51.

-**Dalmau J**, Rosenfeld MR. Autoimmune encephalitis update. *Neuro-oncology*, invited review. 2014;16:771-778.

-**Dalmau J**, Rosenfeld MR. Paraneoplastic neurologic syndromes. In: Armitage J, Niederhuber JE, et al (eds). *Abeloff's Clinical Oncology*, 5th edition. Philadelphia: Elsevier 2014;597-607.

-Rosenfeld MR, **Dalmau J**. Paraneoplastic syndromes, central. In: Aminoff MJ, Daroff RB, eds). *Encyclopedia of Neurological Sciences*, 2nd edition. Vol 1 pp. 787-789, 2014. Oxford: Academic Press.

-Rosenfeld MR, **Dalmau J**. Autoimmune encephalitis affecting synaptic proteins. In: Aminoff MJ, Daroff, RB eds). *Encyclopedia of Neurological Sciences*, 2014, 2nd edition, vol 1, pp. 342-344. Oxford: Academic Press.

-Panzer J, **Dalmau J**. Anti-NMDA receptor encephalitis and other autoimmune and paraneoplastic movement disorders. In: Frucht S (ed). *Movement Disorder Emergencies: Diagnosis and Treatment (Current Clinical Neurology)*, 2nd ed. New York: Humana Press 2013: 286-303.

-**Dalmau J**, Rosenfeld MR. Neurologic paraneoplastic syndromes. In: Longo, Fauci, Kasper, Hauser, Jameson, Loscalzo (eds). *Harrison's Principles of Internal Medicine*, 18th edition. New York: McGraw-Hill, Inc, 2013, 480-485.

-Rosenfeld MR, **Dalmau J**. Diagnosis and management of paraneoplastic neurologic disorders. *Curr Treat Opt Oncol*, 2013;14:528-538.

-Rosenfeld MR, **Dalmau J**. Paraneoplastic disorders of the central nervous system and autoimmune

synaptic encephalitis. In: Schiff D (ed), Continuum (Minneapolis, Minn). 2012 Apr;18(2):366-83.

-Rosenfeld MR, **Dalmau J**. Cancer and the nervous system: Paraneoplastic syndromes. In: Bradley WG, Daroff RB, Fenichel GM, Jankovic J (eds). Neurology in Clinical Practice, 6th ed, Elsevier 2012:1200-1210.

-Rosenfeld MR, **Dalmau J**. Paraneoplastic neurologic disorders: A brief overview. Mag Eur Med Oncol. 2012; 3:197-200.

-Rosenfeld MR, **Dalmau J**. CNS paraneoplastic diseases. In: Grisold W, Soffiatti R, (eds). Handb Clin Neurol. 2012;105:853-64.

-**Dalmau J**. Anti-NMDA receptor encephalitis: Pathogenic mechanisms and treatment algorithm. Rinsho Shinkeigaku 2012;52:978.

-Rosenfeld MR, **Dalmau J**. Paraneoplastic neurologic disorders in leukemia and lymphoma. In: Batchelor T, DeAngelis LM (eds). Lymphoma and leukemia of the nervous system, 2nd ed. Springer, New York, 2012: 329-345.

-Rosenfeld MR, **Dalmau J**. Immune-mediated paraneoplastic neurologic disorders: An overview. In: RJ Packer, D Schiff (eds). Neuro-oncology, 1st edition. John Wiley, 2012: 213-222.

-**Dalmau J**, Rosenfeld MR. Paraneoplastic syndromes causing movement disorders. In: WJ Weiner, E Tolosa (eds). Handb Clin Neurol, (3rd series), Hyperkinetic Movement Disorders. Elsevier, 2011;100:315-321.

-Titulaer, MJ, Soffiatti R, **Dalmau J**, Gilhus NE, Giometto B, Graus F, Grisold W, Honnorat J, Sillevs PAE, Tanasescu R, Vedeler CA, Voltz R, Verschuuren JJGM. Screening for tumours in paraneoplastic syndromes. In: Gilhus NE, Barnes MP, Brainin M (eds). European Handbook of Neurological Management, 2nd ed. Blackwell, New Jersey, 2012;2:309-320.

-**Dalmau J**, Rosenfeld MR. Paraneoplastic neurologic syndromes. In: Hauser SL (ed). Harrison's Neurology in Clinical Medicine, 2nd edition. New York: McGraw-Hill, Inc, 2010, 516-524.

-**Dalmau J**, Rosenfeld MR. Paraneoplastic neurologic syndromes. In: Longo DL (ed). Harrison's Hematology and Oncology. New York: McGraw-Hill, Inc, 2010, 631-639.

-Rosenfeld MR, **Dalmau J**. Paraneoplastic neurologic disorders: General treatment approach and specific syndromes. In: Rees J, Wen P (eds). Neuro-oncology, Blue Books of Practical Neurology, Philadelphia, Elsevier, 2010; 410-430.

-Rosenfeld MR, **Dalmau J**. Update on paraneoplastic and autoimmune disorders of the central nervous system. Semin Neurol 2010;30:320-331.

-Graus F, Saiz A, **Dalmau J**. Antibodies and neuronal autoimmune disorders of the CNS. J Neurol, 2010;257:509-517.

-**Dalmau J**, Rosenfeld MR. Paraneoplastic neurologic disorder. In: Lisak RP, Truong D, Carroll

WM, Bhidayasiri R (eds). *International Neurology: A Clinical Approach*. Oxford, Wiley-Blackwell 2009;550-553.

-Bataller L, **Dalmau J**. Paraneoplastic disorders of the memory and cognition. In: Miler BL, Boeve BF (eds). *Behavioral Neurology of Dementia*. New York: Cambridge University Press 2009: 377-394.

-Rosenfeld MR, **Dalmau J**. Cancer and the nervous system: Paraneoplastic syndromes. In: Bradley WG, Daroff RB, Fenichel GM, Jankovic J (eds). *Neurology in Clinical Practice*, 5th ed. Philadelphia: Elsevier 2008;1405-1415.

-Rosenfeld MR, **Dalmau J**. Paraneoplastic syndromes of the nervous system. In: Schiff D, Kesari S, Wen PY (eds). *Current Clinical Oncology: Cancer Neurology in Clinical Practice*. Totowa, Humana Press, 2008;237-255.

-**Dalmau J**, Rosenfeld MR. Paraneoplastic neurologic syndromes. In: Armitage J, Niederhuber JE, et al (eds). *Abeloff's clinical oncology*, 4th edition. Philadelphia: Elsevier 2008;767-778.

-**Dalmau J**, Rosenfeld MR. Paraneoplastic neurologic syndromes. In: Fauci, Braunwald, Kasper, Hauser, Longo, Jameson, Loscalzo (eds). *Harrison's Principles of Internal Medicine*, 17th edition. New York: McGraw-Hill, Inc, 2008, 623-628.

-**Dalmau J**. Paraneoplastic disorders of the memory and cognition: clinical aspects and therapeutic approaches. In: Vinken PJ, Bruyn GW (eds), *Handbook of Clinical Neurology*. Vol. 89. Amsterdam: Elsevier 2008: 873-876.

-Rosenfeld MR, **Dalmau J**. Paraneoplastic disorders of the nervous system. In: Schapira AHV (ed), *Neurology and Clinical Neurosciences*. Philadelphia: Mosby-Elsevier, 2007, pp 1361-1374.

-**Dalmau J**. Paraneoplastic neurologic syndromes. In: Waxman SG (ed). *Molecular Neurology*. Amsterdam: Elsevier Academic Press 2007;517-533.

-Vernino S, **Dalmau J**. Paraneoplastic neurological disorders. In: Gilman S (ed), *Neurobiology of disease*. Burlington: Elsevier Academic Press 2007;163-169.

-**Dalmau J**. Remote effects of cancer: Treatment of paraneoplastic neurologic syndromes. In: Johnson RT, Griffin JW, McArthur JC (eds). *Current therapy in neurologic disease*, 7th edition. St. Louis: Mosby, 2006, 274-280.

-Bataller L, **Dalmau J**. "Paraneoplastic disorders of the nervous system". In: Schiff D (ed), *Continuum* 2005, Neuro-oncology. American Academy of Neurology, Vol 11 (5): 69-92.

-Rosenfeld MR, **Dalmau J**. Paraneoplastic syndromes and motor dysfunction. In: DS Younger (ed). *Textbook of Motor Disorders*, 2nd edition, Philadelphia, Lippincott Williams & Wilkins, 2005.

-**Dalmau J** and Rosenfeld M. Paraneoplastic neurologic syndromes. In: Fauci, Braunwald, Isselbacher, Wilson, Martin, Kasper, Hauser, Longo (eds). *Harrison's Principles of Internal Medicine*, 16th edition. New York: McGraw-Hill, Inc, 2005, 571-575.

-Verschuuren J, **Dalmau J**. "Paraneoplastic neurologic disorders". In: Antel JP, Birnbaum G, Hartung H-P, Vincent A (eds), *Clinical Neuroimmunology*, 2nd ed. New York: Oxford University Press, 2005:315-325.

-**Dalmau J**, Rosenfeld MR. Paraneoplastic Neurologic Syndromes. In: Abeloff M, Armitage J, Kastan M, et al (eds). *Clinical Oncology*, 3rd edition. Philadelphia: Elsevier, 2004, 993-1006.

-Rosenfeld MR, **Dalmau J**. Paraneoplastic syndromes, Neurological. In: Adelman G, Smith BH (eds). *Encyclopedia of Neuroscience*, 3rd ed. Amsterdam, Elsevier: CD Rom, 2004.

-**Dalmau J, Rosenfeld MR**. Paraneoplastic disorders of the nervous system. In: Bradley WG, Daroff RB, Fenichel GM, Jankovic (eds). *Neurology in Clinical Practice*, 4th edition. Philadelphia, Butterworth-Heinemann, 2004, 1461-1471.

-**Dalmau J**. Introduction to neurological complications of systemic cancer. *Semin Neurol* 2004;24:343-344.

-Bataller L, **Dalmau J**. Paraneoplastic disorders of the central nervous system: update on diagnostic criteria and treatment. In: Dalmau J (ed). "Neurological complications of cancer". *Semin Neurol* 2004;24:461-471.

-Bataller L, **Dalmau J**. Paraneoplastic neurologic syndromes. In: Wen P. and Glantz M (eds). *Neurologic Clinics of North America*, 2003;21:221-247.

-**Dalmau J, Rosenfeld MR**. "Paraneoplastic syndromes of the nervous system". In: Schiff D, Wen P (eds), *Cancer Neurology*. Totowa, New Jersey, Humana Press, 2003, 159-169.

-**Dalmau J**. "Paraneoplastic syndromes, immunology". In: Aminoff MJ, Daroff RB (eds), *Encyclopedia of Neurological Sciences*, Philadelphia, Elsevier, 2003, 787-790.

-**Dalmau J**. "Paraneoplastic syndromes, central". In: Aminoff MJ, Daroff RB (eds), *Encyclopedia of Neurological Sciences*, 1st edition, Philadelphia, Elsevier 2003, 784-787.

-Bataller L, **Dalmau J**. Paraneoplastic neurologic syndromes and their treatment. In: Dalakas M (ed). "Immunotherapy in neurology". *Semin Neurol* 2003;23:215-224.

-**Dalmau J**, Graus F. "Paraneoplastic Syndromes". In: Samuels MA, Feske S (eds), *Office Practice of Neurology*, 2nd ed. New York: Churchill Livingstone Inc. 2003, 1146-1156.

-Bataller L, **Dalmau J**. Anticuerpos antineuronales y síndromes neurológicos paraneoplásticos (Antineuronal antibodies and paraneoplastic neurological syndromes). *Neurología* 2002;17:85-96.

-**Dalmau J**. "Síndromes paraneoplásticos". In: Micheli F, Biller J, Asconapé J, Fernandez-Pardal M, Nogués M (eds), *Tratado de Neurología Clínica*. Editorial Medica Panamericana SA, 2002

-**Dalmau J**. "Paraneoplastic immune-mediated disorders of the nervous system". In: Ransohoff RM (ed), *Neuroimmunology*, American Academy of Neurology, "Continuum", Vol. 7, Number 3, June 2001.

-Rosenfeld MR, **Dalmau J**. "The clinical spectrum and pathogenesis of paraneoplastic disorders of the central nervous system". In: Liang BC (ed), Hematology and Oncology Clinics of North America, Vol 25. Philadelphia, Saunders, 2001, 1109-1128.

-Rosenfeld MR, **Dalmau J**. "Seizures and cancer", In: Delanty N (ed), Seizures: medical causes and management. Totowa, NJ, Humana Press, 2001, 207-232.

-**Dalmau J**, Posner JB. "Paraneoplastic cerebellar ataxia". In: Koller WC (ed) Neurological disease and therapy. Vol 50, Handbook of ataxia disorders, Klockgether T (ed). New York, NY, Marcel Dekker, 2000, 607-632.

-Posner JB, **Dalmau J**. Paraneoplastic syndromes of the nervous system. Clin Chem Lab Med 2000;38:117-122.

-**Dalmau J**, Porta-Etessam J. Síndromes paraneoplásicos cerebrales con manifestación otoneurooftalmológica (Paraneoplastic cerebral syndromes with oto-neuro-ophthalmologic manifestations). Rev Neurol 2000;31:1213-1219.

-**Dalmau J**. Síndromes neurológicos paraneoplásicos: Desde el diagnóstico de exclusión a la utilización de marcadores inmunológicos y moleculares (Paraneoplastic neurological syndromes: from a diagnosis of exclusion to the use of immunologic and molecular markers). Neurología 2000;15:114-126.

-**Dalmau J**. "Paraneoplastic sensory neuronopathy". In: Dropcho E (ed), Paraneoplastic disorders. American Academy of Neurology, "Continuum", Vol. 5, Number 6, December 1999.

-**Dalmau J**. "Paraneoplastic encephalomyelitis", op cit.

-**Dalmau J**. "Paraneoplastic limbic encephalitis", op cit.

-Rosenfeld MR, **Dalmau J**. "Paraneoplastic neurologic disorders and onconeural antigens". In: Pfaff DW, Berrettini WH, Joh TH, Maxson SC (eds), Genetic Influences on Neural and Behavioral Functions. Boca Raton, CRC Press, 1999, 217-230.

-Rosenfeld MR, **Dalmau J**. "Paraneoplastic motor disorders". In: Younger DS (ed), Motor disorders. Philadelphia: Lippincott, Williams & Wilkins, 1999, 397-405.

-Posner JB, **Dalmau J**. "Therapy of paraneoplastic neurologic syndromes". In: Zhang J, Hafler D, Hohlfeld R, Miller A (eds), Immunotherapy in neuroimmunologic diseases. London: Martin Dunitz Publishers, 1998, 139-153.

-**Dalmau J**, Posner JB. Neurologic paraneoplastic syndromes. The Neuroscientist 1998;4:443-453.

-**Dalmau J** and Posner JB. Paraneoplastic syndromes affecting the nervous system. Semin Oncol 1997;24:318-328.

-Rosenfeld M, Verschuuren J, **Dalmau J**. "Paraneoplastic syndromes of the peripheral nervous

system. In: Vinken PJ, Bruyn GW (eds), Handbook of Clinical Neurology. vol 25, Neuro-Oncology, Vecht CJ (ed). Amsterdam: Elsevier, 1997, 373-393.

-**Dalmau J**. Paraneoplastic syndromes of the nervous system: General pathogenic mechanisms and diagnostic approaches". In: Vinken PJ, Bruyn GW (eds), Handbook of Clinical Neurology. Vol 25, Neuro-Oncology, Vecht CJ (ed). Amsterdam: Elsevier, 1997, 319-328.

-Verschuuren J, **Dalmau J**. "Paraneoplastic neurologic disorders". In: Antel JP, Birnbaum G, Hartung H-P (eds), Clinical Neuroimmunology. Massachusetts: Blackwell Scientific Publications, 1997, 148-171.

-**Dalmau J**. "Complicaciones neurológicas en pacientes con cáncer sistémico". In: Rodés J, Guardia J (eds), Tratado de Medicina Interna. Barcelona: Masson-Salvat Medicina, 1997, 2181-2199.

-**Dalmau J**, Graus F. "Paraneoplastic syndromes of the nervous system". In: Black PMcL, Loeffler JS (eds), Cancer of the Nervous System. Massachusetts: Blackwell Scientific Publications, 1997, 674-700.

-Posner JB, **Dalmau J**. Paraneoplastic syndromes. In: Alt F, Marrack P (eds), Current Opinion in Immunology 1997;9:723-729.

-Posner JB, **Dalmau J**. Paraneoplastic syndromes involving the central nervous system. Annu Rev Med 1997;48:157-166.

-**Dalmau J**, Posner JB. "Neurological paraneoplastic syndromes". Springer Semin Immunopathol 1996;18:85-95

-**Dalmau J**, Posner JB. "Purkinje cell (Yo) antibodies". In: Textbook of Autoantibodies. Elsevier. 1996, 655-659.

-**Dalmau J**. Paraneoplastic disorders of the central nervous system. Neurología 1996;11(Suppl 2):26-36.

-**Dalmau J**, Graus F. "Paraneoplastic Syndromes". In: Samuels MA, Feske S (eds), Office Practice of Neurology. New York: Churchill Livingstone Inc. 1995, 925-934.

-Rosenfeld MR, Verschuuren J, **Dalmau J**. "Transfer and expression of anti-oncogenes and paraneoplastic genes in normal and neoplastic cells in vitro and in vivo". In: Kaplitt MG, Loewy AD (eds), Viral Vectors: tools for study and genetic manipulation of the nervous system. Florida: Academic Press, 1995, 275-292.

-**Dalmau J**, Rosenfeld MR. "Characterization of neuronal antigens and antineuronal antibodies". In: Phillips MI (ed), Methods in Neurosciences: Neuroimmunology. California: Academic Press, 1995. Volume 24, 261-271.

-Graus F, **Dalmau J**. "Management of paraneoplastic syndromes". In: Wiley RG (ed), Neurological complications of cancer. New York: Marcel Dekker, 1995, 167-198.

-**Dalmau J**, Rosenfeld MR. Paraneoplastic syndromes in clinical and neurological oncology. Med Clin 1992; 99:379-381.

-Graus F, **Dalmau J**. Paraneoplastic syndromes of the central nervous system. MTA-Medicina Interna 1989; 7(7): 319-348.

-**Dalmau J**. "Spinal cord tumors". In "Neurocodi", Spanish Society of Neurology. Barcelona, 1988.

-**Dalmau J**. Temporal arteritis. JANO 1987; 1:61-67.

-Baguñá J, **Dalmau J**, Ferrer I, Genís D, Martí-Vilalta JL, Perés J, Roig M. Hereditary metabolic neurological disorders. Ferrer Int. Barcelona, 1986.

-Graus F, **Dalmau J**. Peripheral neuropathy associated with cancer. Neurología 1986; 1:161-167.

-**Dalmau J**, Graus F. Cranial nerve palsy associated with cancer. Neurología 1986; 1:202-211.

RECURRING CONTRIBUTIONS TO ON-LINE RESOURCES

-Rosenfeld MR, **Dalmau J**. Anti-NMDA receptor encephalitis. In: Roos RP, Editor-in-Chief, MedLink Neurology. San Diego: MedLink Corporation. (www.medlink.com), 2019-present.

-**Dalmau J**, Rosenfeld MR. Autoimmune (including paraneoplastic) encephalitis: Clinical features and diagnosis. In: UpToDate Neurology, Wolters Kluwer, Waltham, MA, yearly 2023-present

-**Dalmau J**, Rosenfeld MR. Opsoclonus myoclonus syndrome. In: UpToDate Neurology, Wolters Kluwer, Waltham, MA, yearly 2011-present.

-**Dalmau J**, Rosenfeld MR. Paraneoplastic cerebellar degeneration. In: UpToDate Neurology, Wolters Kluwer, Waltham, MA, yearly 2011-present.

-**Dalmau J**, Rosenfeld MR. Paraneoplastic visual syndromes. In: UpToDate Neurology, Wolters Kluwer, Waltham, MA, yearly 2011-present.

-**Dalmau J**, Rosenfeld MR. Paraneoplastic and autoimmune encephalitis. In: UpToDate Neurology, Wolters Kluwer, Waltham, MA, yearly 2011-2022.

-**Dalmau J**, Rosenfeld MR. Overview of paraneoplastic syndromes of the nervous system. In: UpToDate Neurology, Wolters Kluwer, Waltham, MA, yearly 2000-present.

-**Dalmau J**, Rosenfeld MR. Paraneoplastic syndromes affecting spinal cord, peripheral nerves and muscle. In: UpToDate Neurology, Wolters Kluwer, Waltham, MA, yearly 2019-present

Dalmau J, Rosenfeld MR. Paraneoplastic syndromes affecting the peripheral nerves and muscle. In: UpToDate Neurology, Wolters Kluwer, Waltham, MA, yearly 2000-2019

-**Dalmau J**, Rosenfeld MR. Paraneoplastic syndromes affecting the spinal cord and dorsal root ganglia. In: UpToDate Neurology, Wolters Kluwer, Waltham, MA, yearly 2000-2019.

-**Dalmau J**, Rosenfeld MR. Paraneoplastic syndromes affecting the brain and cranial nerves. In: UpToDate Neurology, Wolters Kluwer, Waltham, MA, yearly 2000-2008.

EDITOR

-**Dalmau J** (Guest Editor) Neurologic complications of cancer. *Semin Neurol* 2010;30:215-216.

-**Dalmau J**, Rosenfeld MR. Neuro-oncology section editor. In: Lisak RP, Truong D, Carroll WM, Bhidayasiri R (eds). *International Neurology: A Clinical Approach*. Oxford, Wiley-Blackwell 2009.

-**Dalmau J** (Guest Editor) Neurologic complications of systemic cancer. *Semin Neurol* 2004;24:343-344.

EDITORIALS

-Kunchok A, **Dalmau J**. Can NfL be utilized as a biomarker of disease severity, activity and outcomes in anti-NMDAR encephalitis? *Neurology*.

-**Dalmau J**, Dalakas MC, Kolson DL, Friedemann P, Sanchez-Valle R, Zamvil SS. N2 year in review. *Neurol Neuroimmunol Neuroinflamm* 2023 Jan 3;10(1):e200076.

-Graus F, **Dalmau J**. MOGAD comes of age with new criteria. (Invited editorial comment). *Lancet Neurol* 2023 Jan 24:S1474-4422(22)00520-8.

-Dalakas MC, **Dalmau J**. Comment: Humoral and T-cell immunities to SARS-COV-2 vaccines: Safety, efficacy, and challenges in autoimmune neurology. *Neurol Neuroimmunol Neuroinflamm* 2022;9:e200010.

-**Dalmau J**, Dalakas MC, Kolson DL, Friedemann P, Zamvil SS. N2 year in review. *Neurol Neuroimmunol Neuroinflamm* 2021;8(1):e925.

Dalmau J. A probable case of NMDAR encephalitis from 1830. *Neurol Neuroimmunol Neuroinflamm* 2020;7(6):e901.

Dalmau J. N2 in the time of COVID-19. *Neurol Neuroimmunol Neuroinflamm* 2020 Aug;7(5):e858.

Dalmau J. Time to recharge. *Neurol Neuroimmunol Neuroinflamm* 2020 Jul;7(4):e779.

Dalmau J. The tip of antibody-testing iceberg. *Neurol Neuroimmunol Neuroinflamm* 2020 May;7(3):e716.

Dalmau J. How DIRS is refining concepts. *Neurol Neuroimmunol Neuroinflamm* 2020 Mar;7(2):e677.

-Winkler AS, Knauss S, Schmutzhard E, Leonardi M, Padovani A, Abd-Allah F, Charway-Felli A, Emmerich JV, Thirugnanam U, Satishchandra P, Hoo FK, **Dalmau J**, Oreja-Guevara C, Ferreira

MLB, Pfausler B, Endres M, Klein C, Hemmer B, Sejvar J, Solomon T. A call for a COVID-19 Neuro Research Coalition. *Lancet Neurol* 2020;19(6):482-484.

-Dalmau J, Dalakas MC, Kolson DL, Friedemann P, Zamvil SS. N2 year in review. *Neurol Neuroimmunol Neuroinflamm* 2020;7(1):e644.

-Dalmau J. Learning from adverse treatment effects. *Neurol Neuroimmunol Neuroinflamm* 2019 Oct 28;6(6):e630.

-Dalmau J. “Neurofilament light chain levels in Multiple Sclerosis: At the doorstep of clinical application” *Neurol Neuroimmunol Neuroinflamm* 2019 Aug 16;6(5).

-Dalmau J. Time is tissue in optic neuritis. *Neurol Neuroimmunol Neuroinflamm* 2019 6:e578.

-Dalmau J. A surprise with MuSK antibodies. *Neurol Neuroimmunol Neuroinflamm* 2019;6:3:e564.

-Britton JW, **Dalmau J**. Recognizing autoimmune encephalitis as a cause of seizures: Treating cause and not effect. *Neurology* 2019;92:877-878.

-Dalmau J. Rectifying neurologic diagnosis through autoantibodies. *Neurol Neuroimmunol Neuroinflamm* 2019;6:e540.

-Dalmau J, Kolson DL, Paul F, Zamvil SS. N2 year in review and message from the editor to our readers. *Neurol Neuroimmunol Neuroinflamm* 2018;19:6:e525.

-Dalmau J. Diagnostic and treatment challenges, a new section in N2. *Neurol Neuroimmunol Neuroinflamm* 2018;5:e511.

-Dalmau J. Of primary and secondary CNS autoimmunity. *Neurol Neuroimmunol Neuroinflamm* 2018;5:e494.

-Dalmau J. Body surface area and B-cell repopulation. *Neurol Neuroimmunol Neuroinflamm* 2018;5:e472.

-Dalmau J. Looks can be deceiving. A B-cell-mediated encephalopathy with normal MRI? *Neurol Neuroimmunol Neuroinflamm* 2018;5:e461.

-Dalmau J. The importance of clinical observations. *Neurol Neuroimmunol Neuroinflamm* February 2018;5:e442

-Dalmau J. The earlier, the better. *Neurol Neuroimmunol Neuroinflamm* 2017;4:e408.

-Dalmau J. The case for autoimmune neurology. *Neurol Neuroimmunol Neuroinflamm* 2017;4:e373.

-Dalmau J. MOG antibodies, cortical encephalitis, and more food for thought studies. *Neurol Neuroimmunol Neuroinflamm* 2017;4:e330.

-Gross RA, Worrall BB, Amato AA, Cascino GD, Ciccarelli O, Corboy JR, **Dalmau J**, Gottesman RF, Grossman M, Millichap JJ, Mink JW, Pulst SM, Uitti RJ. Message from the editors to our reviewers. *Neurology* 2017;88:2-10.

-**Dalmau J**, Vincent A. Do we need to measure specific antibodies in patients with limbic encephalitis? *Neurology* 2017;88:508-509.

-**Dalmau J**. Message from the Editor to our reviewers. *Neurol Neuroimmunol Neuroinflamm* 2017 Jan:e310.

-**Dalmau J**. From brain to brawn. *Neurol Neuroimmunol Neuroinflamm* 2016;3:e304.

-**Dalmau J**. Complex relationships. *Neurol Neuroimmunol Neuroinflamm* 2016 August 4;3:e262.

-**Dalmau J**. A box of chocolats. *Neurol Neuroimmunol Neuroinflamm* 2016 Jun 2;3(3):e234.

-**Dalmau J**. Alphabet soup. *Neurol Neuroimmunol Neuroinflamm* 2016 Apr 7;3(2):e217.

-**Dalmau J**. An interesting variety. *Neurol Neuroimmunol Neuroinflamm* 2016 Feb 4;3(1):e201.

-**Dalmau J**. Autoimmunity: the good, the bad, and the ugly. *Neurol Neuroimmunol Neuroinflamm* 2015 Dec 3;2(6):e181.

-**Dalmau J**. Name a brain protein, and an autoantibody shall be found! *Neurol Neuroimmunol Neuroinflamm* 2015, in press.

-**Dalmau J**. The first year anniversary issue. *Neurol Neuroimmunol Neuroinflamm*. 2015 Jul 27;2(4):e137.

-**Dalmau J**. The more we know. *Neurol Neuroimmunol Neuroinflamm* 2015;2:e112.

-**Dalmau J**. Identifying targets for diagnosis, prognosis and treatment. *Neurol Neuroimmunol Neuroinflamm* 2015;2:e87.

-**Dalmau J**. Observations on the evolving fields of neuroimmunology and neuroinflammation. *Neurol Neuroimmunol Neuroinflamm* 2015;2:e67.

-Titulaer MJ, **Dalmau J**. Seizures as first symptom of anti-NMDA receptor encephalitis are more common in men. *Neurology* 2014 Feb 18;82(7):550-551.

-**Dalmau J**. Commentary on “Prospective case series of paraneoplastic neurologic syndromes”. *Journal Watch* 2010;12:61.

-**Dalmau J**. Commentary on “SOX1 antibodies associated with paraneoplastic Lambert-Eaton myasthenic syndrome”. *Journal Watch* May 20, 2008.

-**Dalmau J**. Commentary on “Post-transplant acute limbic encephalitis: Clinical features and relationship to HHV6”. *Journal Watch* 2007;9:85-86.

-Bataller L, **Dalmau J.** Genes, Microarrays y Neurología (Genes, Microarrays and Neurology). Neurología, 2004;19:41-43.

-Posner JB, **Dalmau J.** Yet, another paraneoplastic antibody. Ann Neurol 2001; 49:141-142.

-**Dalmau J.** Editorial comment on “Carcinoma associated paraneoplastic peripheral neuropathies in patients with and without antionconeural antibodies”. J Neurol Neurosurg Psychiatry 1999;67:4.

-**Dalmau J.** Importance of histopathological grading in the treatment of malignant astrocytic gliomas. Neurología 1990;5:1-3.

INTERNET, PODCAST, ALTERNATIVE MEDIA

-**Dalmau J.** Clinical, neuro-immunological, and CSF investigations in first episode psychosis (article published in Neurology), July 7, 2021.

-**Dalmau J.** Comment on: “Drebrin autoantibodies in patients with seizures and suspected encephalitis”, Pitsch J et al., Ann Neurol 2020.

-Clardy S, Graus F, **Dalmau J.** Podcast on “Hashimoto encephalopathy in the XXI century”. Neurology, January 2019.

-**Dalmau J.** Autoimmune encephalitis post-herpes simplex encephalitis: frequency, syndromes, risk factors, and outcome. Lancet Neurol, July 2018.

-Rosenfeld MR, **Dalmau J.** Autoimmune encephalitis affecting synaptic proteins. Reference Module, Neuroscience and Biobehavioral Psychology, Elsevier SciTech Direct (web-based)

-**Dalmau J.** Comment on manuscript “Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitis”. Neurology PracticeUpdate, February 2017.

-Marcuse L, Graus F, **Dalmau J.** Anti-LGI1-associated cognitive impairment: Presentation and long-term outcome. Neurology, August 2016.

-Espay AJ, **Dalmau J.** Interview on the Cotzias Lecture given on the 68th Annual Meeting of the American Academy of Neurology (Vancouver, Canada), “Autoimmune Disorders of the Synapse”. Neurology, June 14, 2016.

-Bartolini L, **Dalmau J.** Interview “Neural Projections: How do you treat anti-NMDA receptor encephalitis?” Neurology® Clinical Practice, Jan 2016.

-Mytinger J, **Dalmau J.** Podcast on manuscript “When a serum test overrides the clinical assessment”. Neurology, April 2015.

-Clardy S, **Dalmau J.** Podcast on “Autoimmune and paraneoplastic encephalitis, Neurology, 1st week February 2015.

-Clardy S, **Dalmau J.** Podcast on “Anti-NMDA receptor encephalitis”, Neurology, 2nd week February 2015.

-Clardy S, **Dalmau J.** Podcast on “Antibodies other than NMDAR in autoimmune encephalitis”, Neurology, 3rd week February 2015.

-Clardy S, **Dalmau J.** Podcast on “Recent discoveries on pathogenic mechanisms of autoimmune encephalitis”, Neurology, 4th week February 2015.

-Interview of Dr. Neeta Garg by Dr. Dalmau. “Leucine-rich glioma-inactivated protein 1-antibody encephalitis: A case report”, podcast for Neurol: Neuroimmunol Neuroinflammation, December 2014.

-Dalmau J. “Living legends in Neurology”, Neurology podcast, December 2014.

-Interview of Dalmau J by Fritz Habekuß: Anti-NMDA receptor encephalitis”. DIE ZEIT, Germany, February 2014.

-Interview of Dalmau J by Lara Bonilla: El meu mes de bogeria”, Diari ARA, Barcelona, March 3, 2013.

-Interview of Dalmau J by Stacey Burling: “Betrayed by the brain”, Philly.com, Philadelphia Inquirer, April 1, 2013.

-Interview of Dalmau J by Dr. Daniela J. Lamas: “When the brain is under attack”, The Boston Globe, May 27, 2013.

-Dalmau J. Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study. Lancet Neurol Podcast, 2013, Jan 9.

-Interview of Dalmau J by Pere Estupinya: “Enloquecer por un anticuerpo”, El PAIS, Jan 24, 2012.

-Dalmau J. *Continuum* Audio (American Academy of Neurology): Autoimmune encephalitis, April 2012. http://www.audio-digest.org/adfwebcasts/mp3/CA0125/ca0125_2.mp3

-Dalmau J. Lesson of the week Neurology podcast (week 1), comments on: Paraneoplastic syndromes causing central nervous system disorders. Neurology, aired in February 2012, 1st week.

-Dalmau J. Lesson of the week Neurology podcast (week 2), comments on: Paraneoplastic syndromes causing peripheral nervous system dysfunction. Neurology, aired in February 2012, 2nd week.

-Dalmau J. Lesson of the week Neurology podcast (week 3), comments on: Anti-NMDA receptor encephalitis. Neurology, aired in February 2012, 3rd week.

-Dalmau J. Lesson of the week Neurology podcast (week 4), comments on: Disease-specific

paraneoplastic disorders. *Neurology*, aired in February 2012, 4th week.

-**Dalmau J.** Interview by Aviva Ziegler, ABC Radio National (Australia): Mystery illness- ovarian teratoma associated encephalitis, Monday 19 December 2011.

<http://www.abc.net.au/radionational/programs/healthreport/mystery-illness---ovarian-teratoma-associated/3665130>

-**Dalmau J.** Comments on manuscript: Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome (*Neurology* 2011;77:1698-1701). *Neurology*, November 1, 2011.

-Prüss, Wandinger, **Dalmau.** Comments on manuscript: Retrospective analysis of anti-glutamate receptor (type NMDA) antibodies in patients with encephalitis of unknown origin (*Neurology* 2010;75:1735-1739). *Neurology*, November 2010.

-**Dalmau J.** Comments on anti-NMDA receptor encephalitis. *Neurology*, December 2009.

-**Dalmau J.** New research on LEMS: Detection of SOX1 antibodies likely contributes to early demonstration of a tumor. *American Academy of Neurology*, 19 March 2008.

http://www.aan.com/news/index.cmf?event=read&article_id=4055

-**Dalmau J.** Exploring the paraneoplastic syndromes. *The Lancet*, 5 May 2009.

[http://www.thelancet.com/journals/laneur/article/PIIS1474-4422\(09\)70097-3/fulltext](http://www.thelancet.com/journals/laneur/article/PIIS1474-4422(09)70097-3/fulltext)

-**Dalmau J.** Emerging concepts: Treatment-responsive autoimmune limbic encephalitis. *American Academy of Neurology*, 7 Feb 2008.

http://www.aan.com/news/?event=read&article_id=3469&page=164.37.37.

-**Dalmau J.** Lesson of the week: Pathophysiology of paraneoplasia. *American Academy of Neurology*, 18 Mar 2008. Podcast.

-**Dalmau J.** Center for Paraneoplastic Disorders. University of Pennsylvania, 1 Jan 2008.

<http://www.penncancer.org/pnd/>

-**Dalmau J.** A case of anti-NMDA receptor encephalitis, Discovery Health Channel, Discovery Communications, 31 Aug 2009. Television.

LETTERS

-Guasp M, **Dalmau J.** Author response: Clinical, neuroimmunologic, and CSF investigations in first episode psychosis. *Neurology* 2022;98:906.

-**Dalmau J.** Letter to the Editor regarding “Serum anti-NMDA (N-Methyl-D-Aspartate)-receptor antibodies and long-term clinical outcome after stroke (PROSCIS-B)”. *Stroke*, 2020 Jan 13:STROKEAHA119027885. doi: 10.1161/STROKEAHA.119.027885.

-**Dalmau J.** Pregnancy, NMDA receptor antibodies, and neuropsychiatric diseases. *Ann Neurol* 2020;87(2):324-325.

-**Dalmau J.** In vitro effects of a human monoclonal antibody against the N-methyl-d-aspartate receptor. *Brain*. 2017;140(2):e9.

-van Sonderen A, Ariño H, **Dalmau J**, Titulaer M. Reply to: The clinical spectrum of Caspr2 antibody-associated disease. *Neurology* 2017;88:333-334.

-Graus F, **Dalmau J.** Reply to: Role of brain [18F] fluorodeoxyglucose (FDG) PET in the syndrome based diagnostic approach to autoimmune encephalitis. *Lancet Neurol* 2016;15:1010.

-Kayser MS, **Dalmau J.** Reply to: N-methyl-D-aspartate receptor autoantibodies in psychiatric illness. *Biol Psychiatry* 2016;79(9):e63.

-Gaig C, Iranzo A, Santamarí J, **Dalmau J**, Graus F. Sleep disorder associated with antibodies to IgLON5: parasomnia or agrypnia?-Authors' reply. *Lancet Neurol*. 2014 Sep;13(9):864-5.

-Graus F, **Dalmau J.** Neuronal antibodies in Creutzfeldt-Jakob disease (reply letter). *JAMA Neurol* 2014;71:514-515.

-Titulaer MJ, **Dalmau J.** Antibodies to NMDA receptor, blood-brain barrier disruption, and schizophrenia: a theory with unproven links. *Mol Psychiatry* 2014;19:1054.

-Merwick A, Dalmau J, Delanty N. Bickerstaff encephalitis and atypical features-Bickerstaff's papers revisited. *J Neurol Sci* 2014;341:173.

-Titulaer MJ, **Dalmau J.** Testing for NMDAR antibodies in new onset psychosis (reply letter). *Lancet Neurol* 2013;12:425-426.

-Masdeu JC, González-Pinto A, Matute C, Ruiz de Azúa S, Palomino A, de Leon J, Berman KF, **Dalmau J.** Serum IgG antibodies against the NMDA receptor not detected in schizophrenia. *Am J Psychiatry* 2012;169:1120-1121.

-Cash SS, Batchelor T, **Dalmau J.** Case 34-2011: a man with memory loss and partial seizures. *N Engl J Med* 2012;366:768-769 (author reply, 369).

-Yeo KK, Walter AW, Miller RE, **Dalmau J.** Rituximab as potential therapy for paraneoplastic cerebellar degeneration in pediatric Hodgkin disease. *Pediatr Blood Cancer* 2012;58:986-987.

-Ohta K, Seki M, **Dalmau J**, Shinohara Y. Perfusion ¹²³IMP-SPECT shows reversible abnormalities in GABA_B receptor antibody associated encephalitis with normal MRI. *Brain Behav* 2011;1:70-72.

-Fett NM, Toporcer MB, **Dalmau J**, Shinohara MM, Vogl DT. Scleromyxedema and dermatoneuro syndrome in a patient with multiple myeloma effectively treated with dexamethasone and bortezomib. *Am J Hematol* 2011;86:893-896.

-Hegde M, Glass GA, **Dalmau J**, Christine CW. A case of slow orthostatic tremor responsive to intravenous immunoglobulin. *Mov Disord* 2011;26:1563-1565.

-Alexopoulos H, Kosmidis ML, Dalmau J, Dalakas M. Paraneoplastic anti-NMDAR encephalitis:

- long-term follow-up reveals persistent serum antibodies. *J Neurol* 2011;258:1568-1570.
- Kawachi I, Saji E, **Dalmau J**, Nishizawa M. Treatment-responsive opsoclonus-ataxia associated with ovarian teratoma. *J Neurol Neurosurg Psychiatry* 2010;81:581-582.
- Simó M, **Dalmau J**. Gliomatosis cerebri mimicking limbic encephalitis [article in Spanish]. *Neurologia* 2009;24:500-501.
- Dalmau J**. Recognizing limbic encephalitis. *J Clin Oncol* 2009;27:1-2.
- Kistler AD, Schwarz U, **Dalmau J**, Rudiger A. Laparoscopic epilepsy surgery. *Intensive Care Med* 2010;36:367-368.
- Eker A, Saka A, **Dalmau J**, Kurne A, Bilen C, Ozen H, Ertoy D, Oğuz KK, Elibol B. Testicular teratoma and anti-N-methyl-D-aspartate receptor associated encephalitis. *J Neurol Neurosurg Psychiatry* 2008;79:1082-1083.
- Tang T, Yaw Tay K, Chai J, Agarwal A, Low J, Lian Lee E, Leong Chuah K, s/o Sittampalan K, Fong Wong C, **Dalmau J**, Ngeow J, Tin Soh L, Tan M-H. A multimodality approach to reversible paraneoplastic encephalitis associated with ovarian teratomas. *Acta Oncol* 2009;28:1-4.
- Dalmau J**. Epitope of autoantibodies to N-methyl-d-aspartate receptor heteromers in paraneoplastic limbic encephalitis. *Ann Neurol* 2008;64:111-112.
- Pruss H, Zschenderlein R, Prass K, **Dalmau J**, Mathew RM. Orchiectomy for suspected microscopic tumor in patients with anti-Ma2-associated encephalitis. *Neurology* 2007;69:709-710.
- Shimazaki H, Ando Y, Nakano I, **Dalmau J**. Reversible limbic encephalitis with antibodies against membranes of neurons of the hippocampus. *J Neurol Neurosurg Psychiatry* 2007;78:324-325.
- Bataller L, **Dalmau J**. Herpes simplex encephalitis in a patient with cancer. *J Neuro-Oncol* 2006;78:211.
- Dalmau J**. Análisis de las consultas neurológicas en un hospital oncológico: contribuciones de la neuro-oncología (Analysis of the neurologic consultations in an oncologic hospital: contributions of neuro-oncology). *Neurología* 2000;15:44.
- Dalmau J**, Gultekin SH, Posner JB. A serological marker of paraneoplastic limbic and brainstem encephalitis in patients with testicular cancer. *N Engl J Med* 1999;341:1475-1476.
- Blumenthal D, Schochet S, Gutmann La, Ellis B, Jaynes M, **Dalmau J**. Small-cell carcinoma of the lung presenting with paraneoplastic microvasculitis and optic neuropathy. *Muscle Nerve* 1998;21:1358-1359.
- Dalmau J**. The use of paraffin-embedded tissue for detection of antineuronal antibodies. *Acta Neuropathol* 1997;94:300-301.
- Dalmau J**, Posner JB. Neurologic paraneoplastic antibodies (anti-Yo; anti-Hu; anti-Ri): the case for a nomenclature based on antibody and antigen specificity. *Neurology* 1995;45:2121-2122

- Hersh B, Dangond F, Geller E, Wen P, **Dalmau J**. Paraneoplastic opsoclonus. *Neurology* 1995;45:1421.
- Dalmau J**, Graus F. Anti-Hu associated paraneoplastic neurological syndromes. *Neurology* 1994;44:1986-1987.
- Dalmau J**, Clouston PD. Subacute cerebellar degeneration and LEMS. *Neurology* 1992; 42:1429.
- Graus F, **Dalmau J**. Enteric neuronal antibodies and pseudoobstruction. *Gastroenterology* 1991; 101:1142-1144.
- Marco M, **Dalmau J**, Ormaza J. Neurological toxicity secondary to amiodarone. *Neurología* 1988; 3:206-207.
- Brullet E, Pouplana M, **Dalmau J**, Marco M. Gastrointestinal endoscopy and epileptic seizures. *Med Clin* 1988; 91:678-679.
- Dalmau J**, Marco M, Montero J. Lumbosacral plexus neuropathy. *Med Clin* 1988; 91:797-798.
- Dalmau J**, Aguilar M, Marco M. Bilateral femoral nerve palsy secondary to abdominal hysterectomy. *Neurología* 1986; 1:266-267.
- Dalmau B, **Dalmau J**, Mas P, Ripoll E. Epileptic seizures secondary to non-ketotic hyperglycemia. *Med Clin* 1985; 83:251.
- Marco M, **Dalmau J**, Aguilar M, Bartomeus F. Tic doloieux associated with contralateral acoustic neuroma. *Med Clin* 1985; 85:601.
- Dalmau J**, Martí-Vilalta JL, Illa I, Pradas J. N-Hexane neuropathy. *Med Clin* 1984; 82:89.
- Martí-Vilalta JL, **Dalmau J**, Santaló M. Prosopagnosia, and transient ischemic attack. *Stroke* 1981; 12:702.

ABSTRACTS

- Lleixà C, Blanco Y, Llufríu S, Sepúlveda M, Martínez-Hernández E, Armangué T, Cabrera-Maqueda JM, Fonseca E, Guasp M, Escudero D, Caballero-Ávila M, Pascual-Goñi E, Martín-Aguilar L, Vidal N, Tejada C, López-Contreras J, Rombauts A, Martínez-Martínez L, **Dalmau J**, Saiz A, Querol L. Antibodies against peripheral nerve antigens after mRNA COVID-19 vaccination. *Peripheral Nerve Society*, June 17-20, Copenhagen, Denmark.
- Maudes E, Marmolejo L, Ruiz-Vives M, Serafim AB, Guasp M, Planagumá J, Radosevic M, Ruiz R, Matute C, **Dalmau J**. White matter alterations in a mouse model of anti-NMDAR encephalitis by active immunization. *European Academy of Neurology*, July 1-4, 20223, Budapest, Hungary
- Guasp M, Rosa-Justicia M, Muñoz-Lopetegui A, Martínez-Hernández E, Armangué T, Sugranyes G, Stein H, Prades L, Ariño H, Planagumà J, De La Serna E, Escudero D, Llufríu S, Sánchez-Valle

R, Santamaria J, Compte A, Castro-Fornieles J, **Dalmau J**. Clinical characterisation of patients in the post-acute stage of anti-NMDA receptor encephalitis: a prospective cohort study and comparison with patients with schizophrenia spectrum disorders. Annual meeting American Academy of Neurology (AAN), April 22-27, 2023, Boston, USA

-Fonseca E, Cabrera Maqueda JM, Ruiz-Garcia R, Naranjo L, Blanco Morgado Y, **Dalmau J**, Graus, F, Martinez-Hernandez E. Clinical characterization and outcome of 47 patients with neurologic adverse events of immune-checkpoint inhibitors. Annual meeting American Academy of Neurology (AAN), April 22-27, 2023, Boston, USA.

-Brenner J, Bastiaansen A, de Bruijn M, Leypoldt F, Honnorat J, **Dalmau J**, Iizuka T, Jansen M, Schroder I, Muniz-Castrillo S, Crijnen Y, de Vries J, Schreurs M, Munoz A, Guasp M, Sillevius Smitt P, Titulaer M. Predicting functional outcome and response to therapy of anti-NMDAR encephalitis, already at diagnosis: The NEOS2 model. Annual meeting American Academy of Neurology (AAN), April 22-27, 2023, Boston, USA.

-Ariño-Rodríguez H, Martínez Hernández E, Armangué-Salvador T, Naranjo-Roldán L, Ruiz-García R, Escudero-Rubí D, **Dalmau J**. Incidencia de encefalitis en la pandemia comparado con el periodo precovid. Estudio retrospectivo. LXXIV Annual Meeting of the Spanish Society of Neurology, Sevilla, Spain, November 16, 2022 (oral presentation)

-Planagumà J, Joubert B, Petit-Pedrol M, Mannara F, Radosevic M, Marsal M, Maudes E, García-Serra A, Aguilar E, Andrés-Bilbé A, Gasull X, Loza-Alvarez P, Sabater L, Rosenfeld MR, **Dalmau J**. Human CASPR2 antibodies reversibly alter memory and the CASPR2 protein complex. Federation of Neuroscience Societies (FENS), Paris, France, July 12, 2022 (poster)

-Maudes E, Mannara F, García-Serra A, Radosevic M, Mellado A, Serafim AB, Marmolejo L, Planagumà J, Sabater L, **Dalmau J**, Spatola M. Human metabotropic glutamate receptor 5 (mGluR5) antibodies induce memory loss, increased anxiety and molecular changes in mice. Federation of Neuroscience Societies (FENS), Paris, France, July 12, 2022 (poster)

-Peixoto-Moledo P, Zamani AP, Barman S, Goebels N, **Dalmau J**, Jercog PE. Interference-based forgetting in a goal-directed spatial navigation task for rodents. Federation of Neuroscience Societies (FENS), Paris, France, July 12, 2022 (poster)

-Zamani A, Tomàs DB, Peixoto P, **Dalmau J**, Jercog PE. Long lasting degradation of hippocampal spatial representation in the mouse model of anti-NMDAR encephalitis. Federation of Neuroscience Societies (FENS), Paris, France, July 12, 2022 (poster)

-Rosa-Justicia M, Guasp M, Muñoz-Lopetegi A, Martinez-Hernandez E, Prades L, Sugranyes G, Compte A, **Dalmau J**, Castro-Fornieles J. Psychiatric and cognitive profile in the post-acute stage of anti-NMDA receptor encephalitis: A comparative analysis with patients with schizophrenia. Annual meeting American Academy of Neurology (AAN), April 17-22, 2021, Virtual.

-Munoz-Lopetegi A, Guasp M, Martinez-Hernandez E, Rosa Justicia M, Santamaria J, **Dalmau J**. Sleep disorders in anti-LGI1 encephalitis. Annual meeting American Academy of Neurology

(AAN), April 17-22, 2021, Virtual.

-Guasp Mar, Landa J, Petit-Pedrol M, Martinez-Hernandez E, Planagumà J, Saiz A, Ruiz-Garcia R, García-Fernández L, Verschuuren J, Saunders-Pullman R, Ramirez-Gomez L, Geschwind M, **Dalmau J**, Sabater L, Graus F. Seizure-related 6 homolog like 2 (SEZ6L2) autoimmunity: Neurologic syndrome and antibody effects. Annual meeting American Academy of Neurology (AAN), April 17-22, 2021, Virtual.

-Spatola M, Petit Pedrol M, Maudes E, Simabukuro M, Muñiz-Castrillo S, Pinto A-L, Wandinger K-P, Spiegler J, Schramm P, Almeida Dutra L, Iorio R, Kornblum C, Höftberger R, Leyboldt F, Titulaer M, Sillevs Smitt P, Honnorat J, Rosenfeld M, Graus F, **Dalmau J**. Anti-metabotropic glutamate receptor (mGluR)1 encephalitis: Identification of prognostic factors and study of antibody effects. Annual meeting American Academy of Neurology (AAN), April 17-22, 2021, remote.

-Guasp M, Martinez-Hernandez E, Landa J, Sabater L, Saiz A, Graus F, **Dalmau J**. Thymoma-associated neuronal surface antibodies and clinical manifestations. Annual meeting American Academy of Neurology (AAN), April 17-22, 2021, remote.

-Martínez-Hernández E, Ruiz-García R, Sepúlveda M, Rodríguez-Gascón D, Armangué T, Muñoz-Lopetegui A, Graus F, **Dalmau J**, Saiz A. Características clínicas de los pacientes con anticuerpos anti-glial fibrillary acidic protein (GFAP). Spanish Academy of Neurology, Seville, Spain, Nov 17-21, 2020, remote.

-van Welzen K, Muñoz-Lopetegui A, Rosa-Justicia M, Stein H, Morató A, Arino H, Martinez-Hernandez E, Armangué T, Sugranyes G, Castro-Fornieles J, **Dalmau J**, Santamaria J, Compte A. Slow-wave potentiation is age-dependent and characterizes early-night sleep in teenagers and young adults. European Sleep Research Society Meeting, Seville, Spain 2020, Sept 22-24, remote. *J Sleep Res* 2020;29 (suppl 1):146-147.

-van Welzen K, Muñoz-Lopetegui A, Stein H, Rosa-Justicia M, Ariño H, Martinez-Hernandez E, Armangué T, Stein H, Morató A, Sugranyes G, Castro-Fornieles J, **Dalmau J**, Santamaria J, Compte A. Early-night slow-wave sleep potentiation is disrupted in anti-N-methyl-D-aspartate receptor encephalitis and schizophrenia. European Sleep Research Society Meeting, Seville, Spain 2020, Sept 22-24, remote. *J Sleep Res* 2020;29 (suppl 1):231.

-Iizarbe D, Masias M, Pariente JC, Muñoz-Moreno E, Rosa M, Fortea A, Baeza I, Compte A, **Dalmau J**, Castro-Fornieles J, Sugranyes G. Hippocampal connectivity in youth with schizophrenia: Comparison with patients with NMDA receptor encephalitis and healthy volunteers. European College of Neuropsychopharmacology (ECNP) Congress, Spain 2020, Sept 12-15, (remote). *Eur Neuropsychopharmacol* 2020;40 (suppl 1):S124-S125.

-Ona-Jodar T, Prat-Ortega G, de la Rocha J, Compte A, **Dalmau J**, Cheng-yu L. History biases and working memory mechanisms alternate but don't interact in a rodent 2AFC task. Virtual Working Memory Symposium, European Society for Cognitive Psychology, Jun 2020.

- Serrano-Porcar B, Marín R, Graell A, Ona-Jodar T, **Dalmau J**, Compte A, de la Rocha J. Novel parametric visuospatial working memory task in mice. Second Annual Touchscreen Symposium Virtual edition (Touchscreen Cognition), Apr 2, 2020.
- Armangue T, Olive-Cirera G, Martinez-Hernandez E, Sepulveda M, Ruiz-Garcia R, Arrambide G, Auger C, Tintore M, Montalban X, Vanderver A, Graus F, Saiz A, **Dalmau J**. Investigations on myelin oligodendrocyte glycoprotein autoimmunity in children. Annual meeting American Academy of Neurology (AAN), Apr 25-May 1, 2020 (remote). Neurology 2020;94(Suppl):4368.
- Landa J, Maudes E, Munoz A, Armangue T, Saiz A, Graus F, **Dalmau J**, Sabater L. Clinical significance of Kelch-like protein 11 antibodies. Annual meeting American Academy of Neurology (AAN), Apr 25-May 1, 2020 (remote). Neurology 2020;94(Suppl):4294.
- Ruiz-Garcia R, Martinez-Hernandez E, Joubert B, Petit-Pedrol M, Sabater L, **Dalmau J**, Graus F. Paraneoplastic cerebellar ataxia and antibodies to metabotropic glutamate receptor 2. Annual meeting American Academy of Neurology (AAN), Apr 25-May 1, 2020 (remote). Neurology 2020;94(Suppl):2689.
- Guasp M, Modena Y, Armangue T, Dalmau J, Graus F. Clinical significance of seronegative, but CSF antibody positive, anti-NMDA receptor encephalitis. European Academy of Neurology, May 23-26, 2020, (remote). Eur J Neurol 2020;27:233.
- Martinez-Hernandez E, Guasp M, Garcia-Serra A, Maudes E, Armangue T, Saiz A, Graus F, **Dalmau J**. Clinical significance of anti-NMDAR concurrent with glial or neuronal surface antibodies. Annual meeting American Academy of Neurology (AAN), Apr 25-May 1, 2020 (remote). Neurology 2020;94(15 Suppl):2616.
- Guasp M, Gine E, Ruiz VC, Guanyabens N, Parellada E, Dalmau J. Prospective assessment of neuronal autoimmunity in first episode of psychosis. Annual meeting American Academy of Neurology (AAN), Apr 25-May 1, 2020 (remote). Neurology 2020;94(15 Suppl):2458.
- Guasp M, Modena-Ouarzi Y, Armangue T, **Dalmau J**, Graus F. Frequency and clinical significance of seronegative anti-NMDAR encephalitis. Annual meeting American Academy of Neurology (AAN), Apr 25-May 1, 2020 (remote). Neurology 2020;94(15 Suppl):2418.
- Ariño H, Muñoz-Lopetegui A, Dalmau J, Armangue T, Martinez-Hernandez E, Santamaria J. Sleep Disorders in anti-NMDAR encephalitis. Annual meeting American Academy of Neurology (AAN), Apr 25-May 1, 2020 (remote). Neurology 2020;94(15 Suppl):1605.
- Spatola M, Armangue T, **Dalmau J**, Alter G. Functional role of antibodies to Herpes Simplex Virus (HSV1) in infection of the nervous system and autoimmunity. Annual meeting American Academy of Neurology (AAN), Apr 25-May 1, 2020 (remote). Neurology 2020;94(15 Suppl):1998.
- Suga H, Iizuka T, Kaneko J, Yanagida A, Kaneko A, Kitamura E, Kanazawa N, Akutsu T, **Dalmau J**, Nishiyama K. Status epilepticus suspected autoimmune: Antibody frequency and main clinical features. Annual meeting American Academy of Neurology (AAN), Apr 25-May 1, 2020 (remote). Neurology 2020;94(15 Suppl):236.

- Sugranyes G, Masias M, Pariente J, Muñoz M, Ilzarbe D, Rosa M, Fortea A, De la Serna E, Baeza I, Compte A, **Dalmau J**, Castro-Fornieles J. Hippocampal connectivity in youth with schizophrenia: comparison with patients with NMDA receptor encephalitis and healthy volunteers. Schizophrenia International Research Society annual meeting, Apr 4-8, 2020, Florence, Italy. Schizophrenia Bulletin 2020;46:S98-99.
- Badia F, Linares D, Compte A, Rosa M, **Dalmau J**, Castro-Fornieles J, Sugranyes G. Sensitivity for motion is weakened in first episode psychosis. Schizophrenia International Research Society annual meeting, Apr 4-8, 2020, Florence, Italy Schizophrenia Bulletin 2020;46:S209.
- Maudes E, Palma A, Serrano-Regal MP, Barman S, Sánchez-Gómez MV, Domercq M, Goebels N, Matute C, **Dalmau J**. NMDA receptor antibodies in autoimmune encephalopathy alter oligodendrocyte function. PhD workshop, Institute of Neurosciences, University of Barcelona, Barcelona, Spain Nov 29, 2019.
- Doncel-Moria A, Ruiz-García R, Esteller D, Llansó L, Saiz S, **Dalmau J**, Graus F, Martínez-Hernández E. Diagnóstico de la encefalitis anti-receptor GABA_B: advertencias sobre la detección de anticuerpos. Spanish Society of Neurology, Seville Nov 19-23, 2019.
- Ona-Jodar T, Serrano B, Jercog P, Li, C, **Dalmau J**, Compte A, de la Rocha J. A two alternative forced choice task to study working memory in mice. Barcelona Computational, Cognitive and Systems Neuroscience (BARCCSYN), Barcelona, Spain, May 2019.
- Martinez E, Ruiz R, Sánchez M, González J, Díaz C, Queralt X, Gállego J, Velasco R, Saiz A, **Dalmau J**, Graus F. Antineuronal /glial antibodies in patients with neurologic adverse events (AEs) associated with immune checkpoint inhibitors (ICIs). Spanish Society of Neurology, Seville Nov 19-23, 2019.
- Govert F, Becktepe J, Balint B, Varley J, Irani S, Titulaer M, de Vries J, Joubert B, Honnorat J, Arino H, **Dalmau J**, Deuschl G, Leypoldt F. The distinct pattern of movement disorders in Caspr2 and LGI1 antibody associated autoimmune encephalitis. Annual Symposium on Etiology, Pathogenesis, and Treatment of Parkinson Disease and Other Movement Disorders, Apr 6, 2019. Move Disord 2019;34(Suppl 2):S129.
- Ruiz-García R, Martínez-Hernández E, Romera MA, Antón MC, Couso R, Saiz A, **Dalmau J**, Graus F. Diagnostic value of a commercial line blot assay for onconeuronal antibody. Spanish Society of Neurology, Seville Nov 19-23, 2019.
- Ona-Jodar T, Serrano B, Jercog P, Li C, **Dalmau J**, Compte A, de la Rocha J. Working memory in a two-alternative auditory task in mice. Spanish Society of Neuroscience (SENC)/Red Española para la Interacción de Neurociencia Cognitiva y Computacional (SINC2). Santiago de Compostela, Spain. Sept 4-6, 2019.
- Sugranyes G, de la Serna E, Masias M, Rosa M, Stein H, Compte A, **Dalmau J**, Castro-Fornieles J. From the synapse to brain volume: a comparative study between youth with schizophrenia and patients with NMDA receptor encephalitis. American Academy of Child & Adolescent Psychiatry, Chicago, USA. Oct 14-19, 2019.

-Armangue T, Arrambide G, Auger C, Munoz-Batista M, Sepulveda M, Mulero P, Olive G, Midaglia L, Gonzalez-Alvarez V, Sola-Valls N, Felipe-Rucian A, Macaya A, Blanco Y, Rovira A, **Dalmau J**, Graus F, Montalban X, Saiz A, Tintore M. Children with a first demyelination syndrome: the importance of applying the 2017 McDonald criteria together with biomarkers. European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Stockholm, Sweden, Sept 11-13, 2019. *Mult Scler J* 2019;25 (suppl 2):595.

-Stein H, Barbosa J, **Dalmau J**, Compte A. The synaptic basis of history biases in spatial working memory. Hellenic Society for Neuroscience, Heraklion, Crete, Greece. Oct 4-6, 2019.

-Stein H, Barbosa J, **Dalmau J**, Compte A. NMDA-receptor dysfunction disrupts serial biases in spatial working memory. The Bernstein Conference, Berlin, Germany. Sept 17-20, 2019.

-Stein H, Barbosa J, **Dalmau J**, Compte A. NMDA-receptor dysfunction disrupts serial biases in spatial working memory. Cognitive Computational Neuroscience conference. Berlin, Germany, Sept 13-16, 2019.

-Stein H, Barbosa J, Galán A, Morato A, Prades L, Rosa M, Martínez-Hernandez E, Ariño H, **Dalmau J**, Compte A. Synaptic dysfunctions underlying reduced working memory serial bias in autoimmune encephalitis and schizophrenia. Computational Neuroscience Meeting - CNS*2019, Barcelona, Spain. Jul 13-17, 2019.

-Stein H, Barbosa J, **Dalmau J**, Compte A. The influence of NMDA receptor dysfunction on serial biases in working memory. Computational Neuroscience Meeting CNS*2019, Barcelona, Spain. Jul 13-17, 2019.

-Spatola M, Maudes E, Mannara F, Radosevic M, Sabater L, Planaguma J, Rosenfeld MR, **Dalmau J**. Cerebroventricular infusion of patients' antibodies cause memory loss and anxiety in a mice model of anti-metabotropic glutamate receptor 5 (mGluR5) encephalitis. Platform Presentation, S21 #001; 71st Annual Meeting American Academy of Neurology (AAN), Philadelphia, PA, May 4-10, 2019.

-Kaneko A, Iizuka T, Suga H, Kaneko J, Yamaguchi Y, Arai H, Matsumoto Y, Tokimura R, Murakami T, Nakatani-Enomoto S, Kanai K, Ugawa Y, Amano E, Kitamura E, Kanazawa N, **Dalmau J**, Nishiyama K. Atypical clinical manifestations and overlapping immunities associated with NMDA receptor antibodies. Platform Presentation, S11 #006; 71st Annual Meeting American Academy of Neurology (AAN), Philadelphia, PA, May 4-10, 2019.

-Iizuka T, Kaneko J, Kaneko A, Yanagida A, Nonoda Y, Onozawa Y, Kanazawa N, **Dalmau J**, Nishiyama K. A clinically-based score that predicts cryptogenic new-onset refractory status epilepticus (C-NORSE). Platform Presentation, S11 #004; 71st Annual Meeting American Academy of Neurology (AAN), Philadelphia, PA, May 4-10, 2019.

-Kaneko J, Iizuka T, Kondo Y, Abe Y, Kaneko A, Hattori K, Kobayashi S, Ugawa Y, Sekiguchi K, Maeda K, Matsumoto Y, Kanazawa N, Kitamura E, **Dalmau J**, Nishiyama K. Neuronal autoantibodies and clinical significance in Stiff-person spectrum disorder. ePoster, P1 #7-002; 71st Annual Meeting American Academy of Neurology (AAN), Philadelphia, PA, May 4-10, 2019.

-Lozano-Soldevilla D, Santamaria J, **Dalmau J**, Compte A. Tonic EEG spectral modulations during resting state in the process of recovery of anti-NMDA receptor encephalitis. 2019 Reunión Anual CIBERER. San Lorenzo de El Escorial, Madrid, Spain. Mar 12-14, 2019.

-Masias Bruns M, Ilzarbe D, Rosa M, Compte A, Castro-Fornieles J, **Dalmau J**, Sugranyes G. N-methyl-D-aspartate receptor encephalitis versus schizophrenia: A comparative brain imaging study using MR spectroscopy. *Eur Neuropsychopharmacol* 2019;29: S637-S638. The European College of Neuropsychopharmacology (ECNP) Workshop for Early Career Scientists, Nice, France. Mar 5-8, 2019.

-Barbosa J, Stein H, Constantinidis C, **Dalmau J**, Compte A. Mechanisms of spatial working memory in the prefrontal cortex. FENS, Berlin, Germany, July 7-11, 2018.

-Ariño H, Simabukuro MM, Graus F, **Dalmau J**. Delayed improvement in severe anti-NMDAR encephalitis. *Lancet summit: Inflammation and Immunity in Disorders of the Brain and Mind*. Barcelona, Spain. Nov 15-17, 2018.

-Petit-Pedrol M, Sell J, Planagumà J, Mannara F, Radosevik M, Haselmann H, Ceanga M, Sabater L, Spatola M, Geis C, **Dalmau J**. Antibodies from patients with anti-LGI1 encephalitis alter memory and reduce the levels of Kv1.1 and AMPA receptors. *Lancet summit: Inflammation and Immunity in Disorders of the Brain and Mind*. Barcelona, Spain. Nov 15-17, 2018.

-Mattozzi S, Sotgiu S, Escudero D, Augé JM, Saiz A, Ariño H, Spatola M, Armangué T, **Dalmau J**, Graus F. Frequency and significance of thyroid peroxidase (TPO) antibodies. *Lancet summit: Inflammation and Immunity in Disorders of the Brain and Mind*. Barcelona, Spain, Nov 15-17, 2018.

-Gaig C, Ercilla G, Iranzo A, Högl B, Heidebreber A, Höftberger R, **Dalmau J**, Graus F, Santamaria J. Anti-IgLON5 disease: another sleep disorder with HLA association. 7th International Narcolepsy Symposium, Boston, USA. Sept 9-13, 2018.

-Petit-Pedrol M, Sell J, Planagumà J, Mannara F, Radosevik M, Haselmann H, Ceanga M, Aguilar E, Alba M, Sabater L, Spatola M, Geis C, **Dalmau J**. Antibodies from patients with anti-LGI1 encephalitis alter memory and plasticity and reduce the levels of Kv1.1 and AMPA receptors. FENS, Berlin, Germany, July 7-11, 2018.

-Graus F, Escudero D, Oleaga L, Bruna J, Villarejo-Galende A, Ballabriga J, Barcelo MI, Gilo F, Popkirov S, Stourac P, **Dalmau J**. Syndrome and outcome of antibody-negative limbic encephalitis. *Eur J Neurol* 2018;25 (suppl 2):36.

-Sell J, Petit-Pedrol M, Haselmann H, Ceanga M, Planagumà J, Mannara F, Aguilar E, Alba M, Sabater L **Dalmau J**, Geis C LGI1 antibodies from patients with autoimmune encephalitis induce synaptic hyperexcitability. FENS, Berlin, Germany, July 7-11, 2018.

-Stein H, Lozano-Soldevilla D, Dalmau J, Compte A. Glutamatergic modulation of serial biases in spatial working memory. FENS, Berlin, Germany, July 7-11, 2018.

-Morales L, de la Rocha J, **Dalmau J**, Jercog P. A novel behavioural task to study the neuronal

representation of long-term spatial memories. FENS, Berlin, Germany, July 7-11, 2018.

-Tomàs-Cuesta D, de la Rocha J, Dalmau J*, Jercog PE*. How spaced learning affects stability of hippocampal neural correlates of learning. BARCCSYN, Barcelona, Spain. May 24-25, 2018 (*=co-last authors).

-Morales L, de la Rocha J, **Dalmau J**, Jercog P. The neural mechanisms of hippocampal long-term spatial memory design of a novel spatial navigation task. BARCCSYN, Barcelona, Spain. May 24-25, 2018.

-Malviya M, Barman S, Golombeck KS, Planagumà J, Mannara F, Strutz-Seebohm N, Wroz C, Demir F, Baksmeier C, Steckel J, Kristin Falk K, Gross CC, Kovac S, Bönke K, Johnen A, Wandinger KP, Martín-García E, Becker AJ, Elger CE, Klöcker N, Wiendl H, Meuth SG, Hartung HP, Seebohm G, Leyboldt F, Maldonado R, Stadelmann-Nessler C, **Dalmau J**, Melzer N, Goebels N. NMDAR encephalitis: passive transfer from man to mouse by a recombinant antibody. Platform Presentation #006; 70th Annual Meeting American Academy of Neurology (AAN), Los Angeles, CA, April 27, 2018.

-Spatola M, Sabater L, Martinez Hernandez E, Iizuka T, Rosenfeld MR, Graus F, **Dalmau J**. Clinical findings, IgG subclass, and antibody effects in encephalitis associated with metabotropic glutamate receptor 5 (mGluR5) antibodies. Poster # 390; 70th Annual Meeting American Academy of Neurology (AAN), Los Angeles, CA, April 26, 2018.

-Hara M, Martinez-Hernandez E, Ariño H, Armangué T, Spatola M, Petit-Pedrol M, Saiz A, Rosenfeld M, Graus F, **Dalmau J**. Clinical and pathogenic significance of IgG, IgA, and IgM antibodies against the NMDA receptor. Poster # 384; 70th Annual Meeting American Academy of Neurology (AAN), Los Angeles, CA, April 22, 2018.

-Spatola M, Sabater L, Martinez-Hernandez, E, Rosenfeld, M, Graus F, **Dalmau J**. Clinical characterization and long-term outcome of patients with autoimmune encephalitis with antibodies against the metabotropic glutamate receptor 5 (mGluR5). Annual Meeting European Academy of Neurology. Eur J Neurol 2017;24 Suppl 1:113.

-Cuervo LL, Ladepeche L, Planaguma J, Borbely JS, Sandoval A, **Dalmau J**, Lakadamyali M. Multi-color STORM in neurons reveals molecular organization of the LGI1 synaptic complex. Annual meeting American Society for Cell Biology. Mol Biol Cell 2017;28:P3212.

-Ladepeche L, Planaguma J, Thakur S, Suarez I, Borbely J, Sandoval A, Cuervo LL, **Dalmau J**, Lakadamyali M. Nanoscale redistribution of NMDA receptors subunits in anti-NMDA receptor autoimmune encephalitis. Annual meeting American Society for Cell Biology. Mol Biol Cell 2017;28:P3213

-Stein H, Lozano-Soldevilla D, **Dalmau J**, Compte A. Glutamatergic modulation of working memory precision and serial biases. Annual Meeting SFN, San Diego, USA, November 2017.

-Guasp Verdaguer M, Escudero D, Ariño Rodríguez H, Gaig C, Martínez Hernández E, Reyes Leiva D, Montejo González C, **Dalmau Obrador J**, Graus Ribas F. Síndromes del SNC asociados a anticuerpos contra antígenos de superficie neuronal en pacientes de edad avanzada sin otra

evidencia de inflamación. LXIX Meeting of the Spanish Society of Neurology, Valencia, Spain; November 21-25, 2017.

-Armangue T, Spatola M, Secondi GC, Orellana G, Montejo C, Sabater L, Rodes M, Ariño H, Aguilar E, Planaguma J, Navarro Moron J, Martínez Hernández E, Rosenfeld M, López Laso E, Neth O, Málaga-Dieguez I, Morist G, Pomar V, Bataller L, Juan Otero M, Erro E, Toledo M, Corral I, Rodríguez E, García Moncó JC, Alsina L, Saiz A, Graus F, **Dalmau J**. Autoinmunidad cerebral tras la encefalitis por el virus herpes simple (HSE): 100 casos. LXIX Meeting of the Spanish Society of Neurology, Valencia, Spain; November 21-25, 2017.

-Martínez Hernández E, Ariño H, Armangué T, Spatola M, Graus F, Saiz A, **Dalmau J**. Significado de la coexistencia de otros anticuerpos de superficie neuronal o contra MOG/AQP4 en pacientes con anticuerpos contra NMDAR. LXIX Meeting of the Spanish Society of Neurology, Valencia, Spain; November 21-25, 2017.

-Armangue T, Martínez-Hernández E, Graus F, **Dalmau J**. Brain autoimmunity following herpes simplex encephalitis (HSE): 100 cases. 69th Annual Meeting American Academy of Neurology (AAN), Boston, MA, April 26, 2017.

-Spatola M, Sabater L, Martínez Hernández E, Rosenfeld MR, Graus F, **Dalmau J**. Novel findings in autoimmune encephalitis with antibodies against the metabotropic glutamate receptor 5 (mGluR5). 69th Annual Meeting American Academy of Neurology (AAN), Boston, MA, April 23, 2017.

-Hara M, Ariño H, Petit-Pedrol M, Sabater L, Titulaer M, Martínez-Hernández E, Schreurs M, Graus F, **Dalmau J**. DPPX-antibody associated encephalitis: main syndrome and antibody effects. 69th Annual Meeting American Academy of Neurology (AAN), Boston, MA, April 24, 2017.

-Iizuka T, Kaneko J, Tominaga N, Kanazawa N, Nonoda Y, Hara A, Onozawa Y, Asari H, Hata T, Kaneko J, Yoshida K, Sugiura Y, Ugawa Y, Watanabe M, Tomita H, Kosakai A, Kaneko A, Ishima D, Kitamura E, **Dalmau J**, Nishiyama K. Antibodies to neuronal surface antigens in possible autoimmune encephalitis and new-onset refractory status epilepticus (NORSE). 69th Annual Meeting American Academy of Neurology (AAN), Boston, MA, April 25, 2017.

-Ercilla G, Gaig C, Palou E, Sabater L, Iranzo A, **Dalmau J**, Graus C, Gelpi E, Santamaria J. A new neurological disorder associated with an HLA-DRB1*10 haplotype. HLA 2016; 87(4):317.

-Spatola M, Petit-Pedrol M, Rosenfeld MR, Graus F, **Dalmau J**. Novel findings in anti-GABAA receptor encephalitis. The PhD Workshop of the Institute of Neurosciences (University of Barcelona), Barcelona Spain, Dec 16, 2016.

-Ramírez-González JA, Rodes M, Martínez-Hernández E, Ariño H, Aguilar E, Caballero E, Spatola M, Saiz G, Graus F, **Dalmau J**, Armangue T. Prospective multicentric study in Pediatric Autoimmune Encephalitis associated to auto-antibodies. 40th Annual Meeting of the Mexican Academy of Neurology, Cancun, Mexico, 24 October-4 Nov, 2016.

-Ramírez-González A, Martínez-Hernández E, Spatola M, Rodes M, López-Laso E, Málaga I, Aguilera Albesa S, Conejo-Moreno D, Tomas-Vila M, Felipe-Rucián A, Neth O, Peña-Segura JL,

Soler-Palacín P, Navarro-Morón J, Turón-Viñas E, Hernández A, Aznar-Lazarín G, Arrabal-Fernández L, Bermejo T, Monlleó L, Escofet C, Ruíz-García C, Paredes F, Dapena M, López-Díaz A, Gili T, Toledo-Bravo L, Camacho-Salas A, Soto-Insuga V, Olabarrieta N, Guillén-Martín S, Duat-Rodríguez A, Lorenzo M, Domingo R, Martínez-González MJ, Cantarín-Extremera V, Martí-Carrera I, Álvarez de Manuel D, Miranda-Herrero MC, González-López MT, Dacruz D, Saiz A, Graus F, **Dalmau J**, Armangue T. Prospective multicentric study in Pediatric Autoimmune Encephalitis associated to auto-antibodies. LXVIII Annual Meeting of Neurology Spanish Society, Valencia, Spain, November, 15-19, 2016.

-Martinez-Hernandez E, Gresa-Arribas N, Planaguma J, Petit-Pedrol M, Armangue T, Graus F, **Dalmau J**. A novel type of autoimmune encephalitis with neuroxin-3 α antibodies. American Neurological Association, Baltimore, MD, October 16-18, 2016. Ann Neurol 2016;80 Suppl 20:S151.

-Spatola M, Petit-Pedrol M, Rosenfeld M, Graus F, **Dalmau J**. New clinical and immunological features of anti-GABAA receptor encephalitis. American Neurological Association, Baltimore, MD, October 16-18, 2016. Ann Neurol 2016;80 Suppl 20:S146.

-Sabater L, Planagumà J, **Dalmau J**, Graus F. Cellular investigations with human antibodies associated with the anti-IgLON5 syndrome. 13th International Society of Neuroimmunology (ISNI) Meeting. Jerusalem, Israel. September 26-29, 2016.

-Malviya M, Barman S, Wroz C, Seebohm G, Stadelmann-Nessler C, Hartung H-P, Planagumà J, Mannara F, **Dalmau J**, Melzer N, Goebels N. Clonally expanded intrathecal plasma cells in NMDA-R encephalitis patients produce pathogenic antibodies. 13th International Society of Neuroimmunology (ISNI) Meeting. Jerusalem, Israel. September 26-29, 2016

-Ramírez González JA, Rodes M, Martínez-Hernández E, Ariño H, Aguilar E, Caballero E, Spatola M, Saiz A, Graus F, **Dalmau J**, Armangue T. Estudio prospectivo multicéntrico de encefalitis pediátricas autoinmunes asociadas a auto-anticuerpos. XIV Congreso Panamericano de Neurología. Rev Mex Neurosci 2016;17(suppl) S1-S350:344.

-Petit-Pedrol M, Planagumà J, Haselmann H, Mannara F, Grünewald B, Aguilar E, Röpke L, Martin-Garcia E, Jercog P, Graus F, Maldonado R, Geis C, **Dalmau J**. Ephrin-b2 abrogates NMDAR antibody effects in a murine model of anti-NMDAR encephalitis. Federation of European Neuroscience Societies, Copenhagen, Denmark, July 3, 2016.

-Morales L, de la Rocha Jaime, **Dalmau J**, Jercog P. The neural mechanism of hippocampal long-term spatial memory: novel use of NMDA receptor antibodies. Annual Meeting, Barcelona Computational, Cognitive and Systems Neuroscience (BARCCSYN). Barcelona, Spain, June 17, 2016.

-Sonderen AV, Ariño H, Petit-Pedrol M, Leypoldt F, Körtvelyessy P, Lancaster E, Wirtz P, Schreurs M, Sillevius Smitt P, Graus F, **Dalmau J**, Titulaer M. The clinical spectrum of Caspr2-antibody associated disease. Annual Meeting American Academy of Neurology (AAN), Vancouver, Canada April 17, 2016.

-Spatola M, Petit-Pedrol M, Rosenfeld M, Graus F, **Dalmau J**. Novel findings in anti-GABAa

receptor encephalitis. Annual Meeting American Academy of Neurology (AAN), Vancouver, Canada April 17, 2016.

-Ariño H, Petit-Pedrol M, Armangue T, Saiz A, **Dalmau J**, Graus F. Anti-LGI1-associated cognitive impairment: Clinical profiles and long-term outcome. Annual Meeting American Academy of Neurology (AAN), Vancouver, Canada April 17, 2016.

-Petit-Pedrol M, Planagumà J, Mannara F, Haselmann H, Grünewald B, Aguilar E, Martin-Garcia E, Maldonado R, Lakadamyali M, Geis C, **Dalmau J**. Ephrin-B2 abrogates NMDAR-antibody effects in a murine model of anti-NMDAR encephalitis. Reunión anual de la Sociedad Española de Neurociencias (SENC), Granada, Spain, September 23, 2015.

-Petit-Pedrol M, Planagumà J, Mannara F, Haselmann H, Grünewald B, Aguilar E, Martin-Garcia E, Maldonado R, Lakadamyali M, Geis C, **Dalmau J**. Ephrin-B2 abrogates NMDAR-antibody effects in a murine model of anti-NMDAR encephalitis. Barcelona Computational, Cognitive and Systems Neuroscience Conference (BARCCSYN), Barcelona, Spain. June 19, 2015.

-Iizuka T, Someko H, Oonuma H, Kubo A, Nakamura M, Ishima D, Kaneko J, Kitamura E, Masuda R, **Dalmau J**, Nishiyama K. Late Cerebellar Atrophy and Long-Term Outcome in Anti-NMDA Receptor Encephalitis. Annual Meeting American Academy of Neurology (AAN), Washington DC, Apr 22, 2015.

-Iizuka T, Nakamura M, Ishima D, Kaneko J, **Dalmau J**, Nishiyama K. Acute Bulbar Palsy as Presentation of Anti-NMDA Receptor Encephalitis: A Case Report. Annual Meeting American Academy of Neurology (AAN), Washington DC, Apr 22, 2015.

-Lewerenz J, Müller H-P, Buchert R, Rau D, Sabater L, Gaig C, Gelpi E, Mogel H, Kassubek J, Tumani H, Uttner I, **Dalmau J**, Graus F. Encephalopathy with IgLON5 antibodies: a description of the first German case. Lancet Neurol meeting on Autoimmune Disorders, Barcelona, March 26-27, 2015.

-Spatola M, Novy J, Du Pasquier R, **Dalmau J**, Rossetti AO. Status epilepticus of inflammatory etiology: a cohort study. Lancet Neurol meeting on Autoimmune Disorders, Barcelona, March 26-27, 2015.

-Leypoldt F, Höftberger R, Titulaer MJ, Armangue T, Gresa-Arribas N, Rostásy K, Wandinger K-P, Rosenfeld MR, Graus F, **Dalmau J**. Investigations on CXCL13 in a cohort of patients with anti-NMDA receptor encephalitis: a potential biomarker of treatment response. Lancet Neurol meeting on Autoimmune Disorders, Barcelona, Spain. April 26-27, 2015.

-Bigi S, Hladio M, Twilt M, **Dalmau J**, Benseler SM. Recognition of antibody-associated inflammatory brain diseases in children: A single-centre cohort study. Lancet Neurol meeting on Autoimmune Disorders, Barcelona, Spain. April 26-27, 2015.

-Sepúlveda, Hofberger R, Armangué T, Blanco Y, Rostásy K, Cobo A, et al. Anticuerpos contra glicoproteína de mielina oligodendrocitaria (anti-MOG) y anti-acuaporina-4 (anti-AQP4) en síndromes desmielinizantes: diferencias y similitudes en pacientes adultos. LXVI Reunión anual de la Sociedad Española de Neurología. Valencia. Spain. 21/11/2014.

-Gaig C, Iranzo de Riquer A, Vilaseca I, Embid C, Sabater L, **Dalmau J**, Graus F, Santamaria J. Características del patrón de sueño en la nueva parasomnia asociada a anticuerpos IgLON5. LXVI Reunión Anual de la Sociedad Española de Neurología. Valencia. Spain. 21/11/2014.

-Ariño H, Gresa N, Armangué T, Petit M, Martínez Hernández E, **Dalmau J**, Saiz A, Graus F. Síndromes neurológicos paraneoplásicos asociados a anticuerpos contra el enzima descarboxilasa del ácido glutámico (GAD65). LXVI Reunión anual de la Sociedad Española de Neurología. Valencia. Spain. 21/11/2014.

-Armangué T, Sepúlveda M, Caballero E, Sanchez A, del Toro M, Ariño H, et al. Síndromes desmielinizantes adquiridos pediátricos: correlación clínico-inmunológica.". LXVI reunión Anual de la Sociedad Española de Neurología. Valencia. Spain. 21/11/2014.

-Martínez Hernández E, Sepúlveda M, Rostasy K, Höftberger R, Graus F, Saiz A, **Dalmau J**. La presencia de diferentes autoanticuerpos en neuritis óptica tiene implicaciones clínicas y pronósticas. LXVI Reunión Anual de la Sociedad española de Neurología. Valencia. Spain. 20/11/2014.

-Leypoldt F, Planagumà J, Mannara F, Gutiérrez-Cuesta J, Martín-García E, Aguilar E, Titulaer MJ, Petit-Pedrol M, Jain A, Balice-Gordon R, Lakadamyali M, Graus F, Maldonado R, **Dalmau J**. Human N-Methyl-D-aspartate receptor antibodies alter memory and behavior in mice/ International Society of Neuroimmunology (ISNI), Mainz, Germany, Nov 9-13, 2014.

-Santamaria Cano J, Sabater L, Gaig C, Gelpi E, Bataller L, Iranzo A, Lewerenz J, Torres-Vega E, Contreras A, Giometto B, Compta Y, Embid C, Vilaseca I, **Dalmau J**, Graus F. A novel NREM and REM parasomnia with sleep breathing disorder associated with antibodies against IgLON5: a case series, pathological features, and characterization of the antigen. Eur J Neurol 2014;21:32. Joint meeting of the EFNS-ENS, Istanbul, Turkey.

-Querol L, Nogales-Gadea G, Rogas-Garcia R, Diaz-Manera J, Pardo J, Ortega-Moreno A, Sedano MJ, Gallardo E, Berciano J, Blesa R, **Dalmau J**, Illa I. Antibodies against neurofascin-155 (NF155) in CIDP associated with disabling tremor, distal weakness and poor response to IVIg. Eur J Neurol 2014;21:83. Joint meeting of the EFNS-ENS, Istanbul, Turkey.

-Ariño H, Arribas-Gresa N, Martinez-Hernandez E, Llufríu S, Blanco Y, **Dalmau J**, Saiz A, Graus F. Cerebellar ataxia associated with glutamic acid decarboxylase 65 autoantibodies (GAD65-ab). Long-term impact of immunotherapy. Eur J Neurol 2014;21:69. Joint meeting of the EFNS-ENS, Istanbul, Turkey.

-Gaig C, Sabater L, Gelpi E, Bataller L, Lewerenz J, Torres-Vega E, Contreas A, Giometto B, Compta Y, Embid C, Vilaseca I, Iranzo A, Santamaria J, **Dalmau J**, Graus F. Antibodies against the cell adhesion molecule IgLON5 identify a novel tauopathy with NREM/REM parasomnia and sleep breathing disorder. Annual Meeting American Academy of Neurology (AAN), Philadelphia, PA, Apr 28-29, 2014.

-Petit M, Armangué T, Peng X, Davis R, McCracken L, Balice-Gordon R, Graus F, **Dalmau J**. Antibodies to GABA(A) receptor associate with seizures, status epilepticus, and remove the receptors from synapses. Annual Meeting American Academy of Neurology (AAN), Philadelphia, PA, Apr 28-29, 2014.

-Chen FC, **Dalmau J**. NMDAR antibody encephalitis: case report of persistent NMDAR antibodies 10 years from initial presentation. Annual Meeting American Academy of Neurology (AAN), Philadelphia, PA, Apr 28-29, 2014.

-Suchecki S, **Dalmau J**. A rare autoimmune encephalitis - due to Dipeptidyl-Peptidase-Like Protein-6 (DPPX) autoantibody- A case report. Annual Meeting American Academy of Neurology (AAN), Philadelphia, PA, Apr 28-29, 2014.

-Gresa-Arribas N, Ariño H, Sabater L, Caballero E, Alba M, Martínez-Hernandez E, Petit M, Saiz A, **Dalmau J**, Graus F. Determination of antibodies to GAD67 and other antigens in patients with GAD65 antibody-associated syndromes. Annual Meeting American Academy of Neurology (AAN), Philadelphia, PA, Apr 28-29, 2014.

-Andrade L, **Dalmau J**. A common movement abnormality in patients with LGI1 limbic encephalitis is a manifestation of tonic seizures. Annual Meeting American Academy of Neurology (AAN), Philadelphia, PA, Apr 28-29, 2014.

-Taraschenko O, **Dalmau J**, Zimmerman ES, McKee MA. Anti-NMDA receptor encephalitis presenting with atrial fibrillation. Annual Meeting American Academy of Neurology (AAN), Philadelphia, PA, Apr 28-29, 2014.

-Mannara F, Gutierrez J, Leyboldt F, Planagumà J, Martin E, Jain A, Graus F, Balice-Gordon R, Maldonado R, **Dalmau J**. From behavior to synapse: a murine model of passive transfer of antibodies from patients with anti-NMDAR encephalitis. Annual Meeting American Academy of Neurology (AAN), Philadelphia, PA, Apr 28-29, 2014.

-Martinez-Hernandez E, Gresa-Arribas N, Petit-Pedrol M, Ariño H, Saiz A, Graus F, **Dalmau J**. Autoimmunity to inhibitory synaptic proteins in Stiff-person spectrum of symptoms. Annual Meeting American Academy of Neurology (AAN), Philadelphia, PA, Apr 28-29, 2014.

-Greene M, Lai Y, **Dalmau J**, Lancaster E. Confirmed: The antigen of paraneoplastic antibodies previously named “anti-Tr” is delta/notch-like epidermal growth factor-related receptor (DNER). Annual Meeting American Academy of Neurology (AAN), Philadelphia, PA, Apr 28-29, 2014.

-Petit M, Armangue T, Martinez-Hernandez E, Davis R, Baraller L, Graus F, **Dalmau J**. Identification of receptor GABA(A) as an autoantigen of encephalitis associated with status epilepticus. Annual meeting of the Spanish Society for Neurology (SEN), Barcelona, Spain, Nov 19-23, 2013.

-Peng X, Hughes EG, Moscato EH, Parsons TD, **Dalmau J**, Balice-Gordon RJ. Loss of surface AMPA receptors and homeostatic changes in inhibitory synaptic transmission caused by anti-AMPA receptor antibodies from patients with autoimmune limbic encephalitis. Society for Neuroscience, San Diego, USA. Nov 9-13, 2013.

-Moscato EH, Peng X, Jain A, Parsons TD, **Dalmau J**, Balice-Gordon RJ. Alterations in synaptic transmission caused by anti-NMDA receptor antibodies from patients with autoimmune encephalitis. Society for Neuroscience, San Diego, USA. Nov 9-13, 2013.

-Gresa-Arribas N, Titulaer M, Aguilar E, Torrents A, Graus F, **Dalmau J**. Investigation of serum and CSF of patients with anti-NMDA receptor encephalitis. Annual meeting of the Spanish Society for Neurology (SEN), Barcelona, Spain. Nov 19-23, 2013.

-Martinez-Hernandez E, Davis R, Arnangue T, Titulaer M, Petit M, Kasner S, Graus F, **Dalmau J**. Status epilepticus in autoimmune encephalitis. Annual meeting of the Spanish Society for Neurology (SEN), Barcelona, Spain. Nov 19-23, 2013.

-Armangue Salvador T, Leypoldt F, Raspall-Chaure M, Málaga I, Nichter C, Vicente-Rasoamalala M, Macaya A, Graus F, **Dalmau J**. Post-herpetic choreoathetosis: antibodies against NMDA receptor are part of the problem. Annual meeting of the Spanish Society for Neurology (SEN), Barcelona, Spain. Nov 19-23, 2013.

-Gresa-Arribas N, Titulaer M, Leypoldt F, Rosenfeld MR, Graus F, **Dalmau J**. Sensitivity of antibody testing, clinical-titer correlations, and epitope repertoire in anti-NMDAR encephalitis. Annual meeting of the American Neurological Association, New Orleans, USA. Oct 13-15, 2013.

-Titulaer MJ, Höftberger R, Iizuka T, Rosenfeld MR, Graus F, Saiz A, **Dalmau J**. Overlap of anti-NMDAR encephalitis with demyelinating disorders. Annual meeting of the American Neurological Association, New Orleans, USA. Oct 13-15, 2013.

-Leypoldt F, Armangue T, Málaga I, Raspall-Chaure M, Marti I, Nichter C, Vicente-Rasoamalala M, Lafuente-Hidalgo M, Macaya A, Glaser C, **Dalmau J**. Viral infection as trigger of synaptic autoimmunity: New evidence that relapses post-herpes simplex encephalitis are caused by NMDA receptor antibodies. Annual meeting of the American Neurological Association, New Orleans, USA. Oct 13-15, 2013.

-Gresa-Arribas N, Sabater L, Ariño H, Caballero E, Alba M, Martínez-Hernandez E, Petit M, Saiz A, **Dalmau J**, Graus F. Characterization of the autoantigen repertoire in neurological disorders associated to GAD autoimmunity. Annual meeting of the Spanish Society for Neuroscience. Oviedo, Spain. Sep 25-27, 2013.

-Hoftberger R, Sabater L, Kruer M, Boyero S, de Felipe A, Saiz A, Graus F, **Dalmau J**. Encephalitis and GABAB receptor antibodies: novel findings in a new cases series of 20 patients (Abstract 0249), 23rd Annual Meeting of the European Neurological Society, Barcelona, Spain, June 8-11, 2013.

-Merwick A, **Dalmau J**, Delanty N. Insights into antibody-associated encephalitis: Bickerstaff's 1950's papers revisited (Abstract 0263), 23rd Annual Meeting of the European Neurological Society, Barcelona, Spain, June 8-11, 2013.

-Grau O, Sanchez-Valle R, Saiz A, Molinuevo JL, **Dalmau J**, Graus F. Should neuronal antibody determination be performed in patients with suspected Creutzfeldt-Jakob disease? (Abstract 0334), 23rd Annual Meeting of the European Neurological Society, Barcelona, Spain, June 8-11, 2013.

-Grau O, Saiz A, **Dalmau J**, Graus F. Analysis of antineuronal antibodies in patients with suspected and pathologically proved Creutzfeldt-Jakob disease. 65th Annual Meeting of the American Academy of Neurology, San Diego, CA, March 16-23, 2013.

-Titulaer MJ, McCracken L, Gabilondo I, Iizuka T, Kawachi I, Torrents A, Saiz A, Rosenfeld MR, Balice-Gordon R, Graus F, **Dalmau J**. Anti-NMDA receptor encephalitis in the elderly associates with delays in diagnosis, treatment, and worse clinical outcome. 65th Annual Meeting of the American Academy of Neurology, San Diego, CA, March 16-23, 2013.

-Kaneko J, Iizuka T, Asari H, Ishima D, Kasakura S, Hara A, Akutsu T, Hata T, Hamada J, **Dalmau J**, Nishiyama K. Retrospective Review of 6 Patients with New-Onset Refractory Status Epilepticus (NORSE) Syndrome: Early Intervention with Intravenous Cyclophosphamide May Improve Outcome. 65th Annual Meeting of the American Academy of Neurology, San Diego, March 21, 2103

-Armangue T, Sabater L, Gresa-Arribas N, Graus F, Titulaer M, **Dalmau J**. Identification of a novel phenotype of opsoclonus-myoclonus syndrome (OMS) that affects teenagers and young adults and responds to treatment. 65th Annual Meeting of the American Academy of Neurology, San Diego, CA, March 16-23, 2013.

-Clardy SL, Pittock SJ, **Dalmau J**, Jones RH Jr. Renaud DL, Harper CM, Matsumoto JY, Lennon VA, McKeon A. Stiff Children. 65th Annual Meeting of the American Academy of Neurology, San Diego, CA, March 16-23, 2013.

-Masdeu JC, González-Pinto A, Matute C, Ruiz de Azúa S, Palomino A, de Leon J, **Dalmau J**. Absence of Serum IgG Antibodies Against the NR1 Subunit of the NMDA Receptor in Patients with Schizophrenia. 65th Annual Meeting of the American Academy of Neurology, San Diego, CA, March 16-23, 2013.

-Boronat Barado A, Gresa Arribas N, Sabater Baudet L, Graus Ribas F, **Dalmau J**. Encefalitis y anticuerpos contra DPPX, una proteína reguladora de la subunidad Kv4.2 de los canales de potasio [Encephalitis and antibodies to DPPX, a regulatory subunit of the Kv4.2 potassium channels]. Spanish Society for Neurology (SEN), Barcelona, Spain 11/2012.

-Petit-Pedrol M, Armangue T, Gresa-Arribas N, Graus F, **Dalmau J**. Estudio clínico e inmunológico de los síndromes asociados a anticuerpos LGI1 y Caspr2 [Clinical and immunological analysis of síndromes associated with LGI1 and Caspr2 antibodies]. Spanish Society for Neurology (SEN), Barcelona, Spain 11/2012.

-Armangue T, Gabilondo I, Petit-Pedrol M, Bataller L, Duart A, Falcón A, González V, Gonzalo-Herrainz, Gómez-Esteban JC, Jadrque R, Jimenez A, López-Pisón J, Macaya A, Málaga-Diéguéz I, Navarro-Mascarell G, Palomeras E, Pellisé A, Simón R, Turón E, Vela A, Vivancos-Mora J, Graus F, **Dalmau J**. Encefalitis anti-NMDAR pediátrica en España [Pediatric anti-NMDAR encephalitis in Spain]. Spanish Society for Neurology (SEN), Barcelona, Spain 11/2012.

-Armangue T, Petit M, Sabater L, Rosenfeld M, Graus F, **Dalmau J**. Opsoclonus-mioclonus-ataxia asociado a teratoma de ovario –descripción de un nuevo síndrome con buena respuesta al tratamiento [Opsoclonus-myoclonus-ataxia associated with ovarian teratoma- report of a new síndrome that is treatment-responsive]. Spanish Society for Neurology (SEN), Barcelona, Spain

11/2012.

-Titulaer MJ, McCracken L, Gabilondo I, Armangue T, Martinez-Hernandez E, Glaser C, Iizuka T, Honig L, Benseler S, Rosenfeld MR, Balice-Gordon R, Graus F, **Dalmau J**. Clinical features, treatment, and outcome of 568 patients with anti-NMDA receptor encephalitis. International Society for Neuroimmunology (ISNI), Boston, MA, 10/2012/

-Sabater L, Höftberger R, Boronat A, Saiz A, **Dalmau J**, Graus F. Antibody repertoire in paraneoplastic cerebellar degeneration associated with small cell lung cancer. International Society for Neuroimmunology (ISNI), Boston, MA, 10/2012

-Boronat-Barado A, Gelfand JM, Gresa-Arribas N, Jeong H-Y, Walsh M, Roberts K, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R, Graus F, Rudy B, **Dalmau J**. Encephalitis and antibodies to DPPX, a regulatory subunit of Kv4.2 potassium channels. Works in Progress, American Neurological Association, Boston, MA 10/2012.

-Titulaer MJ, McCracken L, Armangue T, Gabilondo I, Martinez-Hernandez E, Iizuka T, Honig LS, Benseler S, Rosenfeld MR, Balice-Gordon R, Graus F, Glaser C, **Dalmau J**. Anti-NMDAR encephalitis – A series of 208 children. Works in Progress, American Neurological Association, Boston, MA 10/2012.

-Armangue T, Gabilondo I, Gonzalez V, Del Toro M, Graus F, **Dalmau J**. Pediatric anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in Spain. [Encefalitis anti-N-methyl-D-aspartate receptor (NMDAR) pediátrica en España]. Presented at XXXVI Reunión anual de la Asociación Española de Neurología Pediátrica (SENEP), May 2012.

-Moscato EH, Jain A, Peng X, Parsons TD, **Dalmau J**, Balice-Gordon R. Acute mechanism underlying antibody effects in anti-NMDA receptor encephalitis. Federation of European Neurosciences Forum, Barcelona, Spain July 14-18, 2012. Abstract 27.07

-Armangue T, Monlleo L, Macaya A, Graus F, **Dalmau J**, Del Toro M. Anti-N-methyl-D-aspartate receptor encephalitis: Atypical presentation in 2 children of 3 and 5 years of age [Encefalitis anti-N-methyl-D-aspartate receptor (NMDAR)]. Presentación atípica en dos niños de 3 y 5 años. Presented at XXXVI Reunión anual de la Asociación Española de Neurología Pediátrica (SENEP), May 2012.

-Martínez R, Armangue T, Del Toro M, Graus F, **Dalmau J**, Roig M. Atypical presentation of anti-N-methyl-D-aspartate receptor encephalitis in 2 children [Encefalitis anti-N-methyl-D-aspartate receptor (NMDAR)]. Presentación atípica. Presented at the 61º Congreso de la Asociación Española de Pediatría. May 2012.

-Titulaer MJ, McCracken L, Gabilondo-Cuellar I, Martinez-Hernandez E, Graus F, Balice-Gordon R, **Dalmau J**. Clinical features, treatment, and outcome of 500 patients with anti-NMDA receptor encephalitis. *Neurology* 2012 Apr;78:PL01.001.

-Masdeu J, González-Pinto A, Matute C, Ruiz de Azua S, Palomino A, De Leon J, **Dalmau J**. Serum IgG antibodies against the NMDA receptor not detected in schizophrenia. *Biological Psychiatry (Biol Psychiatry)*, 2012, 71: 53S

-Jain A, **Dalmau J**, Balice-Gordon R. Ventricular infusion of patient antibodies as a mouse model of anti-NMDA receptor encephalitis. Society for Neuroscience, 2011, poster 676.24/BB8.

-Moscato EH, Peng X, Parsons TD, **Dalmau J**, Balice-Gordon R. Acute mechanisms underlying antibody effects in anti-NMDA receptor encephalitis. Society for Neuroscience, 2011, poster 676.25/BB9.

-Lancaster E, Martinez-Hernandez E, Titulaer MJ, Wong S, Xu J, Contractor A, Balice-Gordon R, **Dalmau J**. Antibodies to metabotropic glutamate receptors in the Ophelia syndrome and cerebellitis (abstract). 136th Annual Meeting of the American Neurological Association, ANA, San Diego, CA, September 25-28, 2011.

-Titulaer MJ, Martinez-Hernandez E, McCracken L, Balice-Gordon R, **Dalmau J**. Anti-NMDA-receptor encephalitis: clinical analysis of 457 patients (abstract). 136th Annual Meeting of the American Neurological Association, ANA, San Diego, CA, September 25-28, 2011.

-Lancaster E, Lai M, Huijbers MGM, Barado AB, Wong A, Scherer SS, **Dalmau J**. Two molecular targets, LGI1 and CASPR2, associate with different phenotypes in disorders previously attributed to VGKC. 135th Annual Meeting of the American Neurological Association, ANA, San Francisco, CA, September 14th, 2010.

-Lancaster E, Lai M, Hughes EG, Peng X, Moss SJ, Balice-Gordon R, **Dalmau J**. A novel synaptic autoimmunity against the γ -amino-butyric acid-B (GABA_B) receptor associates with encephalitis, memory loss, and seizures. Annual Meeting of the American Neurological Association, ANA, Baltimore, MD, October 13th, 2009.

-Hughes EG, Peng X, Gleichman AJ, Lai M, Zhou L, Tsou R, Parsons TD, Lynch DR, **Dalmau J**, Balice-Gordon R. Cellular and synaptic mechanisms underlying anti-NMDA receptor encephalitis. *Ann Neurol* 2009;66 (Suppl 13): S63-64.

-Hughes EG, Peng X, Lai M, Zhou L, Tsou R, Gleichman AJ, Lynch DR, **Dalmau J**, Balice-Gordon RJ. Cellular and synaptic mechanisms underlying autoantibodies in anti-NMDA receptor encephalitis. Cold Spring Harbor Labs, *Synapses: From Molecules to Circuits & Behavior*, 2009.

-Gleichman AJ, Lai M, Zhou L, Hughes EG, Peng X, Balice-Gordon RJ, **Dalmau J**, Lynch DR. Antigenicity of glutamate receptors. *Soc Neurosci Ann Meeting* 2009.

-Balice-Gordon RJ, Hughes EG, Peng X, Lai M, Zhou L, Gleichman AJ, Lynch DR, **Dalmau J**. Cellular and synaptic mechanisms underlying autoimmune AMPA receptor encephalitis. *Soc Neurosci Ann Meeting*, 2009.

-Hughes EG, Peng X, Lai M, Zhou L, Tsou R, Gleichman AJ, Lynch DR, **Dalmau J**, Balice-Gordon RJ. Cellular and synaptic mechanisms underlying autoimmune NMDA receptor encephalitis. *Soc Neurosci Ann Meeting*, 2009.

-Gleichman AJ, Rossi JE, Lai M, Hughes EG, Peng X, Balice-Gordon RJ, **Dalmau J**, Lynch DR. Mechanisms of action of anti-NMDA receptor antibodies in anti-NMDAR encephalitis. *Soc Neurosci Ann Meeting* 2008;34:425.13.

-Balice-Gordon RJ, Hughes EG, Peng X, Rossi JE, Lai M, Gleichman AJ, Lynch DR, **Dalmau J**. Reversible loss of NMDA receptor clusters in a cellular model of paraneoplastic anti-NMDA receptor encephalitis associated with ovarian teratoma. Soc Neurosci Ann Meeting 2008;34:425.14.

-Tüzün E, Rossi JE, Rosenfeld MR, **Dalmau J**. Analysis of the IgG distribution and inflammatory infiltrates in encephalitis patients associated with anti-n-methyl-D-aspartate receptor antibody and teratoma. J Neuroimmunol 2008;203:190.

-Ishiura H, Higashihara M, Yamamoto T, Shimizu J, Goto J, **Dalmau J**, Takahashi Y, Tsuji S. Anti-NMDA receptor-related autoantibodies and therapeutic outcome in acute non-herpetic encephalitis accompanied with refractory seizures in young women. Neurology 2008;70:A455.

-**Dalmau J**, Gleichman AJ, Rossi JE, Lai M, Rosenfeld MR, Lynch DR. The syndrome and target epitopes of anti-NMDA receptor encephalitis: a study of 67 patients. Neurology 2008;70:A111-112.

-Godshall AJ, Guedes B, Barr CR, Dalmau J. Paraneoplastic encephalitis associated with benign immature teratoma. Crit Care Med 2007;35(suppl):A286.

-Novillo-López ME, Rossi J, **Dalmau J**, López-Sendón JL, Corral I, Masjuan J. Encefalitis límbica en un varón asociada a anticuerpos contra el receptor NMDA. Neurología 2007;22:590.

-Estévez S, Vera R, Navacerrada FJ, López-Sendón JL, Cruz A, Novillo ME, **Dalmau J**, Masjuan J, García-Barragán N. Encefalitis límbica autoinmune. Revisión de tres casos en nuestro hospital. Neurología 2007;22:261-262.

-Gleichman AJ, Rossi JE, Wu HY, Sheffler-Collins S, **Dalmau J**, Lynch DR. Mechanisms by which NMDAR receptor antibodies mediate a novel autoimmune disease. J Neurosci 2007;875.19/F32.

-Tüzün E, Rossi JE, Rosenfeld MR, Lynch DR, **Dalmau J**. Clinical and pathological analysis of paraneoplastic anti-NMDA receptor encephalitis in 16 patients. Neurology 2007;68:A94.

-Tüzün E, Rossi JE, Karner SF, Centurión AF, **Dalmau J**. Adenylate kinase 5 (AK5) autoimmunity in limbic encephalitis. Neurology 2007;68:A290.

-**Dalmau J**, Tüzün E, Wu HY, Rossi JE, Maronski M, Masjuan J, Dichter M, Rosenfeld MR, Lynch DR. Functional NR2B and NR2A heteromers of the NMDA receptor are the autoantigens of treatment-responsive encephalitis in patients with ovarian teratoma. Ann Neurol 2006;60:A639-640.

-López-Sendón JL, Masjuan J, García-Cossío M, Alonso de Leciana M, Corral I, Estévez S, García-Villanueva M, **Dalmau J**. Limbic encephalitis: association with ovarian teratoma and hippocampal neuropil antibodies. J Neurol 2006;253:A62.

-Diaz-Manera J, Juarez C, Martinex-Ramirez S, Rojas-Garcia R, Gallardo E, **Dalmau J**, Illa I. Severe muscle atrophy and respiratory failure requiring intubation in a 45 year old woman. Eur J Neurol 2006;13 Suppl 2:304.

-Mathew RM, Yamamoto T, Nakamura K, Dropcho E, Tsuji, S, **Dalmau J**. Orchiectomy for

suspected microscopic tumor in patients with paraneoplastic anti-Ma2 encephalitis (Abstract). Neurology 2006;66 Suppl 2 (Contemporary Clinical Issues and Case Studies, Plenary Session: 58th Annual Meeting AAN, San Diego, CA. April 5, 2006).

-Bataller L, Wu GF, Rossi J, **Dalmau J**. Limbic encephalitis: Clinical and immunological phenotypes of 35 patients. *Neurology* 2006;66:A339.

-Diaz-Manera J, Juarez C, Martinez-Ramirez S, Rojas-García R, Gallardo E, **Dalmau J**, Illa I. High titers of AChR, MuSK and VGKC-Abs in one patient: Clinical and immunological evaluation and response to rituximab therapy. *Neurology* 2006;66:A58.

-Matsumoto L, Yamamoto T, Higashihara M, Sugimoto I, Kowa H, Nakamura K, Goto J, Shibahara J, **Dalmau J**, Tsuji S. Severe hypokinesia caused by anti-Ma2 encephalitis associated with bilateral carcinoma *in situ* of the testis. *Neurology* 2006;66:A339-340.

-Vance BA, Carroll RG, Uderman RS, Coukos G, Chu CS, **Dalmau J**, Vonderheide RH. Immune responses to the onconeural protein cdr2 in the absence of paraneoplastic cerebellar degeneration in patients with ovarian cancer. *AACR meeting abstracts* 2005, 361.

-Meneses PI, Zupa-Fernandez A, Maronski M, Dichter MA, **Dalmau J**, Rosenfeld MR. Onconeural and control antibodies are internalized by hippocampal neurons resulting in cell death. *Neurology* 2005;64:A52.

-Vitaliani R, Liebeskind DS, Zwerdling T, Mason WP, Rosenfeld MR, **Dalmau J**. The triad of acute onset encephalitis, seizures, and central hypoventilation associates with ovarian teratoma and highly specific hippocampal antibodies. *Neurology* 2005;63:A52.

-Vitaliani R, Zupa-Fernandez A, Rosenfeld MR, **Dalmau J**. VGKC antibodies in patients with limbic encephalitis: specific detection by immunohistochemistry and evidence of limited epitope repertoire. *Neurology* 2005;63:A63.

-Ances B, Taylor RA, Vitaliani R, Liebeskind DS, Voloschin AD, Houghton DJ, Galetta SL, **Dalmau J**. Reversible encephalitis and novel antibodies to synaptic-enriched regions of the hippocampus: clinical, neuroimaging, and immunologic correlates. *Neurology* 2005;63:A51-52.

-Ahmed SA, Rosenfeld MR, White P, **Dalmau J**. Analysis of antineuronal antibodies in the serum of patients suspected of having lung cancer. *Proc Am Thor Soc* 2004 (http://www.abstracts2view.com/ats/view.php?nu=ATS4L_897)

-Bataller L, Rosenfeld MR, Graus F, Vilchez J, Cheung N-K, **Dalmau J**. Autoantigen diversity in the opsoclonus myoclonus syndrome. *J Neurol* 2003;250 (suppl 2): 44.

-Bataller L, Graus F, Vilchez JJ, Cheung NK, Rosenfeld MR, **Dalmau J**. Identificación de antígenos neuronales en el síndrome opsoclonus mioclonus mediante cribaje de librerías genéticas (Identification of neuronal antigens of opsoclonus myoclonus syndrome using cDNA library screening). *Neurologia* 2002;17:478.

-**Dalmau J**, Bataller L, Graus F, Rosenfeld MR. Los anticuerpos anti-Zic son un nuevo marcador de

síndromes neurológicos paraneoplásicos y cáncer de pulmón de células pequeñas (Anti-Zic antibodies are new markers of paraneoplastic neurologic syndromes (PNS) and small-cell lung cancer). *Neurología* 2002;17:584.

-Bataller L, Wade DF, Rosenfeld MR, **Dalmau J**. Immunity to Zic proteins frequently associates with paraneoplastic neurologic disorders (PND) and predicts small-cell lung cancer (SCLC). *Ann Neurol* 2002; 52 (suppl):S80.

-Aburahma S, **Dalmau J**, Mrak RE, Rosenfeld MR, Rudnicki SA. Absence of antibody mediation in paraneoplastic necrotizing myopathy associated with small-cell lung cancer. *J Child Neurol* 2002;17:5-6.

-Wade D, Eichen JG, Rosenfeld MR, **Dalmau J**. Paraneoplastic Ma proteins: immunodominant regions and differential expression by neuroblastoma cell lines. *Neurology* 2002;58:47-48.

-Stacey DH, Kane CJM, Thomasson KA, **Dalmau J**, Rosenfeld MR. Developmental expression of autoantigens associated with paraneoplastic retinopathy. *Neurology* 2002;58:437-438.

-Bataller L, Rosenfeld MR, **Dalmau J**. The Myc-associated zinc finger protein (MAZ) is a common target of cancer-related immunity and paraneoplastic neurologic disorders (PND). *Neurology* 2002;58:46.

-**Dalmau J**, Bataller L, Wade D, Fuller GN, Rosenfeld MR. Subacute cerebellar degeneration associated with immunity to ZIC: A family of zinc finger proteins expressed in cerebellum and brain tumors. *Neurology* 2002;58:47.

-Nasir SU, Abrey LE, Kris MG, Miller VA, **Dalmau J**. Neurologic complications of small-cell lung cancer. *Neurology* 2000;54:39.

-Croteau D, Owainati M, **Dalmau J**, Rogers L. Paraneoplastic choreiform disorder in a patient with small-cell lung cancer (SCLC): identification of a unique antineuronal antibody and successful clinical response to chemotherapy. *Neurology* 2000;54:38-39.

-**Dalmau J**, Graus F, Barnett M, Pringsheim T, Caminero A, Wennberg R, Ribalta T, Shannon P, Sutton I, Eichen J, Rosenfeld MR. Ta (Ma2) antibodies in women with paraneoplastic neurologic syndromes. *Neurology* 2000;54:37-38.

-Eichen J, Demopoulos A, Thirkill CE, Posner JB, Rosenfeld MR, **Dalmau J**. Autoimmunity against a photoreceptor cell-specific nuclear receptor in paraneoplastic retinopathy and lung cancer. *Neurology* 2000;54:37.

-Voltz R, Gultekin SH, Rosenfeld MR, Gerstner E, Eichen J, Posner JB, **Dalmau J**. A serological marker of paraneoplastic limbic and brainstem encephalitis in patients with testicular cancer. *J Urol*, 2000;163:1044.

-Greenlee JE, Steffens JD, Clawson SA, **Dalmau J**. Anti-Hu antibodies associated with paraneoplastic neuropathy and encephalopathy in the setting of Merkel cell carcinoma. *Ann Neurol* 2001;50:S60.

-Saiz A, **Dalmau J**, Pifarré A, Marín C, Tolosa E, Graus F. Detection of 14-3-3 protein in the cerebrospinal fluid (CSF) of patients with paraneoplastic neurologic disorders (PND). *J Neurol* 1999;246:31.

-Sánchez-Valle R, **Dalmau J**, Reñé R, Saiz A, Baiges J, Foronda J, Girón JM, Peltola J, Vecht Ch, Vila MJ, Graus F. Paraneoplastic cerebellar degeneration (PCD) and Hodgkin's disease (HD) with anti-Tr antibodies (Tr-Ab): Immunological and clinical description of 11 patients. *J Neurol* 1999;246:32.

-**Dalmau J**, Voltz R, Eichen JG, Gultekin SH, Posner JB, Rosenfeld MR. Antibodies against Ma1-Ma5 define distinct paraneoplastic neurologic syndromes associated with limbic, brainstem, or cerebellar dysfunction. *Neurology* 1999;52:197-198.

-Gultekin SH, Eichen JG, Rosenfeld MR, Voltz R, Posner JB, **Dalmau J**. Paraneoplastic limbic encephalitis: tumor association and immunological findings in 39 patients. *Neurology* 1999;52:281.

-**Dalmau J**, Gultekin H, Voltz R, Posner JB, Rosenfeld MR. The novel antibody (anti-Ma) from patients with paraneoplastic brainstem and cerebellar dysfunction recognizes MM1, a protein expressed in brain and testis. *J Neurol* 1998;245:355-356.

-Voltz R, **Dalmau J**, Posner JB, Rosenfeld MR. CD8+ T cells are primarily involved in the pathogenesis of the anti-Hu paraneoplastic syndrome. *J Neurol* 1998;245:412.

-Voltz R, Gultekin H, Posner JB, Rosenfeld MR, **Dalmau J**. Sera of patients with testicular cancer and paraneoplastic limbic/brainstem encephalitis harbor an antineuronal antibody (anti-Ta) that recognizes a novel neuronal protein. *J Neurol* 1998;245: 379.

-Gultekin SH, Demopoulos A, Graus Y, Posner JB, Rosai J, **Dalmau J**, Rosenblum MK. Anti-HuD Fab: a novel marker for neuronal and neuroendocrine neoplasms. *J Neuropathol Exp Neurol* 1998;57:519.

-Gultekin SH, Voltz RD, Gerstner ER, Hoard R, Posner JB, Rosenfeld MR, **Dalmau J**. Characterization of a novel antineuronal antibody (anti-Ta) in the serum of 6 patients with testicular cancer and paraneoplastic limbic encephalopathy (PLE). *Neurology* 1998;50:A383.

-Voltz RD, Carpentier AF, Rosenfeld MR, Posner JB, **Dalmau J**. P/Q-type VGCC antibodies in patients with paraneoplastic disorders of the central nervous system. *Neurology* 1998;50:A422-423.

-Carpentier AF, Rosenfeld MR, Delattre JY, Posner JB, **Dalmau J**. DNA vaccination with HuD inhibits neuroblastoma growth in mice and does not produce neurologic disease. *Neurology* 1998;50:A354-355.

-Rosenfeld MR, Voltz RD, Eichen JG, Deschamps T, **Dalmau JO**, Posner JB. Analysis of TCR usage in the anti-Hu paraneoplastic syndrome. *Neurology* 1998;50:A384.

-**Dalmau J**, Gultekin SH, Batchelor T, Balmaceda C, Hoard R, Voltz R, Posner JB, Rosenfeld MR. Cloning and characterization of two novel antigens (MM1 and MM2) recognized by the serum of patients with paraneoplastic neurologic disorders (PND). *Neurology* 1998;50:A384-385.

-Abrey LE, Mason WP, Grant SC, Miller VA, Kris MG, **Dalmau J**. The prevalence of neurologic disease and autoantibodies in small cell lung cancer (SCLC). *Neurology* 1998;50:A188-189.

-Greenlee JE, Lyons T, Clawson S, Smith RH, Pirch HR, **Dalmau J**. Type I (anti-Yo) antibody-positive paraneoplastic cerebellar degeneration associated with transitional cell carcinoma of the bladder. *Ann Neurol* 1997;42:463-464.

-Carpentier A, Rosenfeld MR, Posner JB, **Dalmau J**. DNA vaccination with HuD inhibits tumor growth of a neuroblastoma in mice. *Multidisciplinary approaches to cancer immunotherapy. New Strategies and Advances Technologies*. Bethesda, Maryland. June 23-24, 1997

-Antunes NL, Khakoo Y, Stram DO, Seeger RC, Matthay KK, **Dalmau J**. Antineuronal antibodies in patients with neuroblastoma and paraneoplastic opsoclonus myoclonus. *Ann Neurol* 1997;42:534-535.

-Abrey LE, **Dalmau J**. Neurologic complications of ovarian cancer. *Ann Neurol* 1997;42:430.

-Abrey LE, Mason W, **Dalmau J**, Posner JB, Kris MG, Miller VA, Grant SC. A prospective study of the prevalence of neurologic disease and autoantibodies in small-cell lung cancer (SCLC). 8th World Conference of Lung Cancer. University College Dublin, 1997.

-**Dalmau J**, Lang B, Graus F, Mason WP, Honnorat J, Delattre J-Y, Antoine JC, Rosenfeld MR, Newsom-Davis J, Posner JB. Association of Lambert-Eaton myasthenic syndrome (LEMS) with paraneoplastic cerebellar degeneration (PCD) in patients with small-cell lung cancer (SCLC). *Neurology*, 1997;48:A32.

-Levin MC, Krichavsky M, Berk J, **Dalmau J**, Posner JB, Jacobson S. Characterization of a novel disease-associated autoantibody response in patients with HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP). *Neurology*, 1997;48:A95.

-Graus FR, **Dalmau JO**, Torà M, Marín C, Real FX. Western blot (WB) analysis of neuronal Hu antigens: distinct specificity of anti-Hu antibodies (HuAb) of small cell lung cancer (SCLC) patients with or without paraneoplastic neurologic disorders (PND). *Neurology*, 1997;48:A32.

-Benyahia B, Mentz F, **Dalmau JO**, Merle-Beral H, Liblau R, Delattre-JY. T-cell mediated autoimmunity in the pathogenesis of anti-Hu associated paraneoplastic encephalomyelitis (PEM) and subacute sensory neuronopathy (PSN). *Neurology*, 1997;48:A32.

-Gultekin SH, Graus Y, Degenhardt A, Rosenblum MK, Posner JB, **Dalmau J**. Anti-HuD reactivity in neoplasms of the central nervous system. *Ann Neurol* 1996; 40:491.

-Posner JB, Malats N, Reñé R, Torà M, Rosell R, Real FX, Rosenfeld M, Graus F, **Dalmau J**. Anti-Hu antibodies as a prognostic marker for SCLC response to therapy. *J Invest Med* 1996;44:234A.

-Levin MC, Berk J, **Dalmau J**, Rosenfeld M, Flerlage N, Clemmens K, Posner JB, Jacobson S. Patients with HTLV-I (Human T-cell lymphotropic virus type I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) produce antibodies that react exclusively with neurons. *Neurology*

1996;46:A269

-Twiinstra A, **Dalmau J**, ten Velde G, Perquin M, De Baets M, van Breda Vriesman P, Verschuuren J. Chemotherapy does not decrease serum anti-Hu antibody titers in small cell lung cancer patients. *Neurology* 1996;46:A472-473

-Graus F, **Dalmau J**, Reñé R, Torà M, Malats N, Verschuuren J, Badell C, Cardenal F, García del Muro J, Rosell R, Viñolas N, Real FX, Posner JB. Anti-Hu antibodies in patients with small cell lung cancer: Association with complete response to therapy and improved survival. *J Neuro-oncol* 1996; 30: 129.

-Rosenfeld MR, Schramm L, **Dalmau J**, Malkin MG. Prevalence of serum antibodies against the p53 tumor suppressor gene protein in patients with primary brain tumors. *Neurology* 1996;46:A362-363

-Verschuuren J, Lang B, Newsom-Davis J, Graus F, **Dalmau J**, Posner JB, Rosenfeld MR. Antibodies to the b-subunit of the voltage gated calcium channel (VGCC) in patients with the Lambert-Eaton Myasthenic Syndrome (LEMS). *Neurology* 1996;46:A128

-Tunkel R, Rosenfeld MR, **Dalmau J**, Posner JB, Verschuuren J. Animals immunized with MysB, a Lambert-Eaton Myasthenic Syndrome (LEMS) antigen, develop high titer antibodies but no evidence of disease. *Neurology* 1996;46:A129

-Degenhardt A, Hoard R, Duvoisin RM, Gultekin H, Posner JB, **Dalmau J**. Glutamate receptor antibodies and paraneoplastic neurologic disorders. *Neurology* 1996;46:A410

-Mason WP, Graus F, Valldeoriola F, Delattre JY, Posner JB, **Dalmau J**. Paraneoplastic cerebellar degeneration (PCD) in small cell lung cancer (SCLC): Impact of anti-Hu antibody (HuAb) on clinical presentation and survival. *Neurology* 1996;46:A127-128

-Levin M, Berk J, **Dalmau J**, Rosenfeld M, Posner JB, Jacobson S. IgG from patients with HAM/TSP react with neurons of the central nervous system (CNS). VIIth International Conference in Human Retrovirology: HTLV. Institut Pasteur, Paris, France, 1995.

-Mason WP, Verschuuren J, Graus F, Grant S, Kris M, Posner JB, **Dalmau J**. Anti-Hu antibodies in patients with small cell lung cancer (SCLC) but no paraneoplastic disorder (PD). *Ann Neurol* 1995;38:341-342

-Graus F, **Dalmau J**, Valldeoriola F, Reñé R, Ferrer I, Arbizu T, Targa C. Immunological characterization of a neuronal autoantibody (Anti-Tr) associated with paraneoplastic cerebellar degeneration (PCD) and Hodgkin's disease (HD). *J Neurol* 1995;40:242

-Verschuuren J, Rossi G, Berk J, Hoard R, Rosenfeld MR, Posner JB, **Dalmau J**. Intra-cerebroventricular injection of anti-sense HuD oligonucleotides in mice results in severe motor dysfunction and seizures. *Ann Neurol* 1995;38:345

-**Dalmau J**, Verschuuren J, Hoard R, Posner JB. Anti-Hu serum is cytotoxic for non-Hu antigen expressing cell lines. *Neurology*, 1995; 45(Suppl 4):A229.

-Twijjnstra A, Verschuuren J, Byrne TN, De Baets M, Posner JB, **Dalmau J**. Prolonged or remitting anti-Hu associated paraneoplastic sensory neuronopathy (PSN) and encephalomyelitis (PEM). *Neurology*, 1995; 45(Suppl 4):A321.

-Sillevis Smitt PAE, Manley GTM, **Dalmau J**, Posner JB. Pitfalls in the immunohistochemical demonstration of intracellular IgG. *Neurology*, 1995; 45(Suppl 4):A320.

-Liu S, Mezrich J, Berk J, Federici M, **Dalmau J**, Posner JB. Expression of Purkinje-cell antigens in ovarian tumor, and presence of anti-Purkinje cell antibodies in the serum of patients without paraneoplastic cerebellar degeneration. *Neurology*, 1995; 45(Suppl 4):A228-229.

-Wayne AS, Grahna N, Casadonte J, Geller D, **Dalmau JO**. Anti-Hu antibody (Ab) paraneoplastic syndrome (PNS) in pediatric neuroblastoma (NB): Response to immunomodulation. *Blood* 1994;84:615a

-Verschuuren JJ, Rosenblum MK, Lieberman FS, Posner JB, **Dalmau J**. Complete absence of Purkinje cells in anti-Yo associated cerebellar degeneration. *J Neuro-oncol* 1994;21:77

-Verschuuren JJ, Meneses PI, Rosenfeld MR, Kaplitt MG, Posner JB, **Dalmau J**. Viral gene transfer of HuD to non-neuronal mammalian cells. *J Neuro-oncol* 1994;21:75

-Verschuuren J, Rosenblum M, Pryor A, Weldon Ph, **Dalmau J**. Complete absence of Purkinje cells in anti-Yo associated cerebellar degeneration. *Ann Neurol* 1994;36:294

-Rosenfeld MR, Meneses P, Kaplitt MG, **Dalmau J**, Posner JB, Cordon-Cardo C. Expression of wild-type p53 after gene transfer with a defective herpes viral vector results in down-regulation of mutant p53 expression and up-regulation of mdm-2. *J Neurol* 1994;241:S146

-**Dalmau J**, Kaplitt MG, Meneses P, Posner JB, Rosenfeld MR. Novel expression of immunoreactive HuD (paraneoplastic encephalomyelitis) antigen in non-neuronal mammalian cells using a defective herpes viral (HSV) vector. *J Neurol* 1994;241:S146

-Weaver S, Rosenblum M, Nicholson G, Demchak PA, **Dalmau J**, Posner JB. Paraneoplastic central nervous system disorders associated with thymoma. *Proc Am Soc Clin Oncol* 1994;12:294

-Manley G, Sillevis Smitt PAE, **Dalmau J**, Posner JB. Molecular characterization of the Hu paraneoplastic encephalitis-related proteins in small cell lung cancer tissues, and analysis of the major immunogenic sites. *Neurology* 1994;44:A156-157

-**Dalmau J**, Kaplitt MG, Meneses P, Rosenfeld MR, Posner JB. Novel expression of the HuD antigen in mammalian cells after gene transfer with a defective herpes viral (HSV) vector. *Neurology* 1994;44:A377-378

-Weaver S, **Dalmau J**, Walker R. Treatment of recurrent or residual ependymoma with carboplatinum. *Neurology* 1994;44:A263

-Kaplitt MG, Rosenfeld MR, **Dalmau J**, Meneses P, Pfaff DW, O'Malley KL, Leone P, During MJ. Adeno-associated virus (AAV) vectors for genetic therapy of neurologic disease. *Neurology*

1994;44:A163

-Hormigo A, **Dalmau J**, Rosenblum M, Ho A, River ME, Morrison JM, Posner JB. Immunological and pathological study of a patient with anti-Ri associated encephalopathy. *Ann Neurol* 1993;34:278.

-Forsyth PA, **Dalmau J**, Graus F, Posner JB. Paraneoplastic motor neuron disease (MND). *Ann Neurol* 1993;34:277.

-**Dalmau J**, Thomson S, Ho A, Atamian A, Cheung NK, Posner JB. The anti-Hu immune response in patients with neuroblastoma -A clinical and immunological study. *Neurology* 1993;43:A208.

-Graus F, **Dalmau J**, Rosenblum M, Ribalta T, Delattre JY. Expression of MHC-class I and II antigens in small-cell lung cancer from patients with anti-Hu associated paraneoplastic encephalomyelitis. *Neurology* 1993;43:A207-208.

-**Dalmau J**, Rosenfeld M.R, Szabo A, Manley G, Wong E, Posner J.B, Furneaux H. HuD pre-mRNA is aberrantly spliced in tumor tissue from paraneoplastic encephalomyelitis/sensory neuronopathy (PEM/SN) patients. *Neurology* 1992;42(Suppl 3):416.

-Rosenfeld M.R, **Dalmau J**, Wong E, Posner J.B, Furneaux H. Lambert-Eaton Myasthenic Syndrome sera recognizes brain cDNA clones homologous to the calcium channel β -subunit. *Neurology* 1992;42(Suppl 3):306.

-**Dalmau J**, Furneaux HM, Posner JB. Identification of Hu-antigen specific lymphocytes in the tumor and brain of patients with paraneoplastic subacute sensory neuropathy. *Proc Am Asso Cancer Res* 1991;32:272.

-**Dalmau J**, Furneaux HM, Posner JB. The expression of the Hu antigen in normal and tumor tissues. *Neurology* 1991;41(Suppl 1):159.

-Manley G, Kotanides H, **Dalmau J**, Wong E, Posner JB, Furneaux HM. Characterization of a small cell lung cancer cDNA recognized by anti-Hu sera. *Neurology* 1991;41(Suppl 1):364

-Posner JB, **Dalmau J**, Furneaux H, Graus F. Paraneoplastic "Anti-Hu" syndrome: A clinical study of 47 patients. *Neurology* 1990;40(suppl 1):165.

-**Dalmau J**, Furneaux H, Rosenblum MK, Graus F, Posner JB. Immunological study of the nervous system and tumor of three patients with paraneoplastic encephalomyelitis and small-cell lung cancer. *Neurology* 1990;40(suppl 1):166.

-**Dalmau J**, Furneaux H, Cordon-Cardo C, Posner JB. Immunohistochemical analysis of the Hu-antigen expression in normal and neoplastic tissues. *Ann Neurol* 1989;26:307.

-**Dalmau J**, Furneaux H, Posner JB. Detection of the anti-Hu antibody in patients with small-cell lung cancer -A quantitative Western Blot assay. *Ann Neurol* 1989;26:179-180.

SUBMITTED MANUSCRIPTS/ SCIENTIFIC PRESENTATIONS

-Zamani A, Peixoto-Moledo P, Tomàs DP, Rotstein H, **Dalmau J**, Jercog P. Anti-NMDAR encephalitis antibodies cause long-lasting degradation of the hippocampal neural representation of memory. Submitted

-Gaig C, Grüter T, Heidbreder A, Sabater L, Iranzo A, Santamaria J, Leypoldt F, **Dalmau J**, Ayzenberg I, Graus F. Development of a composite score for the clinical assessment of anti-IgLON5 disease. Submitted

-Muñoz-Lopetegi A, Guasp M, Prades L, Martínez-Hernández E, Rosa-Justícia M, Patricio V, Armangué T, Rami L, Borràs R, Castro-Fornieles J, Compte A, Gaig C, Santamaria J, **Dalmau J**. Neurologic, psychiatric, and sleep investigations after initial treatment of anti-LGI1 encephalitis: a prospective cohort study. Submitted